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Aims and outline of  this  thesis
The general aim of the research presented in this thesis was to contribute to the 
translation of collagen-based scaffolds from bench-to-bedside. The first part reviews 
recent literature and addresses novel insights and points to consider relevant in the 
process of clinical translation of tissue engineered biomaterials. Chapter 1 is an 
extensive overview of currently available biomaterials and processing methods for 
the preparation of implants in the field of tissue engineering with a strong focus on 
extracellular matrix-derived materials. This chapter also addresses opportunities and 
critical issues for reseachers to optimize collagen scaffolds and to speed up clinical 
translation. In Chapter 2, a systematic overview is provided on all available literature 
on tissue engineering of the urethra including a meta-analysis in order to obtain an 
unbiased and comprehensive overview of the field, ultimately to facilate translation 
of pre-clinical research to the patient. The review reveals trends with regard to the 
use of different biomaterials and the use of (stem) cells in urethral implants in both 
pre-clinical and clinical studies. It also suggests recommendations on how to improve 
clinical translation.
In the second part of this thesis, new techniques are described to modify the 
3D-structure and biomechanical properties of collagen scaffolds, as these are often 
not in compliance with the tissue to be regenerated. Chapter 3 describes a novel 
technique to induce elastic-like characteristics to tubular scaffold consisting of solely 
type I collagen fibrils using straightforward compression, corrugation and chemical 
crosslinking. In Chapter 4, the development of an elastic tubular scaffold is continued 
by applying the processing technique of Chapter 3 to prepare a tubular scaffold with 
radial elasticity. Chapter 5 presents an innovative collagen implant with the ability 
to self-expand upon exposure to water prepared by applying a method opposite to 
the one in Chapter 4. In Chapter 6, a new method is described to create stiff and rigid 
collagen scaffolds, which is based on treatment with concentrated salt solutions. 
This method may be useful for the preparation of collagen-based biomaterials with a 
defined stiffness. Finally, Chapter 7 provides a summary of this thesis as well as future 
perspectives of the results described in this thesis.
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Chapter 1
1.  Introduction
Regenerative medicine (RM) is a new rapidly growing discipline in medical science. The 
need for RM partially originates from the chronic shortage of autologous or allogeneic 
tissues and organs for transplantation in cases of e.g., trauma, organ failure, tumors 
and general necrosis. The drawback of traditional allo- and xenogeneic organ or tissue 
transplantations is that, due to the genetic variation of species and individuals, it is 
subject to immunological compatibility complications which increases the severity 
of the organ shortage [1]. RM is based on combining knowledge gathered from the 
fields of molecular life sciences, biomedical engineering, (bio)materials science, 
reconstructive surgery and transplantation biology, to develop biomedical devices 
and treatments which aid in the repair or replacement of damaged tissues and 
organs [2]. More specifically, these biomedical devices or treatments comprise the 
supplementation to the damaged site of vital cells, extracellular matrix, biomolecules 
or a combination thereof. This central dogma has led to one important strategy, 
namely, the development of materials that mimic the extracellular matrix (ECM). 
The ECM has many functions e.g., providing structural support for cells to reside, 
determining the mechanical properties of the tissues, providing mechanical signals 
to allow for cellular response and acting as a growth factor reservoir. Major ECM 
components in tissues and organs are collagens, elastin, laminins, fibronectins, 
proteoglycans and glycosaminoglycans [3]. The strategy is based on stimulating the 
body’s regenerative capacity by implanting natural or synthetic ECM materials into a 
defect with or without cells. The ECM essentially acts as a template in the early stage 
of regeneration for cells to adhere or migrate to, proliferate and differentiate. Ideally, 
this hinders the formation of scar tissue and subsequently stimulates formation of 
new functional tissues, thus regenerating the organ’s function [4]. These extracellular 
matrices, also referred to as biomatrices or scaffolds, can be classified into two groups: 
the decellularized tissues [5] or molecularly defined constructs comprised of natural 
and/or synthetic biomaterials [6]. 
This chapter aims to provide a fundamental and tutorial overview of the ECM and its 
components and highlights its essential role in RM of (soft) tissues. Subsequently, the 
current techniques used to process the ECM components into scaffolds for different 
applications are summarized and comprehensively reviewed. 
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Extracellular matrix derived biomaterials: Molecularly defined ingredients and processing techniques
2.  The extracellular  matrix
2.1.  Role of  the Extracel lular  Matrix  (ECM)
In multicellular organisms the same set of biological rules generally apply. Cells can 
specialize in certain tasks, which in turn allow them to be more efficient. Due to the 
evolutionary process, cells form tissues in larger organisms, which in turn form organs 
that carry out a special function [7]. The cells are genetically identical, however, their 
gene expression depends on their function. The expression of specific genes leads them 
to produce biomolecules like proteins, carbohydrates, fats and metabolites. The cells 
are surrounded and subsequently held together by the ECM, which is produced by the 
cells themselves. The ECM is a dynamic and multifarious network that surrounds cells, 
providing structural and mechanical support in all tissues, mediating diverse biological 
processes that are crucial for supporting tissue formation and function, and playing an 
important role in wound healing. Cells adhere to the ECM via receptors (e.g. integrins) 
to maintain tissue architecture in vivo. ECMs can therefore regulate cellular functions 
by directly activating intracellular signaling pathways [8]. Depending on the function 
of the organ, the composition of cells and ECM differ tremendously. The composition 
of the ECM is specialized in different tissues in order to employ tissue specific cellular 
functions. For example, organs that have loadbearing functions like bone, cartilage, 
tendons and ligaments often have ECM’s which are either rich in collagen, minerals 
or a combination thereof [9]. Organs with functions that require repetitive motions 
often contain collagen and elastin as the main structural component of the ECM like in 
the skin, lung and diaphragm [10]. In different tissues different ECM structures can be 
found, where for example the epithelial and dermal layer have dissimilar compositions. 
The complexity increases when taking into account that the composition of ECM 
constantly changes along with developmental stages of an organism [11] and also 
through pathological conditions, like fibrosis after trauma [12].
2.2.  ECM constituents
The ECM mainly consists of collagens, elastin, proteoglycans, laminins, fibronectins and 
glycosaminoglycans. Collagen provides tissues with essential tensile strength, enabling 
resistance to plastic deformation and rupture [13]. Type I collagen is the most abundant 
collagen and is present as a fibrillar protein, often accompanied by other collagen types like 
II, III, IV and V [14]. Elastin on the other hand, provides tissues the properties of extensibility 
and reversible recoil, enabling tissues to withstand repetitive mechanical stress [15]. 
The ECM is filled with a viscous interstitial fluid rich in proteoglycans (PGs) and other 
1
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Chapter 1
glycoproteins, containing a complex mixture of proteases, growth factors, cytokines and 
other effector molecules. Fibronectins can be found as a structural insoluble glycoprotein 
or soluble plasma protein, and contains binding domains that can immobilize other ECM 
components. Laminins are large trimeric glycoproteins that can be found in basement 
membranes. Laminins also have the ability to bind ECM components and can interact 
with cells with specific domains. Depending on the organ/tissue function different 
collagens can be found with different combinations of elastin, laminins, fibronectins 
and PGs. PGs consist of a core protein with a varying amount of glycosaminoglycans 
(GAGs) chains attached to them. GAGs are long, linear and strongly negatively charged 
polysaccharides, containing repeating disaccharides. GAGs are an important part 
of the ECM and govern countless functions from cell growth and differentiation to 
wound healing and cell protection. These components will be further elaborated next.
3.  Molecularly def ined biomaterials 
One of the two fundamentally different strategies to design the scaffolds follows the 
“bottom-up” philosophy, making use of molecularly defined biomaterials [3, 16]. 
This section will discuss molecularly defined biomaterials produced from naturally 
occurring ECM components. In contrast to the decellularization strategy, components 
of molecularly defined scaffolds are individually purified and can subsequently be 
used in combination with a variety of processing methods. Substituting the use of 
cadaver tissue can improve standardization, quality and safety issues that inherently 
accompany decellularization strategies (see section 4.6). Advantages of molecularly 
defined materials are related to increased versatility, controllability, reproducibility 
and safety of the products. The potential and subsequent advantages of using 
defined biomaterials have been demonstrated in numerous studies [16-20]. Typically, 
depending on the type of molecularly defined biomaterials, they can be processed 
into different types of scaffolds (discussed in section 4). Biological and mechanical 
prerequisites of the defined biomaterials in question are (i) to support and deliver 
cells, (ii) to induce and differentiate tissue growth, (iii) to function as cell adhesion 
substrate, and (iv) to stimulate cellular response. Other important materials properties 
include (v) formation of a wound-healing barrier, (vi) biocompatibility and controlled 
(non)-biodegradability, (vii) relative ease of processability and malleability into desired 
shapes, (viii) mechanical strength and dimensional stability and (ix) sterilizability [21]. 
The used materials can either be of natural or synthetic origin. In this chapter only 
materials found in the ECM will be discussed. 
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Extracellular matrix derived biomaterials: Molecularly defined ingredients and processing techniques
3.1.  Mammalian ECM-based Materials
Biomaterials isolated from natural sources have been widely used in the RM arena. 
Early research focused on proteins isolated from the human ECM and their roles in 
wound healing. From the primary amino acid sequence up to the tertiary/quaternary 
structure of extracellular matrix proteins, the degree of conservation is generally high 
throughout primates and ungulates. A high degree of homology in structure might 
theoretically reduce the chance of an unsolicited host immune response. Therefore, 
Figure 1:  Iso lat ion of  co l lagen as a  b iomater ia l .  A)  Achilles tendons are removed from bovine legs 
and B)  subsequently freed from macroscopical impurities such as fatty membranes and blood, bar is 1 
cm. C)  The cleaned tendon is pulverized under frozen conditions followed by D)  washing steps with acids, 
bases, chaotropic agents, salts and organic solvents to remove non-collagenous components. E)  This 
procedure results in purified collagen fibrils as a basic material. Several quality assurance steps can be 
taken; F)  transmission electron microscopy (TEM) to visualize the quarter staggered array structure of 
the collagen fibrils, bar is 500 nm and G)  SDS-PAGE to assess protein impurities in the final product. The 
characteristic collagen bands can be observed and the isolated collagen does not contain other proteins 
found in the raw material (tendon). 
1
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Chapter 1
many attempts have been made to identify ubiquitous sources of the ECM specific 
component in question, in genetically related mammalian species. Next to ECM 
proteins, polysaccharides (e.g., GAGs) are also subject to substantial research interest 
due to their versatility and roles they play in the ECM. In general, the organs of interest 
are retrieved from a standardized source after which the surface area is increased 
(pulverization) to facilitate future processing steps. The material is then subjected 
to an array of carefully selected chemicals and enzymes to remove the fractions 
that are not of interest. After isolation, the ECM component is subjected to tests in 
order to determine its purity and (near) native state. This central scheme is found in 
most processes used to obtain ECM components (see figure 1). Proteins and GAGs 
are the main component of the human ECM. However, many other natural materials 
have been isolated from other non-mammalian sources like for example from plants 
or crustaceans. Even though these isolated materials are not native to the human 
physiology, some are biocompatible and can mimic certain functions of the natural 
ECM. In this section an overview will be given of the different available natural materials 
currently being used in RM research.
3.1.1.  Collagen
Collagen is the most abundant protein in man and most other vertebrates. It is a major 
structural polymer which can be found throughout the body providing structural 
integrity and rigidity in tissues like tendons, cartilage and skin [22]. Along with calcium, 
collagen is important for strength and structure in bones and teeth. So far more than 
28 genetically distinct types of collagen have been found, of which type I collagen 
is most abundant [23]. On a cellular level, type I collagen mainly acts as a structural 
component but it also mediates biological functions like cell binding, migration, growth 
and chemotaxis [24]. Type II collagen is predominantly found in cartilage whereas type 
III collagen can be found in more elastic tissues like the skin. Type IV collagen is a 
universal component of the basement membrane, a thin sheet of specialized ECM 
upon which a large number of cell types (epithelium, endothelium, muscle cells) rest 
and which plays an essential role in cell adhesion. Collagen-based biomaterials have 
been widely used for tissue engineering applications for a number of reasons, including 
biocompatibility, biodegradability, low immunogenicity and low antigenicity [25]. 
3.1.1.1.  Col lagen Biosynthesis  and Struc ture
Figure 2 shows a schematic representation of the collagen biosynthesis. The consensus 
sequence (glycine-X-Y)n gives rise to ɲ-chains, the peptide subunit, of the fibril-
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Extracellular matrix derived biomaterials: Molecularly defined ingredients and processing techniques
Figure 2 :  Car toonized scheme of  the synthesis  and s t ruc ture of  co l lagen.  As with all proteins, 
collagen mRNA is translated by ribosomes into individual polypeptides (pre-procollagen subunit) of 
which 3 assemble (procollagen) whilst undergoing post translational modification such as; hydroxylation, 
glycosylation and disulfide bond formation. The triple helix is formed and subsequently transported outside 
the cell where the N- and C-propeptides are cleaved off. The cleaved monomeric collagen (tropocollagen) 
is then involved in the self-assembly into collagen fibers with the characteristic quarter staggered array or 
banding pattern. The monomeric collagen overlaps approximately ¼ of each molecule, creating a dense 
and less-dense area, also referred to as the overlap D-periodicity. The monomers are subsequently fixed 
by crosslinks. In most cases the fibrils bundle and form larger collagen fibers.
1
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forming collagen helix (types I, II, III, V, and XI) [26]. The X and Y can be any amino 
acid however; the positions are frequently occupied by proline and hydroxyproline, 
respectively. The hydroxyproline and proline provide rigidity due to their unusual 
ring-like structure in the peptide backbone and force the peptide chain into a left-
handed helix. Three identical ɲ-chains (homotrimers in the case of e.g. collagen types 
II and III) or two or more different ɲ-chains (heterotrimers in the case of e.g. collagen 
types I and IV) are twisted together to form a right-handed triple helix. This triple 
helix is also known as tropocollagen and is, like DNA, stabilized by hydrogen bonds 
[26]. The smallest amino acid (glycine) allows tight packing of the three ɲ-chains and 
provides flexibility to the peptide backbone. Tropocollagen is the basic molecular 
unit of “collagen” with a general molecular weight of about 300 kDa, length of 280 
nm and width of 1.5 nm [27]. At the ends of the collagen molecule, there are areas 
characterized by a lack of hydroxyproline and proline and subsequent lack of triple 
helical structure. These ‘frayed’ ends of the collagen molecule are also referred to as 
the telopeptide regions (at both the N- and C-terminal ends). The telopeptide region 
is rich in lysine and hydroxylysine residues and has four main functions, namely: i) 
the stabilization of the molecule via intramolecular crosslinking, ii) the formation and 
stabilization of collagen fibrils via intermolecular crosslinking, iii) the crosslinking of 
points with other extracellular matrix proteins and iv) the formation of “sticky ends” 
by disulfide bonds to aid self-assembly [28]. The tropocollagen molecules assemble 
in a quarter-staggered fibril array, so that each molecule overlaps approximately 
one-fourth with its neighboring molecule (67 nm). This process repeats itself until a 
fibril of a certain dimension is formed. This phenomenon can be demonstrated under 
the transmission electron microscope, where a characteristic banding pattern of 
alternating light and dark striation can be seen. This characteristic banding pattern 
has a periodicity of 65-70 nm (depending on the tissue) and is also referred to as the 
D-period [29]. The overlapping arrangement of the collagen molecules are stabilized 
by the formation of intermolecular covalent crosslinks. Most crosslinks are formed 
between N- and C-telopeptide ends and certain residues within the triple helical part 
of other neighboring molecules. During fibril formation non-covalent and reducible 
crosslinks are also formed between the molecules, based on either lysine aldehydes 
(aldimine bonds), hydroxylysine aldehydes (ketoimine bonds) or a combination thereof 
[30]. During maturation of the tissue, these crosslinks are converted into non-reducible 
bonds [31]. The N-telopeptide is believed to play an important role in regulation of fiber 
thickness, although this process is not yet fully understood [32]. 
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Other insights in collagen synthesis have led the community to believe that the 
incorporation of other types of collagen (i.e. type V, IX, XII or XIV) or other non-
collagenous proteins during the fibril formation controls fibril thickness [33]. The fibril 
diameter and the distribution of different fibril dimensions is an important determinant 
of the mechanical properties of the tissue in question. Thick fibrils exhibit great tensile 
strength but are susceptible to creep (plastic-deformation). It has been suggested 
that thinner fibrils may be more efficient at inhibiting creep due to the larger surface 
area in contact with the rest of the matrix over which the shear stress dissipates [34]. 
Every tissue and inherent function has thus a specific distribution of collagen fibers 
with varying diameters [35]. Collagen fibrils can bundle to form even thicker collagen 
fibers [36]. These bundles of fibrils (fibers) are not connected to each other in a similar 
manner as the molecules within the fibrils. Instead the structure can be viewed as a 
highly interwoven set of fibrils/fibers [37].
3.1.1.2 .  Col lagen Appl icat ions
Collagen is regarded as one of the most versatile biomaterials in both hard and soft 
tissue engineering. Along with the mechanical and biological role in the ECM in both 
homeostasis and wound healing, the ubiquitous occurrence of collagen throughout the 
human body makes it an ideal candidate for use as a biomaterial. Due to its natural role 
in the ECM, type I collagen possesses worthy mechanical characteristics for a protein 
[38]. Fibrillar collagen is considered as a robust protein, which can endure relatively 
high temperatures and is, to a certain extent, resistant to corrosive processing 
chemicals like salts, acids, bases and detergents [39]. Its general robustness makes 
collagen compatible with many processing techniques. The properties of collagen 
can be influenced using chemicals, enzymes and physical processes like drying 
or heating [40]. For example, mechanical and biochemical characteristics can be 
modified by crosslinking (see section 4.7) or functionalized by covalent addition of 
glycosaminoglycans [41]. One of collagen’s unique properties is the reversible process 
of pH driven precipitation/fibrillation [42]. Collagen present at pH values where the 
net charge of the collagen molecules is either maximally negative or positive causes 
the molecules to repel each other and subsequently increase water uptake capacity. 
This phenomenon is referred to as ‘swelling’ and can be utilized in modification of its 
properties (see figure 3) [43]. Swollen collagen can be subjected to homogenization 
techniques to create a viscous fibrillar paste, which can then be formed into different 
scaffold types (see section 4). 
1
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Figure 3:  Revers ib le swel l ing and prec ip i tat ion of  co l lagen f ibers . A)  0.5% w/v swollen collagen 
fibril suspension in 0.25 M acetic acid at pH 3.0. B)  Collagen that was precipitated by neutralizing the 
suspension to pH 7.4. SEM images show C)  the acid swollen collagen and D)  the precipitated collagen after 
freezing and freeze-drying displaying either a porous or fibrous structure, bars are 10 ʅm.
Fibrillar collagen has been studied in numerous RM applications where biodegradability, 
porosity and mechanical strength were required [17, 44, 45]. Moreover, fibrillar 
collagen at an acidic pH can subsequently be digested to yield a truncated form of 
molecular collagen where the telo-peptide ends are cleaved using pepsin, resulting in 
atelocollagen [46]. This monomeric collagen resembles the native form of molecular 
collagen (acid soluble collagen) and both exhibit characteristics differing from fibrillar 
collagen. Molecular or monomeric collagen is completely soluble in water or acid and 
subsequently forms a viscous solution. Under physiological conditions (pH, solutes, 
temperature, etc.), fibrillogenesis can occur where de novo collagen fibrils are formed, 
in turn forming a hydrogel. Collagen hydrogels, or hydrogels in general, have a wide 
array of applications which are listed in section 4.2. Although successful in various 
applications, scaffolds based on monomeric collagen suffer from non-physiological 
small fibril dimension and poor mechanical strength [47]. Depending on the ultimate 
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goal, the previously discussed items should be taken into consideration when working 
with collagen as a biomaterial.
3.1.2.  Gelatin
Gelatin, a soluble protein derived from the unfolding or partial hydrolysis of collagen, 
is highly biocompatible and biodegradable in a physiological environment [48]. The 
conversion of collagen into gelatin, or also referred to as a helix-to-coil transition, 
has been extensively studied in various settings [49]. Basically, gelatin is a mixture of 
collagen ɲ-chains (single peptide chain), ɴ-chains (two ɲ-chains) and ɶ-chains (three 
ɲ-chains) or any intermediates thereof. Depending on the state of the collagenous 
material, be it in fibers, fibrils or single molecules, a combination of acids, bases and 
heat treatment can be used to break the covalent and non-covalent bonds in order to 
destabilize the collagen triple helix [50]. The treatment method subsequently affects 
the final properties and generally results in either of two types of gelatin, commercially 
known as type-A gelatin (acid treated, isoelectric point between pH 8 and 9) and type-B 
gelatin (base treated, isoelectric point between pH 4 and 5) [51]. Gelatin has a unique 
combination of properties for a protein, which make it a versatile biomaterial, i.e. from 
thermo-reversible gels to porous materials, films, capsules and electrospun fibers [52]. 
Gelatin is generally regarded as having low-antigenicity and the metabolic products 
thereof are harmless since collagen is normally degraded by proteolytic hydrolysis in 
the body [53]. Due to the aforementioned reasons, gelatin has been frequently used in 
drug carrier and delivery systems [54], as a plasma expander [55], wound dressing [56], 
medical device coating [57] and as a basis for RM applications in sponges, films and 
hydro/cryogels [58]. Gelatin has many applications within RM and is often combined 
with other carbohydrate-based biomaterials (e.g., chitosan, alginate and agarose) and 
an array of processing techniques (electrospinning, coacervation and crosslinking) [59].
3.1.3.  Elast in
Elastin is a vital ECM protein that provides elasticity to tissues and organs [60]. Elastin 
comprises up to 70% of the dry weight in elastic ligaments, 50% in large arteries, 30% 
in lung and 2-4% in skin, where the fibers are present as rope-like structures [61]. Its 
primary role is to allow tissues to undergo repetitive deformation and subsequently 
facilitate the return to its original dimensions when the force is released [62]. It is 
generally accepted that the spontaneous recoil of stretched elastin is entropic in origin, 
where in its extended mode all the energy is taken up by the polypeptide backbone 
and is recovered upon relaxation [63]. Water-soluble tropoelastin monomers are 
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alternatively spliced polypeptides with sizes ranging from 60-70 kDa. The monomers 
have characteristic alternating hydrophobic and crosslinking domains. When the 
tropoelastin molecules are transported outside the cell, the hydrophobic domains 
regulate the association with other tropoelastin molecules and the lysine and alanine-
rich hydrophilic domains ensure the presence of free amine groups for subsequent 
crosslinking by lysyl oxidase to form insoluble elastin [64]. Unique to elastin is the 
formation of desmosine and isodesmosine, where four (modified) lysine residues from 
two tropoelastin molecules react with each other to form tetrafunctional crosslinks [65]. 
Elastin molecules are abundantly crosslinked to stabilize the structure and induce the 
elastic coil properties. Elastin has also been identified as a signaling molecule, governing 
cellular responses like chemotaxis, proliferation and differentiation [66]. Elastin can 
interact directly with cells through different cell-surface receptors like the elastin/
laminin receptor which has been implicated in elastin assembly, cellular processes 
and interaction with other ECM components like GAGs, fibrillin and laminin [67]. 
Due to its versatility, elastin has been subject of investigation for use in RM applications. 
However, due the extensive crosslinking and subsequent insolubility, elastin is very 
difficult to manipulate limiting its use as a biomaterial. Elastin can be solubilized 
by enzymatic or chemical hydrolysis to make it more suitable for use in scaffolding. 
However, along with the solubilization, the elastin partially loses its mechanical 
properties. The soluble elastin can still functionalize biomaterials. Soluble elastin 
can be coated on natural or synthetic polymers to modify the surface hydrophobicity 
[68], decrease thrombogenicity [69], increase angiogenesis [70] and improve the 
cell adhesion properties [71]. Three-dimensional scaffolds have been made from 
solubilized elastin as a hydrogel-based material[72] or as an electrospun sheet or 
tube [73]. Incorporation of both soluble and insoluble elastin in scaffolds has been 
investigated for use in dermal [74] and vascular applications [75]. For more elaborate 
description of the applications of elastin-derived biomaterials the readers are referred 
to excellent reviews by Almine et al. [76], Daamen et al. [77] and Sivaraman et al. [78]. 
3.1.4.  Adhesive glycoproteins 
Cells adhere to the ECM through interaction between cell surface proteins and 
adhesive ECM glycoproteins, including fibronectins, laminins, fibrinogen, entactins, 
vitronectin, thrombospondins, tenascins, nephronectin, and others [79]. Most 
adhesive glycoproteins play an important role in the cell attachment, movement 
and differentiation [80]. Cell surface proteins (mostly integrins) recognize certain 
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domains within the adhesive glycoproteins for example the tripeptide sequence 
Arg-Gly-Asp (RGD). This sequence is crucial for the interaction of the adhesive 
glycoprotein with its respective cell surface receptor [81]. Next to cell surface proteins, 
adhesive glycoproteins possesses multiple binding domains capable of binding other 
ECM components like collagen, elastin, proteoglycans, GAGs and other adhesive 
glycoproteins [82]. This section will shortly describe the adhesive glycoproteins laminin, 
fibronectin and fibrinogen, which are of interest to RM applications. Other adhesive 
glycoproteins have received much less attention as of yet due to their relatively 
unknown role in organogenesis. These include vitronectins, thrombospondins, 
tenascins, entactins and nephronectin, which all have their specific effects on cell and 
protein binding, ECM remodeling and wound healing [83]. Moreover, glycoproteins can 
be involved in tissue transplant rejection and this should be taken into consideration 
in designing RM applications [84]. Taking specific peptide sequences responsible for a 
certain function of the respective proteins, e.g., adhesion, migration or proliferation, 
can circumvent immunogenic responses against these adhesive glycoproteins [85, 
86]. Next to the previously mentioned RGD, the YIGSR and IKVAV sequences are also 
used for cellular adhesion to surfaces [87, 88]. Also, short sequences from collagen [89] 
and proteoglycans [90] are being used in similar manners to controllably elicit desired 
cellular responses. Straightforward peptide chemistry could be used to synthesize 
functional short polypeptides. Hence, expensive preparation methods of full-length 
proteins such as purification from an animal sources or recombinant DNA techniques 
could be avoided.
3.1.4.1.  Laminin
Laminins are considered to be one of the major adhesive glycoproteins and are a 
main component of the basement membrane. Laminins are large heterotrimeric 
glycoproteins consisting of ɲ, ɴ and ɶ chains. Due to alternative mRNA splicing, different 
chains can be synthesized respectively. Around fourteen chain combinations have been 
described in vivo and each molecule is named according to their chain composition 
[91]. It is generally believed that the cross-like structure of laminin facilitates both cell 
adhesion as well as laminin sheet or basement membrane formation. Additionally, 
laminin has a high affinity for type IV collagen and heparan sulfate, which are also 
major components of the basement membrane [92]. Laminins generally play important 
roles in cell adhesion, migration, proliferation, neurite outgrowth, and angiogenesis 
[93]. Due to its high affinity for ECM components and cell surface proteins, laminin is 
widely used in the coating of cell culture surfaces or scaffolds [94]. 
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3.1.4.2 .  F ibronec t in 
Fibronectin shows functional similarities with laminin in its roles in the ECM. 
Fibronectin is a protein dimer produced from a single gene and consisting of nearly 
identical monomers that are linked by disulfide bridges. Each subunit contains three 
types of repeating modules (FN1, FN2 and FN3) linked by short connector modules. 
Due to alternative splicing, which is regulated by cell type and stage of development, 
differences in these subunits are induced and have resulted in over 20 types of human 
fibronectin variants [95]. Early on in ECM formation, fibronectin is assembled into 
a fibrillar network on the cell surface providing deposition points for fibronectin-
interacting ECM proteins like collagens, fibrin and heparan sulfate proteoglycans [96]. 
3.1.4.3.  F ibr inogen
The last major adhesive glycoprotein is fibrinogen. Fibrinogen is a large (349 kDa), 
soluble and complex protein consisting of three different subunits (Aɲ, Bɴ and ɶͿ
varying in amino acid length (610, 461 and 411, respectively) linked by disulfide bonds 
[97]. Fibrinopeptides on the soluble fibrinogen can be cleaved by thrombin to convert 
fibrinogen into insoluble fibrin. Fibrin molecules assemble to form a protofibril, which 
subsequently aggregate into larger fibers. A 3D network, or a fibrin clot, is formed 
which is capable of catching blood platelets to promote aggregation. This is essential 
for forming a hemostatic barrier and the newly formed network offers temporary 
scaffolding for cells involved in wound healing. Transglutaminase (factor XIIIA) 
crosslinks the glutamine and the lysine residues in the fibrin clot which temporarily 
stabilizes the network against chemical, mechanical and proteolytic degradation 
[98]. Fibrin, or forming fibrin clots, also has affinity for some plasma proteins such 
as fibronectin and albumin, which have influence on properties like fibril thickness 
and density [99]. Other (glyco)proteins like thrombospondin, von Willebrand factor 
and fibulin bound to the fibrin clot increase the affinity for blood platelets. Moreover, 
growth factors like FGF-2 and VEGF are also bound to stimulate swift remodeling of the 
damaged site. It is noteworthy, that because of the presence of other proteins, clots 
formed in vivo have different properties compared with clots formed with purified 
components.
3.1.4.4.  Appl icat ion of  Adhesive Glycoproteins 
Laminin, fibronectin and fibrinogen have received much interest from the RM 
community due to their innate role in wound healing and ECM formation [100]. Also 
their role in cell-cell and cell-ECM adhesion during both tissue growth and tissue 
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homeostasis makes them useful components in RM. Being a minor ECM component 
and potentially immunogenic, laminin is less suitable for use as a structural scaffolding 
but more so as a coating material. The most frequent use of laminin can be traced 
to in vitro culture of various cell lines and primary cells [101]. In RM of the central 
nervous system, both synthetic [102] and natural materials [103] have been coated with 
laminin to improve cellular compatibility [104]. Laminin has also been incorporated in 
hydrogels to improve cell adhesion in central nervous system [105], intervertebral disc 
[106] and pancreas [107] applications. As fibronectin also increases cellular adhesion, 
it has been used in similar applications as laminin [108]. Some effort has gone out 
to link fibronectin to biomaterials via laser patterning [109], chemical conjugation 
[110] and genipin crosslinking [111]. Fibronectin has also been used frequently in 
combination with fibrinogen as a scaffolding material [112]. Perhaps the most versatile 
of the adhesive glycoproteins is fibrinogen and/or fibrin. Due to its innate clotting 
ability after cleavage by thrombin, it is highly suitable for use as a surgical adjuvant in 
hemostatic, sealing or adhesive applications [113]. The use of fibrin in modern medicine 
has therefore received most attention and has been applied in the clinic extensively 
[114]. The versatility of fibrinogen/fibrin has been demonstrated by its compatibility of 
a wide range of scaffolding techniques including, but not limited to, hydrogel formation 
[115], electrospinning [116], coating [117], particulate leaching [118] and others. The use 
of fibrin has also been researched for nearly every RM application including adipose 
[119], bone [120], cardiac [121], cartilage [122], muscle [123], neural [124], ocular [125], 
respiratory [126], skin [127], tendon [128], ligament [129] and vascular tissue [130]. For 
further reading, several reviews of fibrin in RM are available [131, 132].
3.1.5.  Keratin
There are countless other proteins inside and outside the cell that were not discussed 
in the previous text. As proteins can be classified by their shape as for example fibrous 
or globular, the structural proteins are usually regarded as fibrous [133]. Despite being 
the main component of horse tail-hair, an early naturally occurring suturing material 
[134, 135], the fibrous protein keratin, has enjoyed only marginal research for RM 
applications. Keratins are epithelial-specific family members of the superfamily of 
intermediate filament structural proteins that are of paramount importance in the 
outer layer of the skin, hair, nails and horns. The keratin sub-family comprises of types I 
and II, of which respectively, 28 and 26 genetic variations are known. Keratins fulfill two 
main fundamental roles in epithelial cells where they provide structural support and 
participate in the regulation of metabolic processes like proliferation, migration and 
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apoptosis [136]. The soluble keratin monomers assemble into bundles and in turn form 
insoluble intermediate filaments [137]. The exact process of assembly remains unclear, 
but for further information the readers are referred to a review by Kölsch et al. [138]. 
Keratin has been considered as a biomaterial by several research groups due to several 
key features. For example, structures containing large amounts of the assembled 
keratin filaments are generally thermostable and possess great mechanical strength 
[139]. Evidence also suggest that keratin is biocompatible and does not induce obvious 
toxic effects both in vitro and in vivo [140]. Moreover, keratin-based biomaterials 
have an advantage in that they do not degrade by the same mechanisms as other 
proteins because of the lack of keratinases in mammals. The breakdown of keratin-
based biomaterials is regulated by phagocytosis and ubiquitin systems [141]. This 
subsequently allows keratin-based scaffolds to persist longer than other protein-
based scaffolds [142]. Keratin-based biomaterials in the form of sponges and films 
have been produced from wool and human hair for various biomedical applications 
such as wound dressings a neural tissue engineering applications [143, 144]. Keratin 
can also be processed into a hydrogel and has shown to support nerve cell migration 
and proliferation [145]. Keratin-based hydrogels in combination with commercially 
available nerve conduits have been used in small mammal studies to replace peripheral 
nerve segments and proved to be equivalent or more effective autografts [142, 146]. 
The use of keratin for its great mechanical strength has also attracted interest from 
the hard tissue arena, where it has also shown to a versatile biomaterial [147, 148].
3.1.6.  Proteoglycans and Glycosaminoglycans 
Proteoglycans (PGs) are a class of proteins that harbor one to many glycosaminoglycans 
(GAGs). A proteoglycan consists of a core protein to which GAGs are covalently attached. 
PGs influence and help regulate ECM assembly and collagen fibril formation [149]. 
This is important during inflammation, tissue repair and remodeling. Moreover, 
PGs play an important role in of a variety of tissues. PGs and GAGs contribute to the 
mechanical resilience of tissues by maintaining optimal visco-elastic characteristics, 
compressive stiffness and tissue homeostasis by sequestering water [150]. A number 
of other functions include regulation of coagulation, lipoprotein clearance in the 
liver, control of growth factor binding, and signaling. As in adhesive glycoproteins, 
PGs participate in both cell-cell and cell-matrix interactions. The attached GAGs 
largely determine the specific properties of a PG. GAGs are long, linear and strongly 
negatively charged polysaccharides, characterized by up to quantity hundred or so 
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 27
27
Extracellular matrix derived biomaterials: Molecularly defined ingredients and processing techniques
repeating disaccharides. GAGs can be either sulfated or non-sulfated which also largely 
determines the overall PG charge. 
Sulfated GAGs are usually classified into five types: heparan sulfate (HS) [151], heparin 
[152], chondroitin sulfate (CS) [153], dermatan sulfate (DS) [153] and keratan sulfate 
(KS) [154]. Hyaluronan (HA) is the only non-sulfated GAG [155]. Important PGs include 
perlecan (basement membrane, HS and CS) [156]; aggrecan (cartilage, CS) [157]; 
versican (connective tissue, CS and DS) [158]; neurocan and brevican (CNS tissue, 
CS) [159, 160]; biglycan, fibromodulin and decorin (collagen rich tissues, CS and DS) 
[161, 162]; bikunin (plasma, CS) [163]; lumican, keratocan, glypicans and syndecans 
(epithelial tissues and cornea, HS and KS) [164, 165]. GAGs also sequester a wide 
range of growth factors, consequently acting as a reservoir. Changes in physiological 
conditions, like trauma or infection, can trigger protease activities that cause local 
release of such depots allowing the rapid and local growth factor-mediated activation 
of cellular functions [166]. 
The structural diversity of the PGs and its respective GAG composition renders each 
PG and GAG unique in its biological function. Because of the ubiquitous presence of 
GAGs in healthy tissue ECM and their diverse functions in tissue homeostasis, GAGs 
have gained interests from biomaterial researchers. In RM, GAGs are frequently used 
to supplement existing scaffolds, made from natural materials, synthetic polymers or 
a combination thereof [167].
3.1.6 .1.  Hepar in and Heparan Sul fate 
Heparin and heparan sulfate (HS) are highly sulfated GAGs where heparin is associated 
with the highest negative charge density of any known biological molecule [168]. Native 
heparin and HS are, like other GAGs, polymers with varying molecular weight (10-70 
kDa and 7-20 kDa, respectively) [169]. They consist of disaccharide units of N-acetyl-
D-glucosamine and D-glucuronic acid, of which the latter sugar can be epimerized 
into L-iduronic acid during subsequent variable modification of the polymer. Other 
modifications include N-deacytelation/N-sulfation, 6-O and 3-O sulfation of the 
glucosamine and 2-O sulfation of the uronic acid. Alternatively, the glucosamine can 
have a free amine group on the C2 position instead, likely due to uncoupling of the 
N-deacetylation and N-sulfation [170]. Together with 3-O sulfation, this is the least 
prevalent modification. Heparin and HS are closely related due to the composition of 
the disaccharide structure, however the main difference being that heparin has about a 
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two-fold increase in N- and O-sulfation and subsequently two times its overall negative 
charge [171]. Whereas heparin is almost uniformly highly sulfated, HS contains domains 
of low, moderate and high sulfation [172]. The exact function of heparin and HS in the 
human body is still being elucidated but current literature holds plenty of evidence 
suggesting that they are both involved in a wide array of functions. Heparin is mainly 
produced and stored by basophils and mast cells, whereas HS can mainly be found 
on the cell surface and in the surrounding ECM. Heparin is used as a pharmaceutical 
anticoagulant. Medical devices that come into direct contact with the blood circulation 
are often coated with heparin to prevent blood clotting. Within the RM theme, heparin 
is utilized for its ability to bind an array of growth factors. Growth factors with heparin 
binding domains can be attached to heparin immobilized on a scaffold surface [173]. 
The attachment of heparin and subsequently heparin-binding growth factors like 
FGF2 and VEGF has shown to increase the angiogenesis in subcutaneously implanted 
collagen scaffolds [41]. Additionally, the attachment of heparin to (non-)biodegradable 
materials can influence the tissue response where the negative charge can influence 
the water holding capacity or the overall hydrophobicity of a construct. For further 
reading regarding the exact differences between heparin and HS the readers are 
referred to other sources [174, 175].
3.1.6 .2 .  Chondroit in Sul fate
Chondroitin sulfate consists of two alternating monosaccharides, D-glucuronic acid 
and sulfated N-acetyl-D-galactosamine. With a molecular weight ranging from 20-60 
kDa, CS is the most prevalent GAG in the human body and is an important component 
of cartilage where it plays a role in resistance of compressing forces [176]. CS comprises 
a group of 8 CS subtypes, CS-A, C, D, E, F, H, K, and O, of which the type is dependent on 
the sulfation pattern of the monosaccharides. The sulfations at different positions of 
the monosaccharide confer different biological activity to the CS-containing PG [177]. 
For example, in cartilage CS containing PGs like aggrecan are tightly packed with the 
collagen structure where the charged sulfate groups of the CS generate electrostatic 
repulsion that provides resistance to compression. For further details regarding 
the different subtypes the reader is referred to an overview [178]. The main medical 
application of CS lies in nutraceutical application for the treatment of osteoarthritis. 
Along with glucosamine, CS has been thought to pose anti-inflammatory properties 
although the possible underlying mechanism is poorly understood [179]. Within RM, 
CS has been subject of research for use in scaffolds to improve the biomechanical 
properties [180]. However, CS is currently mostly limited to osteochondral and cartilage 
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applications [181]. Like heparin (and HS), CS is able to bind growth factors and is 
therefore also able to modulate the bioactivity of the material [182]. CS has also found 
its way into a commercially available biomaterial application for skin regeneration by 
Integra Life Sciences, where a bilayer wound matrix consisting of type I bovine collagen 
bound CS and silicone is applied as a wound dressing [183].
3.1.6 .3.  Dermatan Sul fate
Dermatan sulfate is composed of disaccharide units consisting of N-acetyl-D-
galactosamine and glucuronic/iduronic acid. Like CS, DS is defined by the presence 
of N-acetyl-D-galactosamine, however, the presence of iduronic acid distinguishes it 
from CS. DS is the predominant GAG expressed in the skin but is also found in blood 
vessels, heart valves, tendons and lungs. Several processes involve DS as a co-factor 
or regulator of growth factors, cytokines, and chemokines [184]. Moreover, DS plays 
an important role in signaling in response to the coagulation cascade and cellular 
damage and subsequent regeneration of the fibrous ECM [185]. DS as a biomaterial or 
component of biomaterials have enjoyed little attention [16]. Several attempts have 
been made to study the in vitro effect of DS on chondrocyte, fibroblast and keratinocyte 
function [186]. It is possible that difficulties in procurement of large quantities have 
hampered widespread study of DS in TE/RM applications. For further reading regarding 
the function of DS, an extensive overview is given by Trowbridge et al. [187].
3.1.6 .4.  Keratan Sul fate
Keratan sulfate (KS) is relatively the simplest of the sulfated GAGs, consisting of 
repeating disaccharides composed of galactose and N-acetyl-D-glucosamine with 
sulfation at the 6-O positions. The size of KS is highly variable and can range from 2 to 
24 kDa [188]. KS is the major GAG in the cornea and can also be found in scar tissue of 
the central nervous system and in connective tissues like cartilage [189, 190]. During 
the formation of the cornea, KS interacts with collagen to assure the characteristic 
highly organized collagen fibril structure, which renders it transparent [191]. Like 
other GAGs, KS has water-binding capabilities and thus plays an important role in the 
maintenance of the transparency and general homeostasis of the cornea. The water 
binding in combination with fibrous proteins enables the tissue to endure mechanical 
wear and tear from compression and abrasion. KS has also been linked to the repair of 
corneal tissue where it is believed to paradoxically act as a cell de-adhesion molecule 
but also to facilitate the motility and attachment of the corneal epi- and endothelial 
cells [192, 193]. The application of KS in RM research has to date been limited to use as 
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coatings in cell culture to investigate cell motility [193]. However, synthetic analogues 
to proteoglycans (peptidoglycans) have been used more frequently in scaffold design 
[194]. For further reading please see literature on KS and the physical and biological 
aspects [195, 196].
3.1.6 .5.  Hyaluronic Acid
Hyaluronic acid, also referred to as hyaluronan or hyaluronate, is an anionic non-
sulfated GAG and is composed of repeating disaccharide units containing D-glucuronic 
acid and N-acetyl-D-glucosamine. HA is a major constituent of synovial fluid but is also 
found in connective, neural and epithelial tissues. HA is unique from other GAGs since 
it is non-sulfated, not attached to a core protein and has a greatly varying molecular 
weight which can range from 1 kDa to 10,000 kDa [197]. Like other GAGs, due to its 
negative charge, HA is able to bind large amounts of water which allow it to function as 
a space filler and biological lubricant of joints [198]. HA based applications have been 
used since the 1980s as a surgical aid for eye-related surgery. Since then it has been 
used in viscosupplementation treatments, where HA is injected to supplement synovial 
fluid in (osteo)arthritic joints [199]. Early in the 2000s, HA became a popular ingredient 
for cosmetic surgical applications like injectable fillers for facial wrinkles. In the last 
decade, HA has enjoyed gaining popularity as a biomaterial due to its biocompatibility 
and biodegradability in combination with its gel-forming capabilities. HA can be 
crosslinked directly using formaldehyde or divinyl sulfone to form a weak but stable 
hydrogel. However, HA can also be modified by attaching thiols, methacrylates and 
tyramines to create self-gelling systems [200, 201]. HA is also a component frequently 
used in combination with fibrous proteins like fibronectin and collagen [202].
3.2.  Non-mammalian-based ECM Materials
The biomaterial armamentarium is filled with many non-mammalian raw materials 
isolated from sources such as insects, (shell)fish, plants and microorganisms. In this 
section a selection of frequently used biomaterials is given, most of which are based 
on polysaccharides [203]. Countless mammalian proteins that have been successfully 
produced in transgenic expression systems, using both mammalian and non-
mammalian hosts, are omitted in this review.
3.2.1.  Si lk  Fibroin
Silk is a naturally occurring protein polymer produced by a wide variety of insects and 
arachnids [204]. The natural function of silk is generally to make webs, cocoons and 
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draglines. In its natural form, silk is composed of a filament core protein, silk fibroin, 
and can be coated with glue-like sericin proteins [205]. The composition of different 
silk types vary depending on the organism and subsequent function [206]. However, 
all silks have a similar structure composed of hydrophobic and hydrophilic blocks. The 
hydrophobic blocks are highly conserved and have a repetitive sequence of short-side 
chain amino acids. The hydrophilic blocks form ɴ-sheet structures and have more 
complex sequences that consist of larger side-chain and charged amino acids. The 
combination of the hydrophobic and hydrophilic blocks determines the mechanical 
properties [207]. It is due to the exceptional mechanical properties, that researchers 
in the field of biomaterials have gained great interests in harnessing its capabilities 
[208]. Additionally, depending on the exact species from which it is harvested, silk is 
thermostable up to 250°C which is extremely high for a protein structure [209]. Isolated 
silk fibroin is soluble in aqueous conditions which makes it compatible with many 
processing techniques [210]. The techniques used in combination with silk fibroin, 
ranges from simple casting and drying methods [211] to hydrogel formation [212] and 
from electrospinning [213] or fiber deposition [214] to microporous scaffolds made 
by salt leaching, gas foaming, freeze drying or freeze-thawing [215-217]. For further 
reading, please see elaborate reviews by Wang et al., Altman et al., Harkin et al. and 
Vepari et al. [208-210, 218].
3.2.2.  Alginate
Alginates (also referred to as algin or alginic acid) comprise a broad family of 
polydisperse linear anionic polysaccharides naturally found in brown seaweeds and 
consist of varying sequences of ɴ-D-mannuronic acid (M-blocks), ɲ-L-guluronic acid 
(G-blocks) or mixed sequences (MG-blocks) [219]. Typical alginate size ranges from 
500 – 5.000 residues per chain (100 – 1000 kDa) [220]. Alginate can chelate with divalent 
cations which results in ionic bond driven gelation, also referred to as the “egg-box-
model” [221]. The interaction is mainly driven by interaction of the G-blocks that form 
stronger bonds with the divalent cations than the M-blocks. Depending on the seaweed 
source and growing conditions, the ratio of mannuronic and guluronic acid can vary, 
thereby affecting the alginate biomaterial properties [222]. At this moment the exact 
sequence of alginate, if any, is unknown, and the differences can only be expressed as 
average values of amounts of the different M/G-block combinations. 
Mainly due to the simplicity of the ion driven gel-forming capacity under physiological 
conditions in combination with its low cytotoxicity, the biomaterial community has 
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taken great interest in alginate [223]. Alginate is versatile and can be subjected to other 
processing methods including, but not limited to, freeze-drying [224], electrospinning 
[225], 3D printing [226], and other chemical modifications or crosslinking methods like, 
phase transition [227], cell crosslinking [228], click reactions [229], and free radical 
photo-polymerization [230]. Moreover, due to its gelling properties, alginates are highly 
useful in the design of microspheres for delivery of cells, growth factors, genes and 
other drugs [231, 232]. A vast array of alginate-based scaffolds and other devices have 
thus been made, however most cells require peptide sequences to attach to certain 
surfaces (see figure 4). Since alginate is a polysaccharide it may require modification 
for certain cells to be able to adhere [233]. This can be achieved by attaching RGD or 
other peptides sequences to the alginate chains using carbodiimide crosslinking [234]. 
This technique couples the terminal free amine group of a protein sequence to the 
Figure 4:  A lg inate b iomater ia ls .  A)  Commercial alginate powder. B)  A 5% (w/v) alginate in phosphate 
buffer results in a viscous gel-like solution. C)  Various scaffold shapes can be prepared by exposing the 
alginate solution to divalent cations, ranging from tubes and gels to films and massive strands, bar is 1 cm.
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carboxylic group in alginate [235]. To further enhance the biocompatibility, alginate 
has been extensively used in combination with other biomaterials like decellularized 
ECM powder [236], GAGs [237], collagen [238] and other carbohydrates [239]. For further 
details regarding the extensive subject of alginates the readers are referred to several 
reviews [240-242].
3.2.3.  Chitosan 
Chitin can be found in natural sources ranging from invertebrates, fungi, algae and 
yeasts [243]. Chitosan is a linear polysaccharide derived from the partial deacetylation 
of chitin and is composed of N-acetyl D-glucosamine and D-glucosamine units [244]. The 
deacetylation of chitin can vary from 40% to 100% and the molecular weight depends 
on the source and preparation method (300 to 1000 kDa) [245]. The deacetylation is 
generally achieved by the use of chemical (alkaline) or enzymatic hydrolysis [246]. The 
chitosan properties can be affected by the degree of (de)acetylation which decreases 
the acetyl groups and increases the number of free amine groups on the C2 or C5 
position of the D-glucosamine molecules. 40% of the acetyl groups in chitin should 
be removed before it can be referred to as chitosan [247]. The resulting free amine 
groups in the chitosan structure can be protonated, making it more soluble than chitin 
at slightly acidic conditions [248]. The free amine groups makes chitosan a positively 
charged polysaccharide [249]. Additionally, since amine groups are often involved in 
ionic bonds and formation of covalent peptide bonds, it makes chitosan suitable for 
hybrid products with other protein-based and synthetic biomaterials [250]. 
Numerous studies focusing on chitosan and chitosan hybrid materials have indicated 
low cytotoxicity, biocompatibility and biodegradability [251]. These properties have 
attracted attention from the biomaterial community and have led to study of various 
applications in for example drug delivery [252], gene therapy [253], RM [254] and 
hemostatic applications [255]. For more detailed overviews please see these reviews 
[244, 256, 257].
3.2.4.  Other polysaccharides 
Next to the larger class of biomaterials being used for RM purposes, like GAGs, alginate 
and chitosan a group of polysaccharides such as dextran and cellulose, remain 
underutilized. The biological activity and biocompatibility of polysaccharides have 
been demonstrated in other applications dealing with various cell culture applications. 
However, polysaccharides are attracting attention due to their capability to form 
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hydrogels. Depending on the polysaccharide the hydrogel characteristics can vary 
and have uses in different areas. Glucose-based polysaccharide biomaterials include 
starch, dextran and cellulose, where the differences are noticed in the way the glucose 
molecules are bound or if they are linear or branched. Dextran has long been used as 
an antithrombotic agent by reducing the viscosity of blood. However dextran has also 
been mixed with other biomaterials to modify the gelation properties for scaffolds used 
in an array of applications [258-260]. Starch has also found its way as an ingredient of 
biomaterials that modify the stiffness of the scaffold in question [261, 262]. Cellulose is 
naturally a very strong and versatile polysaccharide and, due to its crystalline structure, 
has been mainly used for hard tissue engineering [263]. More complex polysaccharides 
like agarose and pectin consist of less ubiquitous saccharides like D-galactose and 
derivatives thereof in the case of agarose. Pectins consist of mainly D-galacturonic acid 
with appendant residues such as D-xylose, D-adipose and D-arabinose. Both agarose 
and pectin are slowly starting to find its way into biomaterials for RM [85, 264, 265].
4.  Techniques and major tools  for  scaf folding
Running parallel to the emergence of new biomaterial ingredients is the development 
of techniques to produce scaffolds or tissue engineered constructs from these very 
same ingredients. In comparison to decellularized materials, molecularly defined 
materials can be transformed into a wide array of shapes and sizes, often with a 
controlled morphology. This is also the main advantage in using molecularly defined 
ingredients, where the morphology can be adjusted to the application in question. 
Moreover, in contrast to decellularized materials, the increase in standardization and 
reproducibility should eventually lower the cost of production and thus the eventual 
treatment modality. In general, molecularly defined scaffolds possess morphological 
characteristics having a porous, hydrogel or fabric-like structure [266]. All types of 
scaffolds have their own advantages and limitations [4]. Ideally, the mechanical 
properties of the biomaterial in question should match those of the target tissue 
but should simultaneously passively or actively stimulate cell growth, migration 
and differentiation. Often an optimum between porosity and the correct mechanical 
properties is sought after. The porosity is important to the functioning of the scaffold 
because it impacts the ability of the cells to migrate and nutrients to diffuse throughout 
the scaffold. In this section different tools are described which can be used to create 
scaffolds from natural ECM-based sources with control over the morphology.
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4.1.  Porous Materials
Porous materials represent one of the largest classes of molecularly defined scaffolds 
currently being researched. Methods and fabrication technologies to produce porous 
scaffolds are widely available for both natural and synthetic polymers [267, 268]. Next 
to the obvious requirement that the scaffold should support cell growth, the idea 
behind the use of porous scaffolds consists of two main reasons where the pores should 
facilitate cell infiltration and the supply of nutrients. By inducing pore-like structures, 
the surface area of the scaffold is greatly increased and should subsequently allow 
for cells to create their own microenvironment. An important requirement inherent to 
porous scaffold is the interconnectivity of the pores, which absence would hamper cell 
infiltration and nutrients diffusion [269]. Next to the porosity and interconnectivity, the 
shape and size of pores are important to accurately mimic the target tissue. In the body, 
ECM structures often have special arrangements or alignments to cope with a certain 
function. Depending on the application, porous scaffolds have been used for countless
in vitro and in vivo RM studies. In the case of cartilage tissue, spatial differences in 
collagen fiber orientations provide the tissue with its properties: in the superficial 
Figure 5:  Porous scaf fo lds .  A)  Basic collagen scaffold made using a standard 6 well plate, freezing and 
subsequent freeze-drying, bar is 1 cm. B)  Collagen scaffold made in similar fashion but with a different mold 
consisting of a tube as outer container and a mandrel to create the lumen, bar is 1 cm. (C ,D)  SEM images of 
a basic porous collagen scaffold made using freezing and freeze-drying, bars are 1 mm in C and 100 ʅm in D. 
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zone collagen fibers are arranged parallel to the articular surface to optimally resist 
shear stresses during joint loading. In contrast, the orientation of collagen fibers in the 
deep zone is perpendicular to the articular surface, providing compressive strength 
to the tissue [270]. To impart porosity on biomaterials, e.g., porogens in combination 
with solvents [271], and phase separation in combination with solvent evaporation 
(precipitation [272], gas foaming [273], salt leaching [274], freezing and lyophilization 
[275]) are used. Novel techniques are emerging to make porous scaffolds, like stereo- 
and photolithography [276, 277]. An advantage of these processes is that they are 
promiscuous techniques, compatible with different materials and is easily adapted 
for straightforward scaling-up and subsequent lowered cost of production. 
Using collagen as an example, different porous scaffold types can be made using 
homogenization and subsequent freezing processes (see figure 5) [278]. The shape into 
which the collagen gel was cast prior to the freezing process mainly determines the final 
Figure 6:  Contro l l ing pore s t ruc ture.  A)  Influence of temperature on pore size of a collagen scaffold 
frozen at -20°C and at B)  -80°C, both bars are 100 ʅm. Microscopic C)  and macroscopic D)  appearance of a 
unidirectional collagen scaffold where the direction of the pores was controlled using directional freezing, 
pores are oriented from bottom to top. Bars are 100 ʅm and 1 cm, respectively.
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macroscopical morphology of a collagen-based porous scaffold. The ultrastructure of a 
porous scaffold can be created with freezing and freeze-drying using most ECM-based 
materials, which are either soluble or easily dispersible. Materials less compatible with 
this method may require other methods to impart porosity as previously mentioned.
The freezing temperature influences the formation of ice crystals (which become pores 
after lyophilization), including their size and orientation (see figure 6) [279]. In several 
tissues, the ECM is oriented either unidirectionally (e.g. cartilage) or radially (e.g. 
muscle fibers in the diaphragm). A scaffold with unidirectional pores can be created by 
applying a vertical temperature gradient to a collagen suspension (see figure 6), which 
mimics the ECM of healthy cartilage [278]. A similar principle can be applied to guide 
the generation of muscle cells in the correct orientation using a scaffold with a radial 
pore structure. This can be achieved by applying directional freezing from inside-out 
using a centrally positioned cooled tube [280].
4.2.  Hydrogels
Hydrogels are defined as insoluble, three dimensionally (crosslinked) polymer network 
structures composed of hydrophilic homo- or hetero-co-polymers, which have the 
ability to absorb significant amounts of water [281, 282]. As in porous biomaterials, 
hydrogels can be made from different natural and synthetic homo- and copolymers 
in combination with a variety of preparation methods. A key advantage of hydrogels 
is the preparation versatility, wherein the suspension can pre-seeded with cells before 
the hydrogel is formed, which results in homogeneous distribution [283]. The gels can 
be made using many materials e.g. collagen molecules [284], gelatin [285], elastin 
[286], alginate [287], silk-fibroin [288], cellulose [289], chitosan [290], hyaluronic acid 
[291] and others [58, 292]. However, hydrogels are generally soft structures lacking 
the mechanical properties necessary for many load bearing TE applications [293]. 
Hydrogels are mainly classified according to their physical structure; amorphous, 
semi-crystalline or hydrocolloidal [294]. The formation of the hydrogels is based 
on different techniques; covalent bonds produced by the reaction of one or more 
co-monomers, freeze-thaw cycles, physical crosslinks due to chain entanglement 
or enzymatic reaction, association bonds including hydrogen bonds or strong van 
der Waals interactions between chains, crystallites bringing together two or more 
macromolecular chains and de novo fibril auto assembly [295, 296]. Adjusting 
parameters like concentration, temperature or the application of shear forces or 
magnetic fields during the polymerization process (hydrogel formation) can influence 
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the structure [284, 297]. For further reading the following reviews are recommended 
[298-300].
4.3.  Fi lms and Coatings
Natural ECM components can be processed into thin films or coatings for other (bio)
materials. Several applications might require scaffolds, which are non-porous or, even 
impenetrable for liquids and/or gases. Films are generally regarded as thin, non- or 
low-porous scaffolds with interesting mechanical properties [301]. Coatings can 
often have the same composition as films, but are mainly intended to add certain 
properties, like hydrophilicity and biocompatibility, to other (bio)materials [302]. 
The film components can be varied and used in different combinations to adjust its 
properties like transparency, strength, elasticity, nano-porosity, biodegradability and 
biocompatibility [303, 304]. The science behind design and production of films from 
natural ECM components is often based on the knowledge gathered from synthetic 
or natural polymeric films [305, 306]. Synthetic film formation is frequently based on 
melting/dissolving and subsequent solidification of the polymer. However, the use of 
polysaccharides and relatively fragile proteins call for different approaches that avoid 
high temperatures and corrosive conditions. Soluble proteins and polysaccharides are 
often compatible with an array of techniques such as dip coating, spray coating, spin 
coating, or solvent casting and subsequent drying to produce films or to coat existing 
Figure 7:  F i lms and topography.  A)  Macroscopical image of a collagen film made by air-drying, bar 
is 1 cm. B)  SEM image of a collagen film, bar is 1 ʅm. C)  Surface topography induced by varying casting 
shape, bar is 1 ʅm. (D,E )  Another possible variation of surface topography, made to mimic the rete-ridge 
structure between the dermis and the epidermis, bars in D,E are 100 ʅm [314].
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(bio)materials. Films have been made from many different raw materials including, but 
not limited to collagen [307], gelatin [308], keratin [144], silk [209], alginate [309] and 
chitosan [301]. Due to their high transparency, films have frequently been used in TE of 
the cornea [310], but also for nerve regeneration [311], engineering of skin and adipose 
tissue [312, 313]. In some applications the films require certain structure or topography 
to stimulate directional growth and differentiation of the cells (see figure 7). Techniques 
have been developed which can induce structure using micro-molding [306], casting 
[314], and laser patterning [315]. For further details the readers are referred to reviews 
by Chen et al. and Wibowo et al. [316, 317].
4.4.  Meshes:  Spinnings,  knit tings,  and windings 
Synthetic polymer-based biomaterials are highly compatible with techniques that 
create meshes using for example electrospinning or fabric-based techniques like 
weaving, knitting or winding (see figure 8) [318]. Using biomaterial meshes in construct 
design has several advantages with respect to defined fiber alignment, adjustability, 
reproducibility and versatility. Synthetic polymer meshes have been readily used in the 
surgical arena for decades. Surgical meshes or knittings represent a group of implants 
mainly used for heavy-duty tissue repair, like herniations in the abdominal wall. Two 
major mesh concepts are distinguished, the classical concept including so-called heavy 
weight meshes with small pores and the newer concept including light weight meshes 
with large pores [319]. Techniques used to make these meshes often require corrosive 
chemicals and high temperatures, which can render them unsuitable for use with 
natural ECM components [320]. However, in the recent years, developments in this area 
have resulted in several options to make meshes from more natural ECM components. 
Electrospinning has received bulk of the attention. It is based on the difference in 
(electrical) potential applied to a negative or positively charged solvent containing 
the polymer and a oppositely charged collector surface during extrusion [321]. During 
this process different fiber dimensions can be formed and deposited on wide array 
of surfaces to create an interconnected network or a mesh [322]. Electrospinning 
has been used with natural ECM components like soluble collagen, gelatin, chitosan, 
chitin, cellulose and starch [323]. Due to the interchangeability of the collector surface 
and the possibility to rotate the surface during the electrospinning process allows for 
control over the fiber direction in 2D meshes and 3D tubular constructs [322, 324]. 
Other methods to create meshes from natural ECM components are often two-staged 
where first a fiber or strand should be extruded which can subsequently be processed 
into fabric-like meshes [325]. 
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Not all biomaterials can be extruded into a strand that is mechanically stable enough 
to undergo further processing [112, 326]. However, if a stable strand is formed, it can 
be turned into a fabric using knitting, weaving or winding. Depending on the target 
tissue, one can opt for making a flat mesh using knitting or weaving [327] and tubular 
meshes can be made using adapted knitting techniques or winding methods [328]. 
Different mechanical properties can be induced using different knitting, weaving and 
winding patterns. For example using the stockinette knitting technique, which induces 
anisotropic rigidity, tissues requiring particular mechanical properties in certain 
directions can be partially mimicked [329].
Figure 8 :  App l icat ions o f  kn i t ted po lymers  in  co l lagen scaf fo lds .  A)  A tubular knitting can be 
prepared from any biomaterial (in this case a synthetic polymer, polycaprolactone) that can be processed 
into a flexible strand. B)  A collagen tubular collagen scaffold without reinforcement. C)  A collagen scaffold 
where a biodegradable knitting was incorporated, bar is 0.5 mm.
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 41
41
Extracellular matrix derived biomaterials: Molecularly defined ingredients and processing techniques
4.5.  Computer control led fabrication
Parallel to the rapid advancements in the field of medical imaging, where high-
resolution 3D images of a defect can be easily acquired, runs the development of 
rapid prototyping techniques [330]. Rapid prototyping allows for the medical imaging 
data to be processed with computer-aided design and subsequently automatic 
manufacturing of three-dimensional objects layer-by-layer according to the virtual 
design. The utilization of rapid prototyping in RM enables the production of 3D scaffolds 
with intricate geometries and very detailed structures [331]. The resulting scaffolds 
can be customized and made to match each patient’s individual need [332]. Major 
rapid prototyping methodologies include 3D printing [333], multi-jet modeling [334], 
stereo-lithography [335], selective laser sintering [336] and fused deposition modeling 
[337]. These techniques are very promising for hard tissues since they are generally 
compatible with synthetic polymers that often require high temperatures and corrosive 
solvents [338]. Basically any form of lithography requires liquid-based materials which 
are sensitive to photo-polymerization [339]. Laser sintering and fused deposition 
techniques are generally based on temperature driven fusion (melting), which excludes 
the use of some natural ECM components. Up until now, printing techniques seem to 
be compatible with natural ECM components where researchers have managed to print 
for example collagen [340], gelatin [341], silk fibroin [342] and alginate [343]. Moreover, 
printing technology is also capable of producing patterns using bioactive ingredients 
such as growth factors [344]. In general, printing of the aforementioned biomaterials 
is less developed compared to the printing of synthetic polymers. Currently, problems 
like low resolution and low mechanical strength are being addressed. However along 
with the emergence of printing natural ECM components came the realization that the 
whole process could be conducted under aseptic/sterile conditions allowing for the 
addition of live cells. 
Many variations have been developed but the technique is often referred to as 
‘bioprinting’ or ‘cell printing’ [345]. The printing of single cells using common inkjet 
printer technology was useful for printing monolayers. Consequently, early efforts have 
focused on tissues like the skin where flat constructs were printed layer-by-layer using 
subsequent monolayer of cells and a hydrogel of choice [346]. A logical step forward 
encompassed the printing of cell aggregates or spheres. In this technique cells, in 
magnitude of thousands, are encapsulated in a hydrogel sphere and is subsequently 
printed into another hydrogel which keeps the spheres in place [347]. During culture the 
spheres fuse and the cells subsequently arrange in tissue like formations, subsequently 
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circumventing the need for high-resolution printing [348]. More advanced bioprinting 
techniques have been developed by switching from the inkjet principle to the laser 
printer generation technology, known as laser-assisted bioprinting [349]. More 
variations on computer aided scaffold production are emerging with each method 
baring its limitations. For more information regarding biomaterial printing the reader 
is referred to several reviews [350, 351].
4.6.  Decellularization
Biomaterials derived from natural tissues can be referred to as decellularized matrices 
or extracellular matrix scaffolds. This scaffolding strategy is based on the removal 
of cells and cellular antigens from the allogeneic or xenogeneic tissues (see figure 
9). However, the ECM components, which should be well tolerated by the immune 
system such as collagen, elastin, glycosaminoglycans and are preserved [352]. Over 
the past decades many decellularization methods have been developed [353]. These 
cell extraction methods can impart chemical, physical and enzymatic treatments or a 
combination thereof. Chemical treatments are aimed at disrupting the cell membranes 
and intra- and extracellular structural proteins. Frequently used chemicals include 
detergents [354] e.g., Triton x-100 [355], sodium deoxycholate [356] and sodium dodecyl 
sulfate [357]. Also acids [358] and bases [359], hypo- and hypertonic solutions [360], 
organic solvents [361] and chelating agents [362] can be applied in decellularization 
procedures. Enzymatic treatments are mainly based on enzymes possessing protease 
Figure 9 :  Methods to obtain decel lu lar ized scaf fo lds :  Cadaver organs, in this illustration a trachea, 
are exposed to a wide-array of chemical, biochemical and physical treatments aimed at removing all 
cellular components and unwanted proteins, effectively rendering native ECM. 
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and nuclease activity like for example ones falling within the family of trypsins [363], 
DNAses [364] and RNAses [365]. Physical methods to remove the cellular components 
can include sonication [366], high pressure [367], super-critical CO2 [368], freeze-
thawing [369], agitation [370], and mechanical abrasion [371].Tissues currently under 
investigation include but are not limited to pericardial membrane [372], trachea [373], 
blood vessel [374], kidney [375], tendon and ligament [376], heart [377] and heart valve 
[378], cornea [379], liver [380], small intestinal submucosa [381], lung [382], nerve [383], 
esophagus [384], bladder [385], adipose tissue [386] and skin [387]. 
The advantage inherent to decellularized materials is that they can be used to generate 
a largely identical structure and composition of extremely complex target tissues. 
Depending on the method of isolation, certain components may or may not be targeted 
for removal. For example the use of bases like sodium hydroxide are frequently used as 
a virus inactivation step, however also tend to inactivate growth factors and remove 
GAGs. Detergents like Triton X-100 and sodium dodecyl sulfate (SDS) effectively remove 
nuclear remnants and cytoplasmic proteins. Decellularization methods have thus to 
be carefully selected to balance the scaffold requirements with safety and efficacy. 
Affecting the collagen structure and GAG content may compromise mechanical integrity 
of scaffolds [388]. Decellularization agent remnants may have a toxicological effect 
on the cells, affecting the treatment efficacy [389]. Incomplete decellularization of 
the tissues may lead to the increased immunogenicity, ergo, increasing the possibility 
of eliciting an immune response [390-392]. Moreover, decellularized tissues are by 
nature highly variable as is the production process and it is difficult to show complete 
decellularization without compromising the structural integrity of the construct. 
Nonetheless, decellularized tissues make up a large part of the commercially available 
products. Several examples of FDA approved commercially available decellularized 
ECM scaffolds include; AlloDerm, AlloPatch, NeoForm and Graftjacket (all human 
dermis), Permacol, Strattice and Zimmer Collagen Repair Patch (all porcine dermis), 
TissueMend (fetal bovine dermis), MatriStem (porcine bladder), CuffPatch, OaSIS, 
Surgisis, Restore, FortaFlex and CorMatrix ECM (all porcine small intestinal submucosa), 
IOPatch (human pericardium), OrthAdapt and Unite (equine pericardium), CopiOs, 
Lyoplant and Perimount (all bovine pericardium) and, Hancock II, Mosaic, Freestyle, 
Prima Plus, Epic and SJM Biocor (porcine heart valve) [353]. The majority of the 
commercialized constructs are utilized in heart valves [393], dentistry [394], chronic 
wounds [395] and soft tissue reconstruction in general (hernias, burn wounds, organ 
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slings, etc.) [396, 397]. For further reading in commercially available biomaterials used 
in RM please see the excellent review by Keane et al. [183].
4.7.  Crossl inking
Many of the described natural ECM-derived biomaterials can be subjected to a wide 
array of processing methods to create a 3D construct or environment. However, 
depending on the biomaterial type, the construct can be mechanically unstable and 
subject to rapid degradation. Using crosslinking techniques to enhance the mechanical 
and enzymatic resistance, properties of a biomaterial can be stabilized for use at 
physiological conditions and subsequent implantation purposes. In its essence, 
crosslinking is defined as the formation of bonds within or between the biomaterial 
subunits in question [398]. In general, the bonds formed are mostly covalent, however 
in the case of alginate or chitosan, inducing ionic bonds using polycationic molecules 
can also be regarded as crosslinking [221].
Since the majority of the natural ECM-derived biomaterials are protein or carbohydrate 
based, many of the developed crosslinking techniques are based on creating bonds 
between reactive groups like carboxylic groups and amines. Other reactive moieties 
include but are not limited to sulfhydryl, hydroxyl and carbonyl groups. In general 
there are three types of crosslinking processes: physical, chemical and enzyme-based 
crosslinking. Physical crosslinking methods rely on either irradiation or the use of high 
temperatures. Irradiation can induce free radicals that in turn react with other chemical 
groups near by [399]. Irradiative sources mainly refer to ultra-violet wavelengths (UV) 
but also to gamma and beta irradiation [399, 400]. Thermal sources in combination 
with high vacuum can be used to induce the dehydrothermal crosslinking which allows 
for formation of covalent bonds [401]. Enzymatic crosslinkers like transglutaminase 
can be used to enhance tensile strength and enzymatic resistance of collagen-based 
biomaterials [402]. One should take into account that the enzyme should also be 
inactivated and subsequently removed from the biomaterial in most cases. The use 
of enzymatic crosslinkers can eliminate the risk of inducing cytotoxic effects [403]. 
The largest and most diverse group of crosslinkers are the chemical crosslinkers. 
Glutaraldehyde along with other aldehyde-based chemicals are the most applied 
chemicals to crosslink protein-based biomaterials [404]. The carbodiimide family 
is another class of chemicals used to induce crosslinking [405]. A key feature of this 
method is that some carbodiimides are categorized as zero-length crosslinkers. For 
example EDC (1-ethyl-3-(-3-dimethylaminopropyl carbodiimide hydrochloride) directly 
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couples primary amine groups to carboxylic groups without introducing a linker that 
may elicit an immune response (see figure 10). A less known member of the chemical 
crosslinkers is the isocyanate chemical family [406]. Recently, genipin a chemical 
crosslinker derived from fruit extracts, has shown potential because of its low toxicity 
[407]. In contrast to enzymatic crosslinkers, certain chemical crosslinking techniques 
can potentially form toxic residues or create crosslinks and subsequent metabolic 
products non-native to the human body [408, 409].
Figure 10:  Cross l ink ing col lagen using EDC and NHS:  (A ,B)  EDC and NHS catalyze covalent bindings 
between carboxylic acid and amine groups. Col: collagen. EDC: 1-ethyl-3-(-3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC). NHS: N-hydroxysuccinimide.
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4.8.  Steri l ization of  biomaterials 
Medical devices, such as ECM-based scaffolds, are made to be implanted in the patient. 
To avoid the risk of introducing microbes, viruses or other pathogens, sterilization is 
necessary. The sterilization process aims to reduce the amount of viable pathogens to 
an acceptable standard, since 100% sterility can never be guaranteed. The worldwide 
accepted standard for sterility of implantable medical devices is defined as the chance 
of finding a viable micro-organism in or on a medical device to be at most 10-6 [410]. 
Other pathogens like viruses, endotoxins or prions are not considered as micro-
organisms, and are difficult to remove. However, biomaterials treated with sodium 
hydroxide can reduce the viral load and decrease the chance of prions infection [411]. 
In this respect, it is important to reduce the risk of introducing these pathogens during 
the production processes of the medical device. This can be achieved by using animal 
sources that originate from strictly controlled environments, specifically aimed at 
preventing contact with specific pathogens. For instance, for bovine-derived materials, 
the EDQM (European Directorate for the Quality of Medicine & HealthCare) and FDA 
(Federal Drug Administration, USA) recommend the use of closed-herd cattle from 
countries that have a low-risk for bovine spongiform encephalopathy (BSE) such 
as Australia or New Zealand [412, 413]. Next to that, the production process of the 
ECM-based scaffold should be carried out in cleanroom facilities and under good 
manufacturing practice (GMP) guidelines. Next to these precautions, sterilization 
remains required to ensure acceptable sterility assurance level (SAL) values. Preferably, 
sterilization takes place after packaging to reduce the risk of contamination after 
sterilization.  
Sterilization methods are based on the application of an external stimulus, such 
as heat, ionizing radiation or reactive chemicals, that kills or inactivates the micro-
organisms, leaving the medical device functional. For medical instruments, heat 
sterilization (autoclaving) is often applied. However, biomaterials are not always 
resistant to heat, especially protein-containing materials are sensitive to high 
temperatures and therefore not autoclavable. Alternative sterilization methods based 
on chemicals or radiation are required for biomaterials. In this section the strengths 
and limitations of both approaches will be discussed in addition to highlighting some 
recent developments. 
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4.8.1.  Chemical -based ster i l izat ion
One of most frequently applied forms of chemical sterilization is the use of ethylene 
oxide gas. Microbiological inactivation by ethylene oxide is based on the alkylation 
of hydroxylic, amine and carboxylic groups of cellular components such as DNA or 
proteins [414]. The ECM-based scaffolds themselves can also be affected by this 
powerful sterilizing agent. A recent study of Matuska and McFetridge showed that 
ethylene oxide caused unfavorable structural damage to decellularized collagen 
scaffolds [415]. In addition, ethylene oxide can change the enzymatic degradation rate 
of collagen, although variable results have been found, e.g. decreased degradation 
of dermal sheep collagen [416] versus no effect on bovine type I collagen scaffolds 
[417]. Oxidizing agents such as peracetic acid or hydrogen peroxide are known for 
their efficiency to kill microbes by denaturing proteins and disrupting cell membranes 
[418]. An advantage of these sterilizers, frequently used together, is that they require 
a much shorter cycle time compared to ethylene oxide [419]. In addition, both have a 
low residual toxicity and degrade into non-toxic products, namely water, oxygen and 
carbon dioxide [420]. 
The removal of remnants of chemical sterilization from the scaffold is an important 
issue that should be taken seriously when applying chemical sterilization. As shown 
by Markowicz et al., hydrogen peroxide remnants in porous collagen scaffolds could 
still be detected after gas plasma sterilization [421]. For ethylene oxide, it is also known 
that remnants can be detected in medical devices after sterilization [422]. For each 
type of biomaterial, the bioavailability of the hazardous remnants must be evaluated.
Recent developments in the field of sterilization focus on the improvement of the 
delivery and removal of chemical agents in and out of the medical device. Supercritical 
carbon dioxide may provide an alternative means to deliver chemical sterilizers inside 
scaffolds. This supercritical fluid possesses physicochemical characteristics in between 
a gas and a liquid and therefore exhibits excellent diffusion properties [423]. It has been 
shown that supercritical carbon dioxide in combination with hydrogen peroxide could 
completely sterilize highly porous collagen sponges [424]. Another interesting physical-
chemical technique is gas plasma sterilization. With this technique, a substance is 
brought into the gas phase under vacuum. Next, an electric field is applied on the gas 
resulting in the formation of reactive species, which cause microbiological inactivation. 
In the pure form of this technique, the gas itself has no biocidal effect unless it is 
activated by the electric field [425]. Currently, gas plasma methods are mainly used 
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in combination with a reactive compound such as hydrogen peroxide or peracetic 
acid [426]. Gas plasma techniques can be used at low temperatures, do not generate 
toxic residues and are relatively rapid [427]. In addition, penetration properties of the 
chemicals are superior compared to their liquid counterpart. 
4.8.2.  Radiat ion-based ster i l izat ion
Another conventional sterilization technique is the usage of ionizing radiation such as 
gamma (ɶ) radiation and e-beam (beta, ɴ) radiation. ɶ-Radiation is generally known for 
its efficiency to inactivate microorganisms, however, also for its damaging effect on 
proteins [417, 428, 429]. Therefore, the scaffold and added bioactive molecules such as 
growth factors will always be affected. The addition of preservatives such as glucose 
during irradiation may reduce the side effects of ɶ-radiation by stabilizing the collagen 
molecules [430]. Next to ɶ-radiation, ɴ-radiation (electron-beam) can also be used. An 
advantage of this technique compared to ɶ-radiation is that dangerous radioactive 
sources such as cobalt-60 can be avoided. However, the limited penetration capacity 
of the ɴ-particles, make this technique less suitable for thick medical devices [431]. 
X-ray radiation, produced from an electron beam directed on an X-ray converter, could 
potentially be used to irradiate large packages. The high-energy photons damage living 
organisms by affecting DNA and other cellular structures. However, this technique is 
limited by the inefficiency of the conversion of electrons to high-energy photons, which 
makes the process very costly [411]. Recent developments in high-power and high-
energy electron accelerators may make this sterilization approach more attractive 
[432]. Next to ionizing radiation, microwaves may become applicable in the future. 
Shamis et al. reported the use of non-thermal microwaves for microbial inactivation 
[433]. Unfortunately, current results with doses that do not affect the biomaterial, are 
not in compliance with a SAL value of 10-6. Future research may clarify if this method, 
which avoids hazardous chemicals and radioactive sources, has potential.
4.8.3.  Biomaterial -specif ic  s ter i l izat ion 
Despite the efficiency of reactive chemicals and radiation to inactivate microbes, 
damage to proteins-based scaffolds is inevitable. Moreover, current research in the field 
of RM is focused on creating bioactive scaffolds that contain fragile molecules such as 
growth factors. Therefore, recent efforts focus on developing new technologies that are 
as effective as previously mentioned sterilization methods while avoiding the damaging 
effect on the biomaterial and proteins. In addition, more environmental-friendly 
methods, which are easier to use without the need for severe safety precautions, would 
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be beneficial. Sterilization will always affect the biomaterial and alter the physico-
chemical and mechanical properties of the scaffold itself. In some cases, the alterations 
of the biomaterial can be unfavorable or non-relevant with respect to clinical use, 
while in other cases it can even be used to modify the scaffold to its specific needs. 
Andrews et al. showed that ethylene oxide sterilization could roughen the surface of 
an electrospun scaffold and thereby manipulate cell contact, phenotype or function 
[434]. Also for a collagen-based scaffold, it was reported that sterilization could be used 
to modulate characteristics to favor cellular adhesion [415]. Furthermore, sterilization 
can serve as a tool to modify the biodegradability of the ECM scaffold. Kawasaki et al. 
showed that gamma sterilization influenced the bioabsorption time in vivo for a porous 
hydroxyapatite/collagen scaffold [435]. For clinical applications such as biodegradable 
sutures, gamma sterilization is already used to adjust the bio-absorbability [436]. The 
sterilization method of choice is highly dependent on the type of biomaterial and 
the intended application of the scaffold. Consequently, no perfect method exists 
and researchers have to search for the best alternative for their specific scaffold and 
application. Furthermore, issues surrounding sterilization should be taken into account 
early in the developmental process to make sure that the end-product can be sterilized 
safely and effectively.
4.9.  Regulatory Af fairs
An important issue concerning biomaterials is a frequent lack of adequate attention 
early in the R&D process pertaining the regulatory affairs. This complicated pathway 
can be a huge obstacle in the translation of ECM-based scaffolds to the clinic. Although 
the fundamental legislation is rather similar, most countries/continents have their 
own specific legislation, each with their own nuances. In a world of internationally 
conducted research the differences in legislation make the translational process even 
more difficult. Below a short overview is given on the regulatory affairs in the European 
Union and the United States. Acellular scaffolds generally fall within the category of 
medical devices according to different regulatory agencies. In Europe, medical devices 
are subdivided into four different classes, respectively I, IIa, IIb and III. Class III has the 
highest risk regarding safety issues and encompasses all implantable medical devices 
including scaffolds used in RM [437]. The legislation for medical devices in Europe is 
established by the European Commission and approved by the European Parliament 
(Directive 2007/47/EC). The daily execution of the regulation is controlled by so-called 
“Notified Bodies”, which can be private companies or foundations appointed by the 
European Commission [438].  
1
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A difficulty regarding regulation issues of ECM-based scaffolds is that they are often 
composed of components derived from animal sources. Derivatives of animal tissues 
may contain transmissible pathogens such as viruses, bacteria, endotoxins, and prions. 
Therefore, the European Union (EU) has developed extensive guidelines in order to 
minimize the risk of infectious disease transmission by medical implants / devices. 
In this respect, all relevant information about the animal source should be reported, 
such as -but not limited to- animal species, age, specific tissue used, country of origin, 
methods for health monitoring of the herd, and transportation condition. The F2027-
08 document of the American Society for Testing and Materials (ASTM) provides an 
excellent guidance for the use of biomaterials for the purpose of RM [439]. 
Next to detailed information about starting material, all details on the manufacturing 
process of the scaffold itself, the sterilization procedure, all test methods, test results, 
and acceptance criteria should be described and provided to the regulatory bodies. 
International Organization for Standardization (ISO) guidelines can be of great 
assistance for designing the manufacturing process and aim to ensure that medical 
devices are safe, reliable and of good quality. The regulation pathway for ECM-based 
scaffold is rather complex, however if (stem) cells are introduced in the scaffold, this 
will greatly complicate the regulation progress, since a complex viable entity is added 
instead of a single or a combination of compounds. For a single compound such as a 
growth factor, it can already be hard to predict the in vivo effects. For a complex cell, 
it will even be more complicated. In the EU, cellular scaffolds are classified under the 
advanced therapy medicinal products (ATMPs) and have a different and more complex 
legislation compared to acellular scaffolds, which are classified as medical devices. 
In the US the regulatory system is rather similar to the EU. The regulation for medical 
devices is controlled by the Food and Drugs Administration, specifically the Center for 
Biologics Evaluation and Research, a center within the FDA [440]. For further information 
about the differences in the regulation process between the US and European union, 
readers are directed to a review by Vinck et al. [441]. As the regulation and guideline 
issues surrounding ECM-based scaffold are very complex, most researchers do not 
have the proper knowledge to deal with it. To avoid foreseeable regulatory surprises, 
it is recommended to consult specialists in the field of regulatory issues early in the 
developmental process. These specialists can help researchers to avoid pitfalls and 
redundancy, subsequently accelerating the bench-to-bedside application of ECM-
based scaffolds. 
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5.  Summary and future perspectives
The ECM of the target tissues/organs not only serves as a structural blueprint but 
also as a toolkit for tissue engineers. The natural composition of the ECM provides 
valuable information regarding the properties a final construct or treatment modality 
should mimic. By examining the role of each ECM component in the natural tissue, 
engineers can set priorities as pertaining to which components are most important. 
Major ECM components like collagen, elastin and proteoglycans play important roles 
in the mechanical and biological properties of the natural tissue. Due to their fibrous 
nature, collagen and elastin have been used for providing mechanical strength to a 
construct, in addition to their effects on cell behavior. Depending on the application, 
the state of the collagen (gelatinous, monomeric, fibrillar or fibrous) and the spatial 
arrangement greatly affects the mechanical properties. For molecularly defined 
ECM-based constructs to succeed, control over the properties of the mechanical 
properties (mainly the collagenous fraction) should be increased. In chapters 3 and 6 
of this thesis, new techniques are described to adjust the biomechanical properties 
that mimic the ECM of the target tissue more closely. In most soft-tissue applications, 
other components like elastin and GAGs can be added to fine-tune the mechanical 
properties but will probably not be used in such quantity that it will take over the role 
of collagen as the main constituent. However, in load-bearing tissues such as cartilage, 
the water-sequestering GAGs will greatly affect the success rate of collagenous 
constructs by providing lubrication and shock absorbing capacity, which collagen 
naturally lacks. Even when the ideal mechanical properties have been attained, it 
will be important to ensure optimal biocompatibility, where the correct/desired cells 
are attracted and can subsequently adhere to the construct. Laminin, fibrinogen, 
fibronectin and type IV collagen are main components of the basal membrane that 
regulate cell attachment and related processes. Although not covered in this thesis, 
addition of other components besides collagen may be advantageous for e.g. proper 
cell attachment.
The true challenge for the tissue engineering society will be to cost-effectively create 
constructs with the required mechanical properties and bioactive components. 
Since sterilization of a construct is unavoidable, the mechanical properties should 
not be affected by this and ingredients should be able to fulfill their respective roles 
after sterilization. Difficulties caused by sterilization will greatly limit the speed and 
overall progress of ECM-based constructs in the near future. To make future treatment 
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modalities possible, knowledge regarding the techniques to produce different 
constructs is needed. The work described In this thesis focuses on the development 
of new technologies to prepare novel, collagen-based constructs.
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Abstract
Urethra repair by tissue engineering has been extensively studied in laboratory animals 
and patients, but is not routinely used in clinical practice. The objective of this review 
was to systematically investigate pre-clinical and clinical evidence of the efficacy of 
tissue engineering for urethra repair in order to stimulate translation of pre-clinical 
studies to the clinic.
A systematic search strategy was applied in PubMed and EMBASE. Studies were 
independently screened for relevance by two reviewers, resulting in 80 pre-clinical 
and 23 clinical studies of which 63 and 13 were selected for meta-analysis to assess 
side-effects, functionality, and study completion. Analyses for pre-clinical and clinical 
studies were performed separately. Full circumferential and inlay procedures were 
assessed independently. Evaluated parameters included seeding of cells and type of 
biomaterial.
Meta-analysis revealed that cell seeding significantly reduced the probability of 
encountering side-effects in pre-clinical studies. Remarkably though, cells were only 
sparsely used in the clinic (4/23 studies) and showed no significant reduction of side-
effects. ln 21 out of 23 clinical studies, decellularized templates were used, while in 
pre-clinical studies other biomaterials showed promising outcomes as well. No direct 
comparison to current clinical practice could be made due to the limited number of 
randomized controlled studies.
Due to a lack of controlled (pre-)clinical studies, the efficacy of tissue engineering for 
urethra repair could not be determined. Meta-analysis outcome measures were similar 
to current treatment options described in literature. Surprisingly, it appeared that 
favorable pre-clinical results, i.e. inclusion of cells, were not translated to the clinic. 
Improved (pre-)clinical study designs may enhance clinical translation.
Patient Summary:  We reviewed all available literature on urethral tissue engineering 
to assess the efficacy in pre-clinical and clinical studies. We show that improvements 
to (pre-)clinical study design is required to improve clinical translation of tissue 
engineering technologies. 
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1.  Introduction
Congenital birth defects of the urethra, such as hypospadias (1 in every 300 births) [1, 
2], and acquired urethral abnormalities, such as urethral strictures (1 in every 1,000 
men >65 years of age [3]), represent major clinical entities. Treatment usually involves a 
surgical procedure with risk of (recurrence of) strictures or fistula requiring additional 
care or reintervention. Whenever possible, local tissue flaps or stricture resection 
in combination with end-to-end anastomosis are used for urethra reconstruction 
[4, 5]. Generally, two surgical approaches exist for urethral reconstruction: partial 
replacements using onlay or inlay techniques or the full circumferential procedure, 
which is used in rare cases with significant urethral scarring or lichen sclerosis. 
Depending on patient and local factors, procedures can be performed as one-stage 
procedure or as planned multistage procedure [3]. Autologous tissue transplantation 
such as buccal mucosa or free skin grafts are the standard treatments [6-9]. However, 
due to the limited quantity of available donor tissue, accompanying donor site 
morbidity (16 to 32% for buccal mucosa grafts) and complications (e.g. recurrences or 
infections), alternative treatment options are needed to improve long-term outcome 
[10]. Tissue engineering may overcome some of the aforementioned disadvantages by 
providing a temporary template to guide tissue regeneration [11]. In general, tissue 
engineered templates include decellularized tissue or de-novo prepared materials 
from natural or synthetic origin [12-14]. Templates can be seeded with (stem) cells 
from the patient prior to implantation. These cells may stimulate tissue remodeling 
by excreting cytokines and growth factors and contributing to cellular population of 
the template [15, 16]. 
Despite the potential of tissue engineering shown in in vitro research and pre-clinical 
studies, clinical translation is limited. To improve translation, an evidence-based 
approach, such as systematic reviews, can be applied when designing new tissue 
engineering strategies. This will avoid unnecessary replication of studies and will 
help to select the most optimal experimental design and model. We are the first to 
perform a comprehensive systematic review of evidence for the efficacy of urethral 
tissue engineering in pre-clinical and clinical studies. A meta-analysis was used to 
compare different experimental designs based on clinically relevant outcomes. This 
systematic review aims to improve the translation of urethral tissue engineering from 
bench to bedside.
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2.  Evidence acquisit ion
2.1.  Literature search
To identify all available studies on urethral tissue engineering published and indexed 
up until June 1, 2016, a systematic search strategy was applied in PubMed (Appendix 
1) and Embase (via OvidSP; Appendix 2). This strategy combined a tissue engineering 
search component containing synonyms for tissue engineering related terms [17] with a 
customized search component for urethra or urethra-related diseases. MeSH terms and 
EMTREE terms were used in PubMed and Embase, respectively, together with separate 
words or word combinations in title or abstract. Next, either an animal filter designed 
by Hooijmans et al. (PubMed) [18] or de Vries et al. (Embase) [19] was applied (Appendix 
1 and 2, search component 3A) or a custom filter for clinical studies (Appendix 1 and 
2, search component 3B). In addition, retrieved reviews were screened for primary 
studies not found using the search strategy. Clinical studies found during animal search 
strategy were marked and screened for relevance and vice versa.
2.2.  Study selection
Duplicates in retrieved articles were removed in EndNote (Version X7.2, Thomson 
Reuters). Studies were assessed independently by LV and PdJ. First, clearly irrelevant 
studies were excluded based on title. Next, titles and abstracts of the remaining articles 
were screened for relevance in Early Review Organizing Software (EROS, Buenos Aires, 
Argentina, www.eros-systematic-review.org) using the following exclusion criteria: 1) no 
urethra, 2) no tissue engineering, 3) no animals or patient, 4) no primary study. A study 
was considered to be about tissue engineering when a processed template was used. 
Studies on tissue transplants or reconstructive surgery without the use of a template or 
without a urethra defect were excluded. Of the remaining studies full texts were screened 
using the same exclusion criteria. Articles not available as full text were excluded at 
this stage. No language restrictions were applied in the screening phase. If necessary, 
Google translate was used. Retrieved studies from search updates were directly screened 
in Endnote according to the same principles. In all stages of the selection process, 
discrepancies between reviewers were discussed until consensus was reached.
2.3.  Study characteristics
From all included studies, general information (author, year) and study characteristics 
(age range of patients, animal species, sex, surgical procedure, type of biomaterial, 
type of cells) were extracted and listed in Table 1 for pre-clinical studies and Table 
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 81
81
Tissue engineering of the urethra
2 for clinical studies. For languages other than English, German and French, Google 
Translate was used to retrieve study characteristics. 
2.4.  Ex traction outcome data
Three outcome measures were used to evaluate study outcome: 1) incidence of side 
effects, e.g. strictures, stenosis, fistulae, and infections, 2) functionality, defined as 
the ability to void with continence, and 3) study completion, for animals defined as 
survival until predetermined endpoint and for clinical studies as available for follow-
up or no additional urethroplasty required. Only English, German and French studies 
were considered for quality assessment and meta-analysis. When critical information 
needed (e.g. surgical procedure or number of animals/patients) was incomplete, 
studies were excluded. As only two studies used rats these were also excluded at this 
stage.
2.5.  Quality assessment
Due to the non-randomized, non-controlled nature of most pre-clinical and clinical 
studies, no standard risk of bias analysis could be performed as validated tools are 
unavailable for these types of studies. Instead, overall quality was independently 
scored by PdJ and LV based on the reporting of specific key information (Figure 2, 
Results section). Discrepancies were discussed until agreement was reached.
2.6.  Meta-analysis
The following main research question was considered: “What is the evidence for 
the efficacy of urethral tissue engineeing in pre-clinical and clinical studies?” Sub-
questions included the effects of the addition of (stem) cells to the template, the type 
of biomaterial, as well as potential differences between animal species on the separate 
outcome measures. Analyses for pre-clinical and clinical studies were conducted 
separately, as were full circumferential and inlay procedures. Statistical analyses were 
performed with SAS/STAT® software v9.2 for Windows, copyright© 2002-2008 by SAS 
Institute Inc., Cary, NC, USA.
2.6.1.  Pre -cl inical  s tudies
The following pre-clinical data were extracted for all available time points per study: 
the total number of animals as well as the number of animals without side effects, with 
functionality, and alive at the study endpoint. Time points were categorized in three 
periods: 0-4 weeks, 5-11 weeks and 12 weeks or longer. 
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Per study, the probability of response (e.g. having no side effects) with a corresponding 
95% exact (Clopper-Pearson) confidence interval (CI) was estimated per outcome. 
An additive random-effects logistic meta-regression model was fitted by means of 
a generalized linear mixed model approach. The number of responding animals out 
of the total was used as outcome parameter. In addition, the following independent 
parameters were used: treatment (combining the addition of cells and the type of 
biomaterial) and animal species. Random effects for study and for treatment grouped 
by study, were added. The Akaike Information Criterion [20] showed that models 
based on combined study data were preferable to models based on the period 
data (period as factor), therefore all time points per study were combined. When 
possible, the maximum likelihood approach with adaptive quadrature was used as 
estimation method. If this did not converge, the maximum likelihood with the Laplace 
approximation was applied. The resulting estimated odds were backtransformed 
into percentages and corresponding 95% CIs. In addition, the marginal effects of the 
treatments were estimated by combining the estimated percentages for rabbits and 
dogs, including 95% logit-based CIs, as described by Zou [21]. P-values were based on 
these confidence intervals.
2.6.2.  Cl inical  s tudies
For the analyses of the clinical outcomes, the following data per study were extracted: 
total number of patients, and numbers of patients without side effects, with 
functionality, and completing the study. No separate time points were analyzed in the 
human studies. For each study, the probability of response with corresponding 95% 
exact CIs was estimated per outcome. Due to limited study diversity, meta-regression 
models similar to pre-clinical studies were only fit for inlay repair and biomaterial type 
‘decellularized’. A compound symmetry random effect was added for the addition of 
cells, grouped by study. Estimated odds from meta-regression were backtransformed 
into probabilities and corresponding 95% CIs.
3.  Evidence synthesis
3.1.  Literature search and screening
Figure 1A and B show the results of the literature search and screening of collected 
studies. After the search, 1,524 unique pre-clinical and 5,361 unique clinical studies 
were identified. During title and abstract screening of these studies, 1,349 and 5,282 
were excluded, respectively. After full text screening, 80 pre-clinical studies and 23 
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Figure 1.  Flowchart of search and screening process of A)  pre-clinical studies and B)  clinical studies. The 
search was updated until June 1, 2016.
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clinical studies were included in the study characteristics table (see section 3.2). Only 
63 pre-clinical and 13 clinical studies were eligible for the quality assessment (section 
3.3) and meta-analysis (section 3.4). 
3.2.  Study characteristics
3.2.1.  Pre -cl inical  s tudies
Pre-clinical study characteristics are summarized in Table 1 at the end of this chapter 
(see Appendix 3 for references of listed studies). Only three animal species, rabbits 
(59/80), dogs (19/80) and rats (2/80) were used, which were predominantly males 
(72/80). Full circumferential repair was investigated in 41 studies, inlay repair in 30 
studies, both methods in three, while the procedure was unclear in the remaining 
studies (6/80). In dogs, primarily full defect repairs were performed (14 full vs. 4 inlay), 
while in rabbits both inlay (25) and full repairs (26) were employed.
Due to the wide variety of materials used, they were categorized into three categories: 
decellularized templates (46/80), de novo prepared templates from natural materials 
(18/80), and de novo prepared templates from synthetic materials (12/80). Four (4/80) 
studies used multiple material types in different groups and these were assessed 
separately in the meta-analysis. Synthetic materials were almost exclusively used for 
full repair (10 full vs. 3 inlay). Cells were incorporated into templates in 34 studies, 
of which bladder smooth muscle cells (SMCs) and urothelial cells were mostly 
used (13/34), followed by keratinocytes and fibroblasts from oral tissue (6/34) or a 
combination thereof (2/34), foreskin epidermal cells (2/34) and omental mesothelial 
cells (1/34). Stem cells, mostly derived from adipose tissue, bone marrow or human 
umbilical cord, were used in 10 studies. 
3.2.2.  Cl inical  s tudies
Study characteristics of clinical studies are listed in Table 2 at the end of this chapter 
(see Appendix 4 for references of listed studies). Clinical studies were performed with 
males, except for one study (Table 2, #22). From 23 studies, 16 used an inlay approach, 
two a full circumferential procedure, one used both approaches, while in four studies 
the procedure was unclear. The majority of studies (21/23) used decellularized 
templates, while natural and synthetic templates were both used once. Four studies 
used cell-seeded templates; 2/23 buccal mucosa keratinocytes and/or fibroblasts and 
2/23 bladder SMCs and/or urothelial cells.
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Figure 2 .  Quality assessment of pre-clinical and clinical studies. All studies included for meta-analysis 
were scored on clear reporting of several key parameters (Q1-Q21) showing that study design such as 
inclusion of proper control groups, associated randomization and blinding, reporting of key parameters 
such as representativeness of shown results and drop-outs needs to be improved in pre-clinical studies.
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3.3.  Quality assessment
The quality of reporting was assessed for 63 pre-clinical and 13 clinical studies from 
which outcome data could sufficiently be extracted for inclusion in the meta-analysis 
(Figure 2). Results per study are listed in Appendix 5. Reporting of information regarding 
included animals/patients, such as species and strain, sex, number of animals/patients, 
age/weight and patient inclusion criteria, were generally well described.
Overall quality of the experimental setup was poor. Although the different experimental 
groups were well described, hardly any control groups were present, and randomization 
and blinding were seldomly mentioned in both pre-clinical and clinical studies. Also, 
clinical study protocols were not published. However, surgical procedure, composition, 
size and preparation of the implants were clearly described in most studies. Reporting 
of outcome measures was good for both pre-clinical and clinical studies with respect to 
the description of outcome measures, follow-up time and side effects. The number of 
drop-outs was clearly mentioned in clinical studies, but only in half of the pre-clinical 
studies. For pre-clinical studies, histological sampling location and representativeness 
of the results were poorly described.
3.4.  Meta-analysis
3.4.1.  Pre -cl inical  s tudies
For full circumferential repair (Figure 3A), the addition of cells significantly reduced 
the probability of side effects, independent of the type of biomaterial used (p=0.001). 
Exact point estimates including CI are given in Appendix 6. Regarding the type of 
biomaterial, when no cells were used, estimates show that synthetic materials had a 
higher probability for having no side-effects compared to decellularized and natural 
materials. With cells seeded, estimated probabilities were similar for all materials. 
For functionality and study completion, estimated probabilities were similar for all 
study conditions.
For inlay repair (Figure 3B), the addition of cells significantly reduced the probability 
of side effects (p=0.003), albeit less than for full repair. Estimated probabilities were 
similar for all types of biomaterial regardless of the addition of cells. For functionality 
and study completion, estimated probabilities were similar for all study conditions. 
It was impossible to estimate study completion probability per biomaterial as almost 
all animals survived inlay repair (statistical model did not converge).
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F igure  3 .  Estimated probability including 95% confidence intervals for the absence of side effects, 
functionality and study completion for A)  full circumferential repair and B)  inlay repair in pre-clinical 
studies, both categorized for the use of cells and the type of biomaterial. C)  For the clinical studies, only 
decellularized material with or without cells could be analyzed. The effect of cells on the three outcome 
measures was calculated in estimated probabilities. Overall differences for cellular vs. acellular templates 
were determined for each outcome measure for both full and inlay repair: * p=0.003, ** p=0.001, all other 
differences were not significant (p>0.05). Specific point estimates and confidence interval are given in 
Appendix 6.
Although estimated probabilities for dogs and rabbits were slightly different, 
differences were not statistically significant. Consequently, the animal species had 
only marginal influence on outcome (data not shown). 
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Figure 4.  Number of publications per year for pre-clinical and clinical studies included in this systematic 
review. After several single studies between 1971 and 1994, the number of publications increased. Peaks 
in both clinical and pre-clinical studies were seen around 2005-2008 and again between 2012-2015. 
3.4.2.  Cl inical  s tudies
For clinical studies, a similar meta-analysis was performed (Figure 3C). Only inlay repair 
using decellularized materials with or without cells could be analyzed due to the limited 
number of other combinations. No statistically significant differences were found for 
the inclusion of cells for any of the outcome measures effects, p=0.7 for functionality 
(p=0.5 for side- and p=0.08 for study completion).
When comparing pre-clinical and clinical estimated probabilities, point estimates for 
absence of side-effects after inlay repair seem to be higher in clinical studies for both 
acellular and cellular templates. For functionality, the point estimates were similar. 
The estimated probability for study completion was much lower in clinical studies 
compared to pre-clinical studies regardless of the addition of cells, but these cannot be 
directly compared due to distinctive definitions for study completion and differences 
in disease status.
4.  Discussion 
Reconstructive surgery using biomaterials has been studied as an alternative approach 
for urethral repair since the early seventies and efforts along these lines expanded 
rapidly in the nineties when the term ‘Tissue Engineering’ was introduced (Figure 
4) [11]. Nowadays, pre-clinical studies have been readily performed, but clinical 
studies have not followed this trend. Although many (pre-)clinical studies have been 
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performed, tissue engineering is not used as an alternative treatment in routine clinical 
practice, except for a select patient group with a history of failed repairs [22-24]. In this 
systematic review, all (pre-)clinical publications on urethra tissue engineering until 
June 2016 were analyzed to assess the evidence for the efficacy. For clinical studies, 
the term “effectiveness” may be more suitable, as most studies included in this review 
showed a heterogeneous patient population [25]. However, we used the term “efficacy” 
for pre-clinical and clinical studies throughout this systematic review. For both pre-
clinical and clinical studies, tissue engineering had a high probability for functionality, 
defined as voiding with continence. Study completion was high in pre-clinical studies, 
but not in clinical studies. This may be related to the difference in our definition of 
study completion and in study design. In pre-clinical studies, animals generally only 
need to survive for several months to study the tissue regeneration process, compared 
to patients that need to show a good long term outcome without reintervention and 
without being lost in follow-up. Most patients had a history of failed repairs using 
conventional techniques, while healthy animals were used. As randomized clinical 
studies were lacking, e.g. comparison with standard treatments (free skin graft or 
buccal mucosa urethroplasty) [3], no direct comparisons with current clinical practice 
could be made. Available literature about complex two-stage urethroplasty shows 
complication-free rates, functionality and study completion of approximately 62%, 
67% and 36% [26], similar to the outcome of tissue engineered urethras (based on point 
estimates). This suggests that tissue engineered urethras may perform adequately and 
may be a valid alternative. Clearly, randomized controlled clinical trials are needed to 
clarify this issue. 
Application of cells
There is no consensus on the potential beneficial effects of cell seeding of tissue 
engineered constructs for the urogenital system. For tissue engineering of the bladder, 
the addition of cells did not give an overall beneficial effect on tissue regeneration [27], 
while others claim that cells are required for urethra repair of constructs >0.5 cm [28]. 
For urethra tissue engineering, the inclusion of cells significantly reduced side effects 
in pre-clinical studies for both full (p=0.001) and inlay (p=0.003) defects. In other, less 
comprehensive systematic reviews, a similar outcome regarding the effectiveness of 
the addition of cells was shown [29, 30]. For full defects, cell addition has more added 
value, which may be explained by the fact that cells can only infiltrate from the two 
urethra edges, while in inlay repair cell ingrowth can also occur from the sides, boosting 
cell coverage.
2
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 90
90
Chapter 2
The effects of cell addition on functionality and study completion were not significant, 
regardless of surgical procedure. This may be caused by the short follow-up period 
underestimating long-term complications, such as complete strictures. Meta-analysis 
of clinical studies showed no significant effect of cells for any of the outcome measures. 
Consequently, the use of cells for the repair of urethra in the clinic remains debatable.
Type of biomaterial 
Meta-analysis showed no differences in estimated probabilities for the different 
materials in most of the conditions, with the exception of synthetic materials showing 
better estimated probabilities than natural materials in full circumferential repair 
without cells regarding side-effects. For inlay repair in pre-clinical studies, synthetic 
materials did not perform as well as in full repair, but only a limited number of studies 
was reported. 
Decellularized materials were used in the vast majority of clinical studies. This may 
be related to the experience with decellularized materials in other fields of tissue 
engineering, such as skin tissue engineering [31]. Which type of biomaterial is superior 
to the current state-of-the-art remains to be established.
Selection of animal species
The choice of animal species is often based on financial issues, experience of the 
researchers, ethical arguments and practical restrictions [32-34]. An evidence-based 
approach can aid in selection of the most appropriate model. In this review, differences 
between treatment were not notably influenced by the choice for rabbit or dog, 
however a higher statistical power would strengthen this claim.
Clinical relevance and limitations of pre-clinical and clinical studies
Quality of the experimental designs and reporting of pre-clinical studies was generally 
low. Proper control groups, such as sham operation groups and standard treatment 
groups, were often lacking. Instead, the experimental material without cells was 
generally considered the control. In addition, outcome measures and drop-outs 
were not specifically reported for each animal, complicating data interpretation. 
Also, representativeness of presented data was often not mentioned. This may have 
hampered clinical translation of these pre-clinical findings. To improve this, all design 
parameters and outcomes should be specifically documented for individual animals 
similar to patients in clinical studies. The “Gold standard publication checklist to 
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improve the quality of animal studies” by Hooijmans et al. would be helpful for the 
design and reporting of pre-clinical studies [35].
Another limitation for the level of evidence provided by the pre-clinical studies is the 
use of healthy animals, in which a created defect is immediately closed, compared to 
patients with a history of stricture, lichen sclerosis or hypospadias. From the patients in 
clinical studies 75% had one or more previous treatments, e.g. dilation, urethrotomy or 
urethroplasty, before attempting the tissue engineered constructs. The requirement of 
animal models with injury or disease has been shown in other fields [36] and should also 
be considered in tissue engineering, in this particular situation by inducing strictures.
Clinical studies provided a low level of evidence due to their setup, making the true 
effect of tissue engineering as surrogate for the current standard treatment unclear. 
Only El-Kassaby et al. (Table 2, #3) performed a small randomized controlled study. 
To improve the level of evidence, more randomized controlled studies are needed, 
preferably with larger numbers of patients and longer follow-up. Compared to the pre-
clinical studies, reporting of important parameters was much better, notably regarding 
drop-outs and adverse events. Nevertheless, to further improve the quality of the 
clinical studies, the study protocol should be published with the manuscript and a 
detailed description of patient inclusion criteria (e.g. sex, age and medical history) 
should be provided.
The level of evidence is further limited by original research’s susceptibility to 
publication bias [37], which may lead to overestimation of the treatment effect in pre-
clinical studies. Recognition of this bias may partly explain the poor translation of 
tissue engineering techniques to the clinic. 
Furthermore, pre-clinical studies should better support the clinical need: the majority 
of pre-clinical studies involves full circumferential repair, where clinicians mainly 
perform inlay repair [3]. This may be explained by pre-clinical researchers attempting 
to prove the effectiveness of the experimental treatment for the most problematic 
(circumferential) procedures, assuming that it will also be effective in less complicated 
(inlay) approaches.
Finally, inclusion of cells remains challenging in a clinical setting as no beneficial 
effect was seen (in 11 patients), even though this significantly improved pre-clinical 
2
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outcome. It is possible that inclusion of cells was perceived as too problematic, 
despite better results in a pre-clinical setting and that in the final assessment the 
choice was driven by parameters other then pre-clinical outcome. To consider cells for 
clinical applications, its efficacy has to be proven as the use of cells involves extensive 
regulatory requirements which may hamper clinical application [38-40]. In addition, the 
costs of cellular implants will be higher compared to off-the-shelf acellular implants, 
since two procedures are needed (cell harvesting in urine or biopsy, and urethroplasty) 
and in vitro cell expansion may be needed [41, 42]. 
5.  Conclusions
The efficacy of tissue engineering for urethra repair could not be determined due to a 
lack of controlled (pre-)clinical studies. However, meta-analysis outcomes (side-effects, 
functionality and study completion) were comparable to current treatment options 
described in literature, indicating the potential of tissue engineering for urethra repair. 
The findings of this systematic review may result in improved study design which may 
aid the translation of tissue engineered urethras to the clinic as an alternative for 
autografts. 
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Author Year
Animal 
model
# of 
animals 
Sex
Surgical
Procedure
(defect 
length in mm)
Biomaterial 
(category)
Type of added 
cells
Quality 
Assessment 
+ Meta-
analysis
1 Feng, C. 2011 Rabbit 28 M Inlay (15)
Acellular corpus 
spongiosum, 
porcine (D)
Autologous 
corporal SMC’s 
and lingual 
keratinocytes
Yes
2 Ayyildiz, A. 2006 Rabbit 10 M Inlay (5)
Alloderm® 
+ acellular 
pericardium, 
bovine (D)
- Yes
3 Chen, F. 1999 Rabbit 10 M Inlay (10) BAM, porcine (D) - Yes
4 Chun, S.Y. 2015 Rabbit 10 M Inlay (20) BAM, porcine (D)
Autologous 
minced 
urethral 
muscle and 
urothelial 
tissue
Yes
5 Sayeg, K. 2013 Rabbit 18 M Inlay (35) BAM, porcine (D)
Autologous 
bladder SMC’s
Yes
6 Huang, J.W. 2014 Rabbit 30 M Inlay (15) BAM, rabbit (D) - Yes
7 Li, C. 2008 Rabbit 24 M Inlay (20) BAM, rabbit (D)
Autologous 
oral 
keratinocytes
Yes
8 Li, C. 2013 Rabbit 27 M Inlay (20) BAM, rabbit (D)
Autologous 
oral 
kereatincytes 
and TGF-ɴ
siRNA 
transfected 
fibroblasts
Yes
9 Li, H. 2014 Rabbit 36 M Inlay (20) BAM, rabbit (D)
Epithelial-
differentiated 
rabbit adipose-
derived stem 
cells
Yes
10 Wang, F. 2014 Rabbit 12 M Inlay (10)
Denuded amnion, 
human (D)
Rabbit 
urothelial cells
Yes
11
Kajbafzadeh, 
A.M. 
2014 Rabbit 12 M Inlay  (5)
Preputial acellular 
matrix, human (D)
- Yes
12 Kawano, P.R. 2012 Rabbit 24 M Inlay  (10)
SIS, 1- and 4 –layer, 
porcine (D)
- Yes
13 Guo, H. 2015 Rabbit 24 M Inlay (20) SIS, porcine (D)
Autologous 
keratinocytes 
and TIMP siRNA 
transfected 
fibroblasts
Yes
14 Kropp, B.P. 1998 Rabbit 8 M Inlay(10) SIS, porcine (D) - Yes
Table 1:  Study characteristics of all 80 pre-clinical studies sorted on inclusion in meta-analysis, surgical 
procedure and biomaterial.
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Author Year
Animal 
model
# of 
animals 
Sex
Surgical
Procedure
(defect 
length in mm)
Biomaterial 
(category)
Type of added 
cells
Quality 
Assessment 
+ Meta-
analysis
15 Rotariu, P. 2002 Rabbit 7 M Inlay (25) SIS, porcine (D) - Yes
16 Villoldo, G.M. 2013 Rabbit 15 M Inlay(10) SIS, porcine (D) - Yes
17 Shokeir, A. 2003 Dog 21 M Inlay (30) UAM, dog (D) - Yes
18 Huang, J.W. 2015 Rabbit 30 M Inlay (20) Cellulose (N)
Rabbit Lingual 
keratinocytes
Yes
19 Xie, M. 2013 Dog 10 F Inlay (50) Silk fibroin (N)
Autologous 
oral 
keratinocytes 
and fibroblasts
Yes
20 Xie, M. 2013 Dog 9 F Inlay (30) Silk fibroin (N) 
Dog urothelial 
cells
Yes
21 Sun, D. 2014 Rabbit 21 M Inlay (5)
Subcutaneous 
implanted 
autologous minced 
muscle (N)
Human 
umbilical cord 
MSC’s
Yes
22 Xu, Y. 2014 Rabbit 21 M+F Inlay (5)
Subcutaneous 
implanted 
autologous muscle 
microsomes (N)
Human 
umbilical cord 
MSC’s
Yes
23 Zhang, K. 2015 Rabbit 12 M Inlay (20)
P(LA/CL) + type 
I collagen in 
combination with 
ICG-001 (Wnt-
pathway inhibitor) 
(S)
Rabbit bladder 
urothelial cells
Yes
24 Wang, D.J. 2015 Rabbit 24 M Inlay (5) Polylactid acid (S) Rabbit AdSC’s Yes
25 Kelami, A. 1971 Dog 10 M Inlay (30)
PTFE (S) + 
lyophilized dura, 
human (D)
- Yes
26 Chung, Y.G. 2014 Rabbit 8 M Inlay (20)
Silk fibroin (N) + 
SIS (D)
- Yes
27 Lv, X. 2016 Rabbit 18 M Inlay (15)
Silk-Keratin-
Gelatin-Calcium 
peroxide (N) + SIS, 
porcine (D)
- Yes
28
Nuininga, 
J.E. 
2003 Rabbit 18 M Inlay (10)
SIS, 1 - and 4 - 
layer, porcine (D) + 
Type I collagen (N)
- Yes
29 Zhang, Q. 2008 Rabbit 12 M Full (10)
Acellular amnion, 
human (D)
Homologous 
endothelial 
progenitor 
cells
Yes
30
Parnigotto, 
P.P. 
2000 Rabbit 12 M Full (10)
Acellular aorta, 
rabbit (D)
- Yes
Tab le 1  (cont inued) :  Study characteristics of all 80 pre-clinical studies sorted on inclusion in meta-
analysis, surgical procedure and biomaterial.
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Author Year
Animal 
model
# of 
animals 
Sex
Surgical
Procedure
(defect 
length in mm)
Biomaterial 
(category)
Type of added 
cells
Quality 
Assessment 
+ Meta-
analysis
31
DeFilippo, 
R.E 
2002 Rabbit 24 M Full (10) BAM (D)
Autologous 
bladder SMC’s 
and urothelial 
cells
Yes
32 El-Tabey, N. 2012 Dog 14 F Full (30) BAM (D)
Autologous 
bladder SMC’s 
and urothelial 
cells
Yes
33 Wang, J.H. 2013 Rabbit 18 M Full (30)
BAM with 
polylactid acid 
–glycolic acid with 
VEGF (D)
- Yes
34
DeFilippo, 
R.E. 
2015 Rabbit 15 M Full (30) BAM, porcine (D)
Autologous 
bladder SMC’s 
and urothelial 
cells
Yes
35 Dorin, R.P 2008 Rabbit 12 M Full (5-30) BAM, porcine (D) - Yes
36 Orabi, H. 2012 Dog 21 M Full (60) BAM, porcine (D)
Autologous 
bladder SMS’s 
and urothelial 
cells
Yes
37 Fu, Q. 2007 Rabbit 18 M Full (15) BAM, rabbit (D)
Autologous 
foreskin 
epidermal cells
Yes
38 Fu, Q. 2008 Rabbit 18 M Full (15) BAM, rabbit (D)
Autologous 
foreskin 
epidermal cells
Yes
39 Gu, G.I. 2012 Rabbit 18 M Full (15) BAM, rabbit (D)
Autologous 
mesothelial 
cells
Yes
40 Li, C.L. 2013 Rabbit 30 M Full (30) BAM, rabbit (D)
Autologous 
bone-marrow 
derived MSC’s 
and SMC’s
Yes
41 Li, B. 2013 Rabbit 12 M Full (15)
Frozen-thawed 
bladder mucosa, 
dog (D)
- Yes
42 Kjaer, T.B. 1976 Dog 9 M Full (30)
Lyophilized vein, 
dog (D)
- Yes
43 Shokeir, A. 2004 Dog 14 M+F Full (30) UAM, dog (D) - Yes
44 Sievert, K.D. 2001 Rabbit 14 M Full (8-11)
UAM, dog and 
rabbit (D)
- Yes
45 Sievert, K.D. 2000 Rabbit 30 M Full (8-11) UAM, rabbit (D) - Yes
46 Lv, X. 2016 Dog 18 F Full (20)
Bacterial cellulose 
+ potato starch (N)
Dog lingual 
muscle cells
Yes
Tab le 1  (cont inued) :  Study characteristics of all 80 pre-clinical studies sorted on inclusion in meta-
analysis, surgical procedure and biomaterial.
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Author Year
Animal 
model
# of 
animals 
Sex
Surgical
Procedure
(defect 
length in mm)
Biomaterial 
(category)
Type of added 
cells
Quality 
Assessment 
+ Meta-
analysis
47 Gu, G.I. 2010 Rabbit 9 M Full (15)
De-novo created 
tissue in peritoneal 
cavity (N)
- Yes
48 Jia, W. 2015 Dog 10 M Full (50)
Type I collagen 
scaffold +/- 3VEGF 
(N)
- Yes
49
A. Da Silva, 
L.F. 
2014 Rabbit 16 M Full (10)
Type I collagen, 
bovine (N)
Autologous 
bladder SMC’s
Yes
50
Nuininga, 
J.E. 
2010 Rabbit 32 M Full (10)
Type I collagen, 
bovine (N)
- Yes
51 Kanatani, I. 2007 Rabbit 28 M Full (15)
Type I collagen, 
porcine + P(LA/
CL) (N)
- Yes
52 Micol, L.A. 2012 Rabbit 16 M Full (10)
Type I collagen, rat 
tail (N)
Autologous 
bladder SMC’s
Yes
53 Mikami, H. 2012 Dog 10 M Full (20)
Type I collagen, rat 
tail (N)
Autologous 
oral epithelial 
and muscle 
cells
Yes
54 Italiano, G. 1997 Rabbit 14 M Full (15)
Hyaluronan benzyl 
ester (S)
- Yes
55 Italiano, G. 1998 Rabbit 4 M Full (15)
Hyaluronan benzyl 
ester (S)
- Yes
56 Fu, Q. 2014 Dog 18 M Full (15) PGA (S)
Oral mucosal 
epithelial cells 
and AdSC’s
Yes
57 Hakky, S.I. 1977 Dog 15 M Full (50)
Polyethylene 
terephthalate (S)
- Yes
58 Hakky, S.I. 1977 Dog 9 M Full (50)
Polyethylene 
terephthalate (S)
- Yes
59 Olsen, L. 1992 Dog 6 M Full (30-40)
Polyglactin fiber 
coated with 
polyhydroxybutyric 
acid (S)
- Yes
60 Anwar, H. 1984 Dog 10 ? Full (25) PTFE (S) - Yes
61 Dreikorn, K. 1979 Dog 12 M Full (30-80) PTFE (S) - Yes
63 El-Assmy, A. 2004 Rabbit 18 M
Inlay + Full 
(15)
SIS (D) - Yes
64 Wang, Y.Q. 2005 Rabbit 14 M Inlay (10) BAM, human (D) - No (CN)†
65 Beintker, M. 2007 Rat 20 M Inlay (?) SIS (D) - No*
66
Glybochko, 
P.V.
2014 Rabbit Unknown M Full (?)
Acellular artery, 
human (D)
- No (RU)†
Tab le 1  (cont inued) :  Study characteristics of all 80 pre-clinical studies sorted on inclusion in meta-
analysis, surgical procedure and biomaterial.
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Author Year
Animal 
model
# of 
animals 
Sex
Surgical
Procedure
(defect 
length in mm)
Biomaterial 
(category)
Type of added 
cells
Quality 
Assessment 
+ Meta-
analysis
67 Peng, W.B. 2013 Rabbit Unknown M Full (25) BAM (D)
Rabbit hair 
follicle stem 
cells
No (CN)†
68 Hu, Y.F. 2008 Rabbit 30 M Full (10-15) UAM, rabbit (D) - No‡
69 Hu, Y.F. 2009 Rabbit 20 M Full (10-15) UAM, rabbit (D) - No (CN)†
70 Yang, S.X. 2004 Rabbit 30 M Full (10-15) UAM, rabbit (D) - No‡
71 Lebret, T. 1994 Rat 7 F Full (?)
Type IV collagen, 
human (N)
- No*
72 Fu, W.J. 2009 Rabbit 32 M Full (10-15) PLLA (S)
Autologous 
urothelial cells
No‡
73 Verit, A. 2003 Dog 2 M Full (10) PTFE (S) - No (TR)†
74 Huang, X. 2006 Rabbit 12 M Inlay + Full (?) SIS, porcine (D) - No (CN)†
75 Fu, Q. 2006 Rabbit 12 M
Unclear (10-
30)
BAM, rabbit (D) - No (CN)†
76 Xu, L.S. 2007 Rabbit 48 M Unclear (?) UAM, porcine (D) - No‡
77 Han, P. 2009 Rabbit 24 M Unclear (20) UAM, rabbit (D)
Rabbit bladder 
SMC’s
No (CN)†
78 Huang, H.J. 2007 Rabbit 48 M Unclear (?) UAM, rabbit (D)
Rabbit bone 
marrow 
derived MSC’s
No (CN)†
79 Zhang, Y. 2011 Rabbit Unknown M Unclear (?) Silk fibroin (N) Rabbit AdSC’s No (CN)†
80 Liu, C. 2008 Dog 12 M
Unclear (15-
30)
Silk fibroin (N) - No (CN)†
† Excluded from meta-analysis due to language restrictions defined in section 2.5.
* Excluded from meta analysis because only two studies used rats (insufficient for statistical analysis).
‡ Excluded from meta analysis due to unclear experimental setup.
? = unclear, AdSC = adipose-derived stem cells, BAM = bladder acellular matrix, CN = Chinese, D = decellularized, MSC = 
mesenchymal stem cells, N = natural, P(LA/CL) = copoly(L-lactide/࠱-caprolactone), PTFE = Polytetrafluoroethylene, RU = 
Russian, S = synthetic, SIS = small intestinal submucosa, SMC = Smooth muscle cell, TR = Turkish, UAM = urethral acellular 
matrix, VEGF = vascular endothelial growth factor.
Tab le 1  (cont inued) :  Study characteristics of all 80 pre-clinical studies sorted on inclusion in meta-
analysis, surgical procedure and biomaterial.
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Table 2:  Study characteristics of all 23 clinical studies sorted on inclusion in meta-analysis, surgical procedure and biomaterial.
Author Year Number 
of 
patients
Sex Age 
range
Number 
of 
patients 
with 
prior 
surgery
Surgical 
procedure 
(defect 
length in 
mm)
Biomaterial 
(category)
Availability 
biomaterial
Type of 
added cells
Quality 
Assessment 
+ Meta-
analysis
1 Atala, A. 1999 4 M 4 – 20 y 4
Inlay (50-
150)
BAM, human (D) Exp - Yes
2 El-Kassaby, A.W. 2003 28 M 22 – 61 y Unknown
Inlay (15-
160)
BAM, human (D) Exp - Yes
3 El-Kassaby, A.W. 2008 15 M 21 – 59 y 9
Inlay (20-
180)
BAM, human (D) Exp - Yes
4 Le Roux, P.J. 2005 9 M 15 – 56 y 5
Inlay (10-
50)
SIS, porcine (D) Com - Yes
5 Palminteri, E. 2006 20 M 20 – 74 y 16
Inlay (20-
80)
SIS, porcine (D) Com - Yes
6 Donkov, I.I. 2006 9 M 26 – 45 y 5
Inlay (40-
60)
SIS, 4-layer, 
porcine (D) 
Com - Yes
7 Fiala, R. 2007 50 M 45 – 73 y Unknown
Inlay (40-
140)
SIS, 4-layer, 
porcine (D)
Com - Yes
8 Orabi, H. 2013 12 M 1.5 – 15 y 3
Inlay (15-
35)
SIS, 4-layer, 
porcine (D)
Com - Yes
9 Xu, Y.M. 2013 28 M 2 – 69 y 28
Inlay (35-
70)
SIS, 4-layer, 
porcine (D)
Com - Yes
10 Hauser, S. 2006 5 M 61 – 80 y 5
Inlay (35-
100)
SIS, 1- and 4 –
layer, porcine (D) 
Com - Yes
11 Osman, N.I. 2014 5 M 36 – 66 y 4 Inlay (?)
De-epidermised 
dermis, human (D) 
Exp
Autologous 
buccal 
mucosa-
derived 
keratinocytes 
and 
fibroblasts
Yes
12 Fossum, M. 2012 6 M 14 -44 m Unknown Inlay (?)
Acellular skin, 
human (D) 
Exp
Autologous 
urothelial 
cells
Yes
13 Raya-Rivera, A. 2013 5 M 10 – 14 y 2
Full (40-
60)
Polyglycolic acid 
and poly-(lactide-
co-glycolide acid) 
(S)
Exp
Autologous 
bladder 
SMC’s and 
urothelial 
cells
Yes
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Table 2 (cont inued):  Study characteristics of all 23 clinical studies sorted on inclusion in meta-analysis, surgical procedure 
and biomaterial.
Author Year Number 
of 
patients
Sex Age 
range
Number 
of 
patients 
with 
prior 
surgery
Surgical 
procedure 
(defect 
length in 
mm)
Biomaterial 
(category)
Availability 
biomaterial
Type of 
added cells
Quality 
Assessment 
+ Meta-
analysis
14 Bhargava, S. 2008 5 ? Unknown 5 Inlay (?)
De-epidermised 
dermis, human (D)
Exp
Autologous 
buccal 
mucosa-
derived 
keratinocytes 
and 
fibroblasts
No #
15 Carpenter, C.P. 2012 1 M 68 y 1 Inlay (25) Alloderm® (D) Com - No‡
16 Kim, J.Y. 2005 1 M 48 y 0 Inlay (40) Alloderm® (D) Com - No‡
17 Mantovani, F. 2003 1 M 72 y 1 Inlay (?) SIS, porcine (D) Com - No‡
18 Lin, J. 2005 16 M 18 – 46 y Unknown Full (?)
Acellular skin, 
human (D) 
Exp - No (CN)†
19 Villavicencio, H. 1989 22 ? 28 – 80 y Unknown
Inlay + full 
(?)
Lyophilized dura, 
human (D)
Exp - No (ES)†
20 Glybochko, P. 2015 1 M 64 y Unknown Unclear (?)
Acellular artery, 
human (D)
Exp
Autologous 
buccal 
mucosa-
derived 
keratinocytes
No (RU)†
21 Yang, W.Z. 2011 8 M 4 – 23 y 0 Unclear (?)
Acellular skin 
human (D)  
Exp - No*
22 Mantovani, F. 2002 5 M+F 70 – 79 y Unknown Unclear (?) SIS, porcine (D) Com - No (IT)†
23 Li, P. 2009 8 M 8 – 36 m Unknown
Unclear 
(25-45)
Gelating sponge 
(N)
Exp - No (CN)†
# Excluded from meta-analysis because same patients were included in long-term follow-up study by Osman et al., 2014 (#11).
‡ Excluded from meta analysis due to case study.
† Excluded from meta-analysis due to language restrictions defined in section 2.5.
* Excluded from meta analysis due to unclear surgical procedure.
? = unclear,  BAM = bladder acellular matrix, CN = Chinese, Com = Commercial availability, D = decellularized, ES = Spanish, Exp = Experimental 
availability, IT = Italian, MSC = mesenchymal stem cells, N = natural, RU = Russian, S = synthetic, SIS = small intestinal submucosa, SMC = Smooth 
muscle cell.
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Appendix 1
Search strategy to retrieve all relevant literature using PubMed. Individual search 
components for tissue engineering, urethra, pre-clinical- and clinical studies were 
designed using relevant MeSH terms and other relevant synonyms and related terms. 
Search components 1, 2 and 3A were combined to retrieve all relevant pre-clinical 
studies, while search components 1,2 and 3B were combined to retrieve all clinical 
studies.
Search component 1:  T issue Engineering
tissue engineering [MeSH] OR tissue culture techniques [MeSH] OR organ culture techniques [MeSH] OR 
organoids [MeSH] OR guided tissue regeneration [MeSH] OR regenerative medicine [MeSH] OR artificial 
organs [MeSH] OR tissue scaffolds [MeSH] OR biocompatible materials [MeSH] OR bioreactors [MeSH] 
OR (regenerative [tiab] AND (medicine [tiab] OR medicines [tiab])) OR ((decellularized [tiab] OR acellular 
[tiab] OR cell-free [tiab] bioartificial [tiab] OR bio-artificial [tiab] OR artificial [tiab] OR tissue [tiab] OR 
tissues [tiab] OR organ [tiab] OR organs [tiab] OR culture [tiab] OR cultures [tiab]) AND (autograft [tiab] 
OR autografts [tiab] OR graft [tiab] OR grafts [tiab] OR matrix [tiab] OR matrices [tiab] OR biomatrix [tiab] 
OR biomatrices [tiab] or biomaterial [tiab] OR biomaterials [tiab] OR scaffold [tiab] OR scaffolds [tiab] 
OR scaffolding [tiab] OR engineering [tiab] OR engineer [tiab] OR culture [tiab] OR cultures [tiab] OR 
regeneration [tiab] OR regenerated [tiab] OR regenerating [tiab] OR reconstruction [tiab] OR reconstructed 
[tiab] OR reconstructing [tiab])) OR tissue-engineered [tiab] OR tissue engineering [tiab] OR bio-engineering 
[tiab] OR bioengineering [tiab] OR bioengineered [tiab] OR bio-engineered [tiab] OR organoids [tiab] OR 
organoid [tiab] OR bioartificial [tiab] OR bio-artificial [tiab] OR artificial [tiab] OR scaffold [tiab] OR scaffolds 
[tiab] OR scaffolding [tiab] OR matrix [tiab] OR matrices [tiab] OR biomatrix [tiab] OR biomatrices [tiab] OR 
biomaterial [tiab] OR biomaterials [tiab] OR bioreactor [tiab] OR bioreactors [tiab]
Search component 2:  Urethra
urethra [MeSH] OR urethral diseases [MeSH] OR urethra [tiab] OR urethral [tiab] OR urethras [tiab] OR 
urethrotomy [tiab] OR urethrotomies OR ureterotomy [tiab] OR ureterotomies [tiab] OR urethrotomia [tiab] 
OR urethroplasty OR urethroplasties [tiab] OR ((stricture [tiab] OR strictures [tiab]) AND (urology [tiab] OR 
urinary [tiab] OR urine [tiab] OR urological [tiab])) OR hypospadias [tiab] OR epispadias [tiab] OR urethritis 
[tiab] OR (meatus [tiab] AND (urology [tiab] OR urinary [tiab] OR urine [tiab] OR urological [tiab])) OR chordee 
[tiab] OR (perineal [tiab] AND (urology [tiab] OR urinary [tiab] OR urine [tiab] OR urological [tiab]))
Search component 3A:  precl inical  studies
(“animal experimentation”[MeSH Terms] OR “models, animal”[MeSH Terms] OR “invertebrates”[MeSH 
Terms] OR “Animals”[Mesh:noexp] OR “animal population groups”[MeSH Terms] OR “chordata”[MeSH 
Terms:noexp] OR “chordata, nonvertebrate”[MeSH Terms] OR “vertebrates”[MeSH Terms:noexp] OR 
“amphibians”[MeSH Terms] OR “birds”[MeSH Terms] OR “fishes”[MeSH Terms] OR “reptiles”[MeSH Terms] 
OR “mammals”[MeSH Terms:noexp] OR “primates”[MeSH Terms:noexp] OR “artiodactyla”[MeSH Terms] OR 
“carnivora”[MeSH Terms] OR “cetacea”[MeSH Terms] OR “chiroptera”[MeSH Terms] OR “elephants”[MeSH 
Terms] OR “hyraxes”[MeSH Terms] OR “insectivora”[MeSH Terms] OR “lagomorpha”[MeSH Terms] OR 
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“marsupialia”[MeSH Terms] OR “monotremata”[MeSH Terms] OR “perissodactyla”[MeSH Terms] OR 
“rodentia”[MeSH Terms] OR “scandentia”[MeSH Terms] OR “sirenia”[MeSH Terms] OR “xenarthra”[MeSH 
Terms] OR “haplorhini”[MeSH Terms:noexp] OR “strepsirhini”[MeSH Terms] OR “platyrrhini”[MeSH Terms] 
OR “tarsii”[MeSH Terms] OR “catarrhini”[MeSH Terms:noexp] OR “cercopithecidae”[MeSH Terms] OR 
“hylobatidae”[MeSH Terms] OR “hominidae”[MeSH Terms:noexp] OR “gorilla gorilla”[MeSH Terms] OR 
“pan paniscus”[MeSH Terms] OR “pan troglodytes”[MeSH Terms] OR “pongo pygmaeus”[MeSH Terms]) 
OR ((animals[tiab] OR animal[tiab] OR mice[Tiab] OR mus[Tiab] OR mouse[Tiab] OR murine[Tiab] OR 
woodmouse[tiab] OR rats[Tiab] OR rat[Tiab] OR murinae[Tiab] OR muridae[Tiab] OR cottonrat[tiab] OR 
cottonrats[tiab] OR hamster[tiab] OR hamsters[tiab] OR cricetinae[tiab] OR rodentia[Tiab] OR rodent[Tiab] 
OR rodents[Tiab] OR pigs[Tiab] OR pig[Tiab] OR swine[tiab] OR swines[tiab] OR piglets[tiab] OR piglet[tiab] 
OR boar[tiab] OR boars[tiab] OR “sus scrofa”[tiab] OR ferrets[tiab] OR ferret[tiab] OR polecat[tiab] OR 
polecats[tiab] OR “mustela putorius”[tiab] OR “guinea pigs”[Tiab] OR “guinea pig”[Tiab] OR cavia[Tiab] 
OR callithrix[Tiab] OR marmoset[Tiab] OR marmosets[Tiab] OR cebuella[Tiab] OR hapale[Tiab] OR 
octodon[Tiab] OR chinchilla[Tiab] OR chinchillas[Tiab] OR gerbillinae[Tiab] OR gerbil[Tiab] OR gerbils[Tiab] 
OR jird[Tiab] OR jirds[Tiab] OR merione[Tiab] OR meriones[Tiab] OR rabbits[Tiab] OR rabbit[Tiab] OR 
hares[Tiab] OR hare[Tiab] OR diptera[Tiab] OR flies[Tiab] OR fly[Tiab] OR dipteral[Tiab] OR drosophila[Tiab] 
OR drosophilidae[Tiab] OR cats[Tiab] OR cat[Tiab] OR carus[Tiab] OR felis[Tiab] OR nematoda[Tiab] OR 
nematode[Tiab] OR nematodes[Tiab] OR sipunculida[Tiab] OR dogs[Tiab] OR dog[Tiab] OR canine[Tiab] 
OR canines[Tiab] OR canis[Tiab] OR sheep[Tiab] OR sheeps[Tiab] OR mouflon[Tiab] OR mouflons[Tiab] 
OR ovis[Tiab] OR goats[Tiab] OR goat[Tiab] OR capra[Tiab] OR capras[Tiab] OR rupicapra[Tiab] OR 
rupicapras[Tiab] OR chamois[Tiab] OR haplorhini[Tiab] OR monkey[Tiab] OR monkeys[Tiab] OR 
anthropoidea[Tiab] OR anthropoids[Tiab] OR saguinus[Tiab] OR tamarin[Tiab] OR tamarins[Tiab] OR 
leontopithecus[Tiab] OR hominidae[Tiab] OR ape[Tiab] OR apes[Tiab] OR “pan paniscus”[Tiab] OR 
bonobo[Tiab] OR bonobos[Tiab] OR “pan troglodytes”[Tiab] OR gibbon[Tiab] OR gibbons[Tiab] OR 
siamang[Tiab] OR siamangs[Tiab] OR nomascus[Tiab] OR symphalangus[Tiab] OR chimpanzee[Tiab] 
OR chimpanzees[Tiab] OR prosimian[Tiab] OR prosimians[Tiab] OR “bush baby”[Tiab] OR bush 
babies[Tiab] OR galagos[Tiab] OR galago[Tiab] OR pongidae[Tiab] OR gorilla[Tiab] OR gorillas[Tiab] OR 
“pongo pygmaeus”[Tiab] OR orangutan[Tiab] OR orangutans[Tiab] OR lemur[Tiab] OR lemurs[Tiab] OR 
lemuridae[Tiab] OR horse[Tiab] OR horses[Tiab] OR equus[Tiab] OR cow[Tiab] OR calf[Tiab] OR bull[Tiab] OR 
chicken[Tiab] OR chickens[Tiab] OR gallus[Tiab] OR quail[Tiab] OR bird[Tiab] OR birds[Tiab] OR quails[Tiab] 
OR poultry[Tiab] OR poultries[Tiab] OR fowl[Tiab] OR fowls[Tiab] OR reptile[Tiab] OR reptilia[Tiab] OR 
reptiles[Tiab] OR snakes[Tiab] OR snake[Tiab] OR lizard[Tiab] OR lizards[Tiab] OR alligator[Tiab] OR 
alligators[Tiab] OR crocodile[Tiab] OR crocodiles[Tiab] OR turtle[Tiab] OR turtles[Tiab] OR amphibian[Tiab] 
OR amphibians[Tiab] OR amphibia[Tiab] OR frog[Tiab] OR frogs[Tiab] OR bombina[Tiab] OR salientia[Tiab] 
OR toad[Tiab] OR toads[Tiab] OR “epidalea calamita”[Tiab] OR salamander[Tiab] OR salamanders[Tiab] 
OR eel[Tiab] OR eels[Tiab] OR fish[Tiab] OR fishes[Tiab] OR pisces[Tiab] OR catfish[Tiab] OR catfishes[Tiab] 
OR siluriformes[Tiab] OR arius[Tiab] OR heteropneustes[Tiab] OR sheatfish[Tiab] OR perch[Tiab] OR 
perches[Tiab] OR percidae[Tiab] OR perca[Tiab] OR trout[Tiab] OR trouts[Tiab] OR char[Tiab] OR chars[Tiab] 
OR salvelinus[Tiab] OR minnow[Tiab] OR cyprinidae[Tiab] OR carps[Tiab] OR carp[Tiab] OR zebrafish[Tiab] 
OR zebrafishes[Tiab] OR goldfish[Tiab] OR goldfishes[Tiab] OR guppy[Tiab] OR guppies[Tiab] OR 
chub[Tiab] OR chubs[Tiab] OR tinca[Tiab] OR barbels[Tiab] OR barbus[Tiab] OR pimephales[Tiab] OR 
promelas[Tiab] OR “poecilia reticulata”[Tiab] OR mullet[Tiab] OR mullets[Tiab] OR eel[Tiab] OR eels[Tiab] 
OR seahorse[Tiab] OR seahorses[Tiab] OR mugil curema[Tiab] OR atlantic cod[Tiab] OR shark[Tiab] OR 
sharks[Tiab] OR catshark[Tiab] OR anguilla[Tiab] OR salmonid[Tiab] OR salmonids[Tiab] OR whitefish[Tiab] 
OR whitefishes[Tiab] OR salmon[Tiab] OR salmons[Tiab] OR sole[Tiab] OR solea[Tiab] OR lamprey[Tiab] 
OR lampreys[Tiab] OR pumpkinseed[Tiab] OR sunfish[Tiab] OR sunfishes[Tiab] OR tilapia[Tiab] OR 
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tilapias[Tiab] OR turbot[Tiab] OR turbots[Tiab] OR flatfish[Tiab] OR flatfishes[Tiab] OR sciuridae[Tiab] OR 
squirrel[Tiab] OR squirrels[Tiab] OR chipmunk[Tiab] OR chipmunks[Tiab] OR suslik[Tiab] OR susliks[Tiab] 
OR vole[Tiab] OR voles[Tiab] OR lemming[Tiab] OR lemmings[Tiab] OR muskrat[Tiab] OR muskrats[Tiab] 
OR lemmus[Tiab] OR otter[Tiab] OR otters[Tiab] OR marten[Tiab] OR martens[Tiab] OR martes[Tiab] 
OR weasel[Tiab] OR badger[Tiab] OR badgers[Tiab] OR ermine[Tiab] OR mink[Tiab] OR minks[Tiab] OR 
sable[Tiab] OR sables[Tiab] OR gulo[Tiab] OR gulos[Tiab] OR wolverine[Tiab] OR wolverines[Tiab] OR 
mustela[Tiab] OR llama[Tiab] OR llamas[Tiab] OR alpaca[Tiab] OR alpacas[Tiab] OR camelid[Tiab] OR 
camelids[Tiab] OR guanaco[Tiab] OR guanacos[Tiab] OR chiroptera[Tiab] OR chiropteras[Tiab] OR bat[Tiab] 
OR bats[Tiab] OR fox[Tiab] OR foxes[Tiab] OR iguana[Tiab] OR iguanas[Tiab] OR xenopus laevis[Tiab] OR 
parakeet[Tiab] OR parakeets[Tiab] OR parrot[Tiab] OR parrots[Tiab] OR donkey[Tiab] OR donkeys[Tiab] OR 
mule[Tiab] OR mules[Tiab] OR zebra[Tiab] OR zebras[Tiab] OR shrew[Tiab] OR shrews[Tiab] OR bison[Tiab] 
OR bisons[Tiab] OR buffalo[Tiab] OR buffaloes[Tiab] OR deer[Tiab] OR deers[Tiab] OR bear[Tiab] OR 
bears[Tiab] OR panda[Tiab] OR pandas[Tiab] OR “wild hog”[Tiab] OR “wild boar”[Tiab] OR fitchew[Tiab] 
OR fitch[Tiab] OR beaver[Tiab] OR beavers[Tiab] OR jerboa[Tiab] OR jerboas[Tiab] OR capybara[Tiab] OR 
capybaras[Tiab]) NOT medline[sb])
Search component 3B:  cl inical  studies
(((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication 
Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH 
Subheading])) OR ((Human[tiab] OR humans[tiab] OR patient[tiab] OR patients[tiab]) AND (study[tiab] OR 
studies[tiab] OR research[tiab] OR investigat*[tiab] OR clinic*[tiab] OR therapy[tiab] OR treatment[tiab] 
OR surgery[tiab] OR surgical[tiab]))
Appendix 2
Search strategy to retrieve all relevant literature using Embase. Individual search 
components for tissue engineering, urethra, pre-clinical- and clinical studies were 
designed using relevant EMTree-terms and relevant synonyms and related terms. 
Search components 1, 2 and 3A were combined to retrieve all relevant pre-clinical 
studies, while search components 1,2 and 3B were combined to retrieve all clinical 
studies.
Search component 1:  T issue Engineering
Exp tissue engineering/ OR Exp tissue culture/ OR Exp organ culture/ OR Exp tissue regeneration/ OR 
Exp regenerative medicine/ OR Exp artificial organ/ OR Exp tissue scaffold/ OR Exp biomaterial/ OR Exp 
bioreactor/ OR (regenerative AND (medicine OR medicines)).ti,ab. OR ((decellularized OR acellular OR 
cell-free bioartificial OR bio-artificial OR artificial OR tissue OR tissues OR organ OR organs OR culture 
OR cultures) AND (autograft OR autografts OR graft OR grafts OR matrix OR matrices OR biomatrix OR 
biomatrices OR biomaterial OR biomaterials OR scaffold OR scaffolds OR scaffolding OR engineering OR 
engineer OR culture OR cultures OR regeneration OR regenerated OR regenerating OR reconstruction OR 
reconstructed OR reconstructing)).ti,ab. OR (tissue-engineered OR tissue engineering OR bio-engineering 
OR bioengineering OR bioengineered OR bio-engineered OR organoids OR organoid OR bioartificial OR 
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bio-artificial OR artificial OR scaffold OR scaffolds OR scaffolding OR matrix OR matrices OR biomatrix OR 
biomatrices OR biomaterial OR biomaterials OR bioreactor OR bioreactors).ti,ab.
Search component 2:  Urethra
Exp urethra/ OR Exp urethra disease/ OR Exp urethra surgery/ OR urethra.ti,ab. OR urethral.ti,ab. OR 
urethras.ti,ab. OR urethrotomy.ti,ab. OR urethrotomies.ti,ab. OR ureterotomy.ti,ab. OR ureterotomies.
ti,ab. OR urethrotomia.ti,ab. OR urethroplasty.ti,ab. OR urethroplasties.ti,ab. OR ((stricture OR strictures) 
AND (urology OR urinary OR urine OR urological)).ti,ab. OR hypospadias.ti,ab. OR epispadias.ti,ab. OR 
urethritis.ti,ab. OR (meatus AND (urology OR urinary OR urine OR urological)).ti,ab. OR chordee.ti,ab. OR 
(perineal AND (urology OR urinary OR urine OR urological)).ti,ab.
Search component 3A:  precl inical  studies 
exp animal experiment/ or exp animal model/ or exp experimental animal/ or exp transgenic animal/ or 
exp male animal/ or exp female animal/ or exp juvenile animal/ OR animal/ OR chordata/ OR vertebrate/ 
OR tetrapod/ OR exp fish/ OR amniote/ OR exp amphibia/ OR mammal/ OR exp reptile/ OR exp sauropsid/ 
OR therian/OR exp monotremate/ OR placental mammals/ OR exp marsupial/ OR Euarchontoglires/ OR 
exp Afrotheria/ OR exp Boreoeutheria/ OR exp Laurasiatheria/ OR exp Xenarthra/ OR primate/ OR exp 
Dermoptera/ OR exp Glires/ OR exp Scandentia/ OR Haplorhini/ OR exp prosimian/ OR simian/ OR exp 
tarsiiform/ OR Catarrhini/ OR exp Platyrrhini/ OR ape/ OR exp Cercopithecidae/ OR hominid/ OR exp 
hylobatidae/ OR exp chimpanzee/ OR exp gorilla/ OR exp orang utan/ OR (animal OR animals OR pisces 
OR fish OR fishes OR catfish OR catfishes OR sheatfish OR silurus OR arius OR heteropneustes OR clarias 
OR gariepinus OR fathead minnow OR fathead minnows OR pimephales OR promelas OR cichlidae OR 
trout OR trouts OR char OR chars OR salvelinus OR salmo OR oncorhynchus OR guppy OR guppies OR 
millionfish OR poecilia OR goldfish OR goldfishes OR carassius OR auratus OR mullet OR mullets OR mugil 
OR curema OR shark OR sharks OR cod OR cods OR gadus OR morhua OR carp OR carps OR cyprinus OR 
carpio OR killifish OR eel OR eels OR anguilla OR zander OR sander OR lucioperca OR stizostedion OR 
turbot OR turbots OR psetta OR flatfish OR flatfishes OR plaice OR pleuronectes OR platessa OR tilapia 
OR tilapias OR oreochromis OR sarotherodon OR common sole OR dover sole OR solea OR zebrafish OR 
zebrafishes OR danio OR rerio OR seabass OR dicentrarchus OR labrax OR morone OR lamprey OR lampreys 
OR petromyzon OR pumpkinseed OR pumpkinseeds OR lepomis OR gibbosus OR herring OR clupea OR 
harengus OR amphibia OR amphibian OR amphibians OR anura OR salientia OR frog OR frogs OR rana OR 
toad OR toads OR bufo OR xenopus OR laevis OR bombina OR epidalea OR calamita OR salamander OR 
salamanders OR newt OR newts OR triturus OR reptilia OR reptile OR reptiles OR bearded dragon OR pogona 
OR vitticeps OR iguana OR iguanas OR lizard OR lizards OR anguis fragilis OR turtle OR turtles OR snakes 
OR snake OR aves OR bird OR birds OR quail OR quails OR coturnix OR bobwhite OR colinus OR virginianus 
OR poultry OR poultries OR fowl OR fowls OR chicken OR chickens OR gallus OR zebra finch OR taeniopygia 
OR guttata OR canary OR canaries OR serinus OR canaria OR parakeet OR parakeets OR grasskeet OR 
parrot OR parrots OR psittacine OR psittacines OR shelduck OR tadorna OR goose OR geese OR branta OR 
leucopsis OR woodlark OR lullula OR flycatcher OR ficedula OR hypoleuca OR dove OR doves OR geopelia 
OR cuneata OR duck OR ducks OR greylag OR graylag OR anser OR harrier OR circus pygargus OR red knot 
OR great knot OR calidris OR canutus OR godwit OR limosa OR lapponica OR meleagris OR gallopavo OR 
jackdaw OR corvus OR monedula OR ruff OR philomachus OR pugnax OR lapwing OR peewit OR plover OR 
vanellus OR swan OR cygnus OR columbianus OR bewickii OR gull OR chroicocephalus OR ridibundus OR 
albifrons OR great tit OR parus OR aythya OR fuligula OR streptopelia OR risoria OR spoonbill OR platalea 
OR leucorodia OR blackbird OR turdus OR merula OR blue tit OR cyanistes OR pigeon OR pigeons OR 
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columba OR pintail OR anas OR starling OR sturnus OR owl OR athene noctua OR pochard OR ferina OR 
cockatiel OR nymphicus OR hollandicus OR skylark OR alauda OR tern OR sterna OR teal OR crecca OR 
oystercatcher OR haematopus OR ostralegus OR shrew OR shrews OR sorex OR araneus OR crocidura OR 
russula OR european mole OR talpa OR chiroptera OR bat OR bats OR eptesicus OR serotinus OR myotis 
OR dasycneme OR daubentonii OR pipistrelle OR pipistrellus OR cat OR cats OR felis OR catus OR feline 
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gorilla OR gorillas OR troglodytes).ti,ab.
Search component 3B:  cl inical  studies 
Exp clinical trial/ OR (clinical AND (trial OR trials)).ti,ab. OR Exp randomization/ OR Exp therapy/ OR Exp 
treatment outcome/ OR Exp controlled study/ OR exp health care quality/ OR random:.tw. or clinical trial:.
mp.
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Appendix 5
Quality assessment score per study for A)  pre-clinical studies and B)  clinical studies. Quality was scored 
based on 19 questions for pre-clinical studies and 17 questions for clinical studies (see Figure 2). Detailed 
scores per study are available upon request.
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Appendix 6
Numerical data on which Figure 3 is based. Estimated probability including 95% 
confidence intervals for the absence of side effects, functionality and study completion 
for A) full circumferential repair and B) inlay repair in pre-clinical studies, both 
categorized for the use of cells and the type of biomaterial. C) For the clinical studies, 
only decellularized material with or without cells could be analyzed. The effect of cells 
on the three outcome measures was calculated in estimated probabilities. Overall 
differences for cellular vs. acellular templates were determined for each outcome 
measure for both full and inlay repair: * p=0.003, ** p=0.001, all other differences were 
not significant (p>0.05).
A. Pre-clinical studies – Full circumferential repair
Point estimate and 95% CI [lower:upper]
Biomaterial type No side-effects Functionality Study completion
Ac
el
lu
la
r
Decellularized 0.04 [0.001:0.46] 0.76 [0.09:0.99] 1.0 [0.63:1.0]
Natural 0.24 [0.07:0.57] 0.87 [0.04:1.0] 0.95 [0.26:1.0]
Synthetic 0.80 [0.56:0.93] 0.96 [0.25:1.0] 0.98 [0.49:1.0]
Overall 0.36 [0.26:0.48] 0.81 [0.14:0.99] 0.98 [0.66:1:0]
Ce
llu
la
r
Decellularized 0.99 [0.68:1.0] 0.77 [0.01:0.99] 1.0 [0.58:1.0]
Natural 0.73 [0.19:0.97] 1.0 [0.59:1.0] 1.0 [0.52:1.0]
Synthetic 1.0 [0.00:1.0] unable to estimate 1.0 [0.03:1.0]
Overall 0.91 [0.59:0.99] 0.87 [0.07:1.0] 1:0 [0.88:1.0]
B.  Pre-clinical studies – Inlay repair
Point estimate and 95% CI [lower:upper]
Biomaterial type No side-effects Functionality Study completion
Ac
el
lu
la
r
Decellularized 0.49 [0.26:0.73] 0.98 [0.88:1.0] unable to estimate
Natural 0.74 [0.04:1.0] 1.0 [0.36:1.0] unable to estimate
Synthetic 0.26 [0.22:0.29] 0.73 [0.26:0.95] unable to estimate
Overall 0.50 [0.20:0.80] 0.90 [0.66:0.98] 1.0 [0.92:1.0]
Ce
llu
la
r
Decellularized 0.85 [0.03:1.0] 1.0 [0.34:1.0] unable to estimate
Natural 1.0 [1.0:1.0] 1.0 [0.42:1.0] unable to estimate
Synthetic 0.40 [0.29:0.52] 0.86 [0.31:0.99] unable to estimate
Overall 0.75 [0.44:0.92] 0.95 [0.66:0.99] 1:0 [0.75:1.0]
C.  Clinical studies – Inlay repair
Point estimate and 95% CI [lower:upper]
Biomaterial type No side-effects Functionality Study completion
De
ce
l. Acellular 0.70 [0.49:0.85] 0.84 [0.64:0.94] 0.55 [0.18:0.87]
Cellular 1.0 [0.20:1.0] 0.94 [0.43:1.0] 0.04 [0.002:0.43]
2
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Abstract
Type I collagen is widely applied as a biomaterial for tissue regeneration. In the 
extracellular matrix, collagen provides strength but not elasticity under large 
deformations, a characteristic crucial for dynamic organs and generally imparted 
by elastic fibers. In this study, a methodology is described to induce elastic-like 
characteristics in a scaffold consisting of solely type I collagen.
Tubular scaffolds are prepared from collagen fibrils by a casting, molding, freezing and 
lyophilization process. The lyophilized constructs are compressed, corrugated and 
subsequently chemically crosslinked with carbodiimide in the corrugated position. 
This procedure induces elastic-like properties in the scaffolds that could be repeatedly 
stretched five times their original length for at least 1000 cycles. The induced elasticity 
is entropy driven and can be explained by the introduction of hydrophobic patches that 
are disrupted upon stretching thus increasing the hydrophobic-hydrophilic interface. 
The scaffolds are cytocompatible as demonstrated by fibroblast cell culture. 
In conclusion, a new straightforward technique is described to endow unique elastic 
characteristics to scaffolds prepared from type I collagen alone. Scaffolds may be 
useful for engineering of dynamic tissues such as blood vessels, ligaments, and lung.
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1.  Introduction
Insoluble type I collagen is a biomaterial that has been extensively used in the field of tissue 
engineering and regenerative medicine as scaffolding material. In the native extracellular 
matrix, collagen provides structural support to tissues. Individual triple helical collagen 
monomers are densely packed into collagen fibrils that are subsequently organized 
in bundles called fibers which add strength and prevent the tissue from rupturing 
upon exposure to mechanical stress. Ideally, in tissue engineering the scaffold should 
temporarily take over the role of the native extracellular matrix and in this respect type I 
collagen is often applied. Collagen is widely available from animal sources, easy to purify, 
biodegradable and well-recognized for its excellent cross-species biocompatibility [1]. In 
addition, collagen is easy to modify with functional groups, such as glycosaminoglycans 
or growth factors, and moreover, its biodegradability can be regulated by crosslinking 
technique [2]. Numerous type I collagen based scaffolds in the field of tissue engineering 
are already used in the clinical setting showing the value of collagen as a biomaterial [3].
Collagen-based scaffolds generally do not exhibit elastic properties at high 
deformations, which is of importance for the mechanical compliance of dynamic 
tissues. Many of these organs, such as lungs, heart valves, ligaments, blood vessels, 
skin, and bladder, need to be both strong and elastic to prevent ruptures and to 
reversibly deform [4, 5]. The extracellular matrix of such organs contains elastic fibers, 
which give the tissue the required resilience and ensure that it regains its original shape 
after every deformation. Elastic fibers are mainly composed of the protein elastin which 
is responsible for the elasticity of the tissue [6]. The elastic fibers together with the 
collagen fibers largely determine the overall mechanical properties of a specific tissue.
In several studies, insoluble elastin-collagen scaffolds have been designed in order to 
mimic the natural matrix of elastic tissues [7, 8]. However the use of insoluble elastin 
fibers comes with several disadvantages. A major problem is that elastin usually 
induces calcification in vivo, which may lead to life threatening side-effects [2, 9-11]. 
Calcification in porcine heart valves for example, is a major clinical problem and has 
especially been observed in children [12], possibly in line with calcification of elastic 
fibrils in young animals [13]. Many attempts have been performed to improve clinical 
applicability including recellularization, surface treatment, enzyme treatment, but 
the clinical efficacy remains debatable [14]. In addition, the extreme insolubility of 
elastic fibers complicates the scaffold production process and will further complicate 
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clinical approval since it is an additional animal derived component. Hydrolyzed or 
solubilized elastin are easier to handle and have been shown to stimulate synthesis of 
native elastin fibers [15], but they do not endow the initial scaffolds with major elastic 
properties. Conferring elasticity to collagen-only scaffolds would therefore be a major 
advantage in the design of functional scaffolds for tissue engineering of organs/tissues 
which are subjected to considerable deformations. 
In this manuscript, we describe a new method to induce elasticity in scaffolds consisting 
of only type I collagen fibrils, thereby circumventing the issues that are associated 
with the use of elastin. By compression and corrugation of lyophilized porous collagen 
constructs followed by carbodiimide crosslinking under physical restraint, we were 
able to alter the morphology, and induce elastic-like, entropy-driven, characteristics. 
The combination of both strength and elastic-like properties in a one-component 
scaffold offers new opportunities for tissue engineering of dynamic tissues. 
2.  Materials  and methods
2.1.  Type I  col lagen f ibri ls
Highly-purified type I collagen fibrils were obtained as previously described [16]. Briefly, 
bovine achilles tendons were pulverized under liquid nitrogen-cooled conditions using a 
universal cutting mill (Pulverisette19, Fritsch GmbH, Idar-Oberstein, Germany) with a sieve-
opening of 0.5 mm. The purification process included washings with aqueous solutions 
of NaCl (1.0 M), urea (6.0 M), and acetic acid (0.25 M), acetone and demineralized water.
2.2.  Scaf fold construction
2.2.1.  Preparat ion of  a  porous col lagen scaf fold
A 0.8% (w/v) collagen suspension was prepared by mixing purified type I collagen fibrils 
with 0.25 M acetic acid. This suspension was swollen overnight and homogenized using 
a Silverson L5M-A laboratory mixer (Silverson, Chesham, UK) by mixing 3 min at 2,500 
rpm using a general purpose disintegrating workhead, followed by 3 min at 2,500 rpm 
with a slotted workhead. The suspension was deaerated using centrifugation at 100 g. 
All steps were performed at 4°C to prevent denaturation of the collagen. The collagen 
suspension was poured into a 10 mL polypropylene mold with a 6 mm stainless steel 
(grade 304) mandrel inside and frozen for at least 4 h at -20°C in aluminum freezing 
blocks. After removal of the mandrel the frozen constructs were lyophilized (Zirbus 
sublimator 500II, Bad Grund, Germany).
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2.2.2.  Preparat ion of  compressed and corrugated col lagen 
scaf folds
After freeze-drying, the porous constructs (P-tube), with the mandrels again put in 
place, were uniformly compressed around the mandrel by gently squeezing them 
between two plane surfaces under a rolling motion to create porous compressed 
scaffolds (PC-tube, Figure 1A). Next, in order to create porous compressed and 
corrugated scaffolds (PCC-tube), two discs fitting exactly over the mandrels were 
positioned around each side of the scaffold and subsequently pushed together until 
10 mm space was left in between (Figure 1A). The discs were replaced by 6 mm rubber 
O-rings to hold the scaffold in its corrugated state. Next, the scaffolds were crosslinked 
using a zero-length crosslinking method applying EDC (Merck Schuchardt OHG, 
Hohenbrunn, Germany) and NHS (Fluka Chemie AG, Buchs, Switserland) [17]. In brief, 
scaffolds were crosslinked for 3 h at room temperature in 50 mM 2-morpholinoethane 
sulphonic acid (MES buffer, pH 5.0) (USB, Ohio, USA) containing 40% (v/v) ethanol, 33 
mM EDC and 6 mM NHS and subsequently washed in 0.1 M Na2HPO4, (2x), 1 M NaCl (2x), 
2 M NaCl (4x), and demineralized water (6x). Finally, scaffolds were placed in 70% (v/v) 
ethanol and stored at -20°C until use.
2.3.  Scaf fold Characterization
2.3.1.  Macroscopic evaluation and video recording
Macroscopic images were taken and videos were recorded using a Canon 1d X with 
a EF macro lens camera (Canon, Melville, NY, USA). High-speed videos (1000 frames 
per second) were recorded using a Casio EX-ZR100 (Casio, Tokyo, Japan) with camera 
speed settings at HS1000 and resolution at 224x64 pixels.
2.3.2.  Scanning elec tron microscopy
Scanning electron microscopy(SEM) was used to analyze the morphology and structure 
of the tubular scaffolds. Samples were lyophilized, fixed on a stub with double-sided 
carbon tape and sputtered with an ultrathin gold layer in a Polaron E5100 Coating 
System. Examination was performed in a JEOL SEM 6310 apparatus (JEOL Ltd, Tokyo, 
Japan) with an accelerating voltage of 10 kV.
2.3.3.  Ef fec t  of  f luids with dif ferent polar it ies  on elast ic- l ike 
charac ter ist ics
PCC-tubes were restrained in a stretched position and air-dried. Next, the stretched 
scaffolds were placed in fluids of different polarities (i.e. water, ethylene glycol, 
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methanol, ethanol, 1-propanol, 1-butanol, acetone and chloroform (all from Sigma-
Aldrich) [18]. Before use, non-polar fluids were dehydrated by adding anhydrous 
Cu(II)SO4 crystals (Sigma-Aldrich). The ability of the stretched scaffold to return to its 
original corrugated state was measured as a percentage of the maximal corrugation 
(corrugation in water was set to 100%). This experiment was performed three times 
independently. In addition, to visualize the influence of polarity of the fluid on the 
ability of the scaffold to return to its corrugated position, an experimental set up 
combining water and chloroform was applied. An air-dried stretched scaffold was 
placed in a tube and chloroform was added until half of the scaffold was submerged. 
Next, water with Cu(II)SO4 (to increase the contrast between the two layers) was added 
on top of the chloroform and the scaffold was monitored over time. Images were taken 
using a Sony Cyber-shot DSC-H10.
2.3.4.  Mechanical  proper ties
To characterize the mechanical properties of the scaffolds, force-monitored ultimate 
tensile strength experiments were performed and force-displacement curves were 
determined by using a Zwick/Roell Z2.5 testing machine (Zwick/Roell, Ulm, Germany). 
From these curves ultimate tensile strength was derived. In addition, the work needed 
for break was determined by calculating the area under the curve. Curves were converted 
into force-strain curves in which strain was calculated as percentage of the original 
scaffold length after crosslinking. Tests were performed by clamping 2 mm of the scaffolds 
between two custom made clamps (Supplementary Figure 1) and pulling them apart in 
opposite direction with 50 mm min.-1 (n=19). For fatigue tests, corrugated scaffolds were 
stretched and released 1,000 times with a speed of 167 mm min.-1 over a distance at 
which the corrugated structure was totally unfolded while continuously measuring the 
force (n=4). Scaffolds were wetted with 0.1 M phosphate buffered saline (pH 7.4) using 
a peristaltic pump. Data was processed using TestXpert II V3.5 software (Zwick/Roell). 
2.3.5.  Evaluation of crossl ink ing by assaying primary amine groups 
The degree of crosslinking of P, PC and PCC-tubes was evaluated by the loss of primary 
amine groups upon crosslinking as measured by a trinitrobenzene sulfonic acid assay 
[7]. In brief, freeze-dried samples were incubated for 30 min. in 4% (w/v) NaHPO4 (Merck, 
Darmstadt, Germany) at room temperature. Next, 0.5% (w/v) 2,4,6-trinitrobenzesulfonic 
acid (Fluka Chemie AG, Buchs, Switzerland) was added and samples were incubated for 
2 h at 40°C followed by a hydrolysis step with 6 M HCl for 1.5 h at 60 °C. Demineralized 
water was added to dilute the samples before they were measured at 420 nm with a 
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spectrophotometer (Bio-Tek, Bad Friedrichshall, Germany). Glycine (Scharlau Chemie, 
Barcelona, Spain) was used for the calibration curve. Analysis was in triplicate in three 
independent experiments.
2.4.  In vitro evaluation
2.4.1.  Cel l  culture
NIH/3T3 fibroblasts (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified 
Eagle’s Medium Glutamax (Life Technologies, Carlsbad, CA, USA) containing 10% (v/v) 
fetal bovine serum (GE Healthcare, PAA Laboratories, Pasching, Austria), penicillin 
(1,000 IU mL-1) and streptomycin (1,000 Pg mL-1, PAA Laboratories) at 37°C under an 
atmosphere containing 5% CO2. Confluent cells were harvested using 0.25% (w/v) 
trypsin-EDTA (Life Technologies).
2.4.2.  Cel l  seeding on scaf folds
For cell seeding experiments, scaffolds were cut into strips of 0.5 x 2 cm (P-tube and 
PC-tube), and 0.5 cm x 1 cm for the PCC-tube. The strips were disinfected by six washing 
steps with 70% (v/v) ethanol including one overnight step. To remove ethanol, six 
washings with sterile 0.1 M phosphate buffered saline, pH 7.4 (PBS, Braun, Melsungen, 
Germany) were performed with one overnight step. Finally, strips were incubated in 
culture medium for 1 h prior to cell seeding. The strips were transferred to a 6-well 
suspension plate and 4.5 x 105 cells in 0.75 mL were added to each scaffold. After 3h, 
3.25 mL of culture media was added. Constructs were cultured for four days and media 
was renewed every other day. 
2.4.3.  Alamar Blue cel l  v iabi l i t y  assay
To investigate the cell viability of the 3T3 fibroblasts seeded on the scaffold, an Alamar 
Blue assay (Life Technologies, Carlsbad, CA, USA) was performed. For each scaffold 
type, 6 mm punches were taken and subsequently placed in 96-wells plates. Next, 1.0 
x 104 cells in 25 PL were seeded in each well in triplicate and after three hours 200 PL 
culture media was added. Alamar Blue was added 4, 24 and 96 hours after seeding. 
Fluorescence was measured using an excitation wavelength of 540 nm and an emission 
wavelength 620 nm. This experiment was performed three times independently. 
2.4.4.  Histological  evaluation of  scaf folds
For histology, constructs were embedded in Tissue-Tek (Sakura, Torrance, USA) and 
frozen in dry-ice cooled 2-methylbutane (Sigma-Aldrich, St. Louis, USA). Next, they 
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were sectioned (5 Pm) using a cryostat microtome (Heidelberg, Heidelberg, Germany), 
mounted on superfrost slides (Thermo Scientific, Menzel GmbH & Co KG, Braunschweig, 
Germany) and stored at -20 °C until use. Before staining, fixation with cold acetone (-20 
°C) was applied for 15 min. Sections were stained with haematoxylin and eosin (HE), 
DAPI (nuclear stain) and immunostained for type I collagen. For the latter, sections 
were blocked for 15 min. in 1% (v/v) BSA in PBS, pH 7.4, and subsequently incubated 
for 45 min. with a rabbit-anti-bovine type I collagen antibody (dilution 1:250, Millipore, 
Cambridge, UK) followed by 3 x 5 min. washings with PBS. Bound antibodies were 
visualized by incubation for 45 min. using Alexa Fluor 594-conjugated goat-anti-
rabbit IgG (dilution 1:250, Invitrogen, Eugene, OR, USA). For nuclear staining, section 
were washed 3 x 5 min. with PBS and stained with 4′,6-diamidino-2-phenylindole 
dihydrochloride (DAPI, 10 Pg mL-1 in PBS, Sigma Aldrich, St. Louis MO, USA). After 
extensive washings with PBS, cover slips were mounted using Mowiol (Calbiochem, 
San Diego, CA, USA). Sections were analyzed using a Leica CTR6000 microscope (Leica 
Microsystems GmbH, Wetzlar, Germany). 
2.5.  Statistical  analysis
Statistical analysis on all data was performed in GraphPad PRISM 5, version 5.03 
(GraphPad Software Inc, La Jolla, CA, USA). For the mechanical characterization 
(section 2.3.4.) and the TNBS-assay (section 2.3.5.) groups were compared using a 
one-way ANOVA with Bonferroni post-hoc tests. For the Alamar Blue cell viability 
(section 2.4.3.) the differences for P-, PC- and PCC-tube between each time-point 
were analyzed using a one-way ANOVA with Bonferroni post-hoc tests. Differences 
between the scaffolds within one time-point were analyzed with a two-way ANOVA 
with Bonferroni post-hoc test.
3.  Results
3.1.  Scaf fold morphology and degree of  crossl inking
Swelling, homogenization, freezing and freeze-drying of bovine collagen resulted in 
porous tubular scaffolds, which were comparable to scaffolds previously described in 
literature (Figure 1B-D) [19, 20]. The freeze-dried porous tubular scaffold (P-tube) was 
used as a starting point to produce collagen scaffolds with elastic-like characteristics. 
Compressing this porous scaffold around the mandrel resulted in a dense tube with 
a more compact and longitudinal porosity (PC-tube, Figure 1E-G). Corrugation of this 
compressed PC-tube tube led to a tubular scaffold a pleated/corrugated wall structure 
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with compact porosity (PCC-tube, Figure 1H-J). Chemical crosslinking of the scaffolds in 
situ resulted in fixation of the morphology. The degree of crosslinking was determined by 
measuring the content of free amine groups. Non-crosslinked collagen showed an average 
of 247±15 nmol of free amine groups per mg collagen, whereas crosslinked P-tube, PC-
tube and PCC-tube had averages of 128±17, 102±14 and 112±16 nmol free amine groups 
per mg collagen respectively, corresponding to a reduction of free amine groups of 
approximately 48, 59 and 55% (Table 1). PC-tube and PCC-tube were statically different 
from the P-tube. Between PC and PCC tubes no statistical differences were observed.
Figure 1.  Scaf fo ld preparat ion and morphologica l  charac ter is t ic s .  A)  Schematic representation 
of the method used to construct a porous compressed tube (PC-tube) out of a porous tube (P-tube), and 
porous compressed and corrugated tube (PCC-tube) out of a PC-tube. B-D) Macroscopic image, SEM image 
and H&E stained image of the P-tube, where the porous morphology is clearly seen. E-G) Same images for 
the PC-tube, where compressed pore structure is visible. H-J)  Images of PCC-tube where the corrugated 
structure of the scaffold is apparent. Scale bars: Macroscopic image = 5 mm, SEM = 100 Pm, H&E = 200 Pm.
3
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3.2.  Mechanical  characteristics
Only the PCC-tube scaffolds displayed reversible elastic-like behavior upon stretching. 
Scaffolds could be elongated, and did return to their relaxed corrugated position 
upon release of the force (Figure 2A-D and Movie 1). The initial elongation/unfolding 
of the PCC-tube scaffolds did only cost marginal effort. The mechanical properties of 
the scaffolds were analyzed using a custom-made clamp system, which could hold 
the entire tubular scaffold during a force-monitored tensile test (Figure A.1). During 
tensile testing, the three scaffolds displayed very distinct mechanical properties as 
seen by the shape of the force-strain curves (Figure 2E). The PCC-tube scaffold did 
not need a large force (0.1 N) in order to be extended up to about 5 times its length. 
On average the PCC-tube could be elongated most until rupture (675 ± 46% of the 
length in the relaxed state), followed by P-tube (126 ± 4%) and PC-tube (117 ± 3%) 
(Figure 2F). The PC-tube was significantly stronger (4.2 ± 1.1 N) than PCC-tube (3.4 ± 
1.0 N) and P-tube (1.8 ± 0.5N) (Figure 2G). Work needed for break (or area under the 
force-displacement curve) showed that the PCC-tube required significantly more work 
until scaffold failure (36 ± 8.6 mJ) than PC-tube (24 ± 9.2 mJ) and P-tube (16 ± 5.7 mJ) 
(Figure 2H). The persistence of elastic-like behavior of the PCC-tube was tested using 
a fatigue test where the scaffolds were subjected to 1,000 cycles of elongation up to 
a defined distance whilst recording the force (Figure 2I). The fatigue curve showed 
an initial decline of tensile force from approximately 0.4 N to 0.37 N in the first 200 
cycles, corresponding to a decline of 1.5 x 10-4 N cycle-1. In the following 800 cycles, the 
approximate rate of decline was only 3.0x10-5 N cycle-1 (0.37 N to 0.346 N). The fatigue 
curve graph is derived from the averages of the peak force values of every cycle from 
four independent measurements as depicted in figure 2J which is a zoomed in view 
of figure 2I from cycle 800 to 810.
3.3.  Mechanism underlying elastic- l ike proper ties 
The mechanism behind the elastic-like behavior was investigated using liquids with 
different relative polarities. In the experiment, the PCC tube was air-dried in a stretched 
instead of a corrugated state. When the PCC-tube was air-dried in a stretched state, 
it remained in this position. Upon rehydration in water, it returned to its original 
corrugated length (Figure 3A and Movie 2). Without crosslinking this phenomenon 
was not observed. When liquids with lower polarities than water were tested in this 
scenario, it was observed that a decrease in relative polarity prevented the return of 
the PCC-tube to the corrugated state (Figure 3A-B). To elaborate on this phenomenon, 
a test was designed where the PCC-tube dried in the elongated state was placed in a 
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 125
125
Design of an elasticized collagen scaffold: A method to induce elasticity in a rigid protein
Figure 2 .  Mechanica l  charac ter izat ion of  porous (P) - tube,  Porous compressed (PC) - tube and 
porous compressed and corrugated (PCC) -tube scaf fo lds .  A)  PCC-tube in relaxed position. B)  PCC-
tube in semi-extended position. C)  PCC-tube in fully extended position. D)  PCC-tube again in relaxed 
position after applied force is released. E)  Representative force-strain graph of P-tube, PC-tube, PCC-tube, 
with differences in extendibility indicated. F)  Average force and strain at failure for P-tube, PC-tube and 
PCC-tube (n=19 per scaffold type) showing the range at which the scaffolds fail. G-H)  Ultimate tensile 
strength and work (area under force-displacement graph) for the three scaffold types derived from force-
distance graphs (not shown here), n=19; One-way ANOVA with Bonferroni post-hoc test, * = P < 0.05, ** P 
< 0.01, *** P < 0.001. I )  Fatigue test of PCC-tube, showing persistence of elastic characteristic for at least 
1000 stretch and release cycles (n=4). J )  Zoomed-in area of a representative part of the force graph from 
which peak forces per cycle were determined. Scale bar in A-D = ~5 mm.
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test-tube with two liquids of different polarity (water and chloroform). Since the liquids 
are immiscible, they formed a sharp barrier which was visualized by staining water with 
Cu(II)SO4 [21]. The scaffold was placed in the chloroform layer after which the water 
was added on top. The part of the PCC-tube scaffold protruding in the water layer 
returned to the corrugated state, whereas the PCC-tube segment in the chloroform 
Figure 3.  Mechanism of e las t ic- l ike behavior of  the porous ,  compressed and corrugated (PCC) 
tube scaf fo ld .  A)  Stretched PCC-tubes were air-dried (left) and exposed to fluids with various polarity. 
At low polarity, the PCC tube scaffold did not return to its original corrugated state. B)  Effect of polarity of 
fluid on the ability of air-dried PCC-tube to return to the original corrugated state (n=3). C)  Time-lapse of an 
stretched air-dried PCC-tube in a two layer system with chloroform (bottom half, colorless) and water (top 
half, light blue), showing that the part of scaffold in contact with water returned to the original corrugated 
state, while the part exposed to chloroform remained stretched. Over time the scaffold becomes hydrated 
and migrated towards the aqueous layer. Red arrow indicates the base of the scaffold. 
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remained stretched. Over time, the PCC-tube attracted water, with a part of the PCC-
tube protruding in the chloroform layer (Figure 3C). This is likely due to the hydrated 
scaffold being more dense than water.
3.4.  Cy tocompatibi l i ty  of  scaf folds
To study the effect of compression and corrugation on cells, a viability assay was 
performed. Cells seeded on PC- and PCC-tubes were able to proliferate to the same 
extent as cells without compression and corrugation. The number of cells increased in 
time (Figure 4A). Histological evaluation (Figure 4B-D) further confirmed the outcome 
the proliferative capacity of cells as indicated by the increase in number of cells 
compared to the time of seeding. Compression and corrugation resulted in a more 
closed surface and consequently cells seeded on PC- and PCC-tubes did not penetrate 
as deep as those seeded on P-tubes. Cells formed large sheets on top of the scaffold 
resulting in local higher cell densities. 
Figure 4 .  Cy tocompat ib i l i t y  o f  porous (P) - tube,  porous ,  compressed (PC) - tube and porous , 
compressed and cor rugated (PCC) - tube.  A)  Alamar blue cell viability assay at 4, 24 and 96 h after cell 
seeding (one way ANOVA with Bonferroni post-hoc test). Differences within time points were analyzed using 
a two-way ANOVA with Bonferroni post-hoc test. * = P < 0.05, ** P < 0.01, *** P < 0.001. B-D) Microscopical 
images of a cross-section of P-tube B) , PC-tube C)  and PCC-tube D)  cultured for 4 days with fibroblasts, 
and stained for type I collagen (red) and cell nuclei (blue). Bar = 200 Pm. 
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4.  Discussion
4.1.  Scaf fold characteristics
Methods to modulate the mechanical properties of porous collagen scaffolds have 
been extensively studied [17, 22-24], focusing on increasing the overall strength 
either by chemical modification, by introduction of additional components such as 
synthetic polymers [22, 25] or by compressing porous collagen scaffolds [20, 26]. In this 
manuscript we have modulated collagen in such a way that new mechanical properties 
arise. A combination of compression, corrugation and chemical crosslinking under 
physical restraint resulted in the introduction of elastic characteristics in collagen-
only constructs. In this way, the collagen adopted properties of another component 
of the extracellular matrix i.e. elastin. A fatigue test (1000 cycles of folding-unfolding) 
indicated the elastic behavior to be durable. 
4.2.  Proposed mechanism for  elasticity
The PCC-tube scaffold has elastic-like properties where the scaffold can be elongated 
and returns to its relaxed state. It is unlikely the rigid collagen fibrils themselves display 
elastic properties since they are relatively inelastic [27]. The elastic-like properties 
of corrugated collagen fibrils in native artery tissue has been previously described, 
where the corrugated fibrils contribute to the elasticity of the arteries [27]. However, 
the mechanism behind the phenomenon of an elasticized collagen scaffold (PCC-tube) 
has, to the best of our knowledge, not been described in previous literature. 
Several dedicated experiments were designed to elucidate the mechanism behind 
the elastic-like properties. The scaffold displayed elastic-like properties when it was 
wetted, but not when it was dried, a characteristic similar to native elastic fibers. 
Applying fluids with varying polarity influenced the elastic-like behavior: the less polar 
the fluid, the less capacity of a dry scaffold to return to its corrugated state. Finally, 
without crosslinking no elastic behavior was observed. 
Taking these data into account, the following mechanism for the elastic-like properties 
of collagen is proposed (Figure 5). Compression and subsequent corrugation during 
carbodiimide crosslinking results in the creation of hydrophobic regions at places 
where the collagen fibrils are densely packed together. The crosslinking process will 
reduce the amount of free (charged) amine and carboxylic groups (by the formation of 
amide bonds), thus reducing the overall hydrophilicity of the collagen and increasing 
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the hydrophobicity. At locations where fibrils are densely packed thermodynamically 
favored hydrophobic regions are formed which stabilize the corrugated shape. Once 
tensile force is applied (stretching) the hydrophobic areas will be exposed to the 
aqueous surroundings, which is thermodynamically unfavorable (Figure 5). When 
the force is released (relaxation) an entropy-driven force returns the scaffold to the 
corrugated shape in which the scaffold was crosslinked. Thus, stretching of the fibrils 
in the scaffold increases the interface between water molecules and the hydrophobic 
Figure 5:  Proposed molecular mechanism of e last ic- l ike proper t ies of porous ,  compressed and 
cor rugated tube scaf fo lds .  Crosslinking of scaffolds in the corrugated state introduces hydrophobic 
areas due to loss of free amine and carboxylic groups. Upon stretching hydrophobic areas become exposed 
to the aqueous environment resulting in an increase of thermodynamically unfavorable interfaces. Upon 
release of the mechanical stress the scaffolds return to the original corrugated state. 
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areas associated with the fibrils, a process that results in more – energetically 
unfavorable – ordering of water molecules (i.e. loss of entropy). The proposed 
mechanism resembles entropy-driven mechanism associated with the elasticity of 
elastin [28-30].
4.3.  Cy tocompatibi l ity
Collagen is a highly characterized biomaterial and the cellular response to collagen-
based biomaterials is generally well understood [31-33]. However, modification of the 
collagen structure or chemical make-up can influence the cellular response [34]. In the 
case of the compressed (PC-tube) and corrugated (PCC-tube) scaffolds, the effect of 
compression, corrugation and subsequent crosslinking was unknown. In this respect it 
was necessary to determine the biocompatibility of the constructs after the processing 
steps. In the PC-tube and PCC-tube cells did not penetrate the scaffold and appear to 
form multilayer sheet-like structures on top of the scaffold. 
Cells can adhere directly to collagen via e.g. ɲ1ɴ1 integrins, or indirectly via ɲVɴ3 
and ɲ5ɴ1 integrins to fibronectin present in culture medium [35, 36]. Carbodiimide 
crosslinking, as used in this study, may affect binding sites for integrins on collagen 
[37], and therefore initial binding of fibroblasts to collagenous scaffolds may have been 
through serum-derived fibronectin. 
In this study, it was shown that after 96 h of culturing, both PC-tube and PCC-tube 
scaffolds seem to contain an equal or higher amount of viable cells compared to P-tube 
scaffolds. As the biocompatibility of the P-tube has been extensively studied in both in 
vitro and in vivo studies, it is a suitable benchmark for the PC-tube and PCC-tube [38-41]. 
Overall, the cytocompatibility of the PC-tube and PCC-tube seems to be comparable to 
the P-tube indicating that the compression, corrugation and subsequent crosslinking 
do not negatively affect the intrinsic biocompatibility of collagen.
4.4.  Implications and applications
To the best of our knowledge, no studies have been reported where a scaffold 
consisting solely of collagen is given elastic-like characteristics. Other approaches to 
provide collagen-based scaffolds with elasticity mainly involve the addition of other 
components, like (recombinant or natural) elastin, silk and synthetic polymers [42, 
43]. Using elasticized collagen-only materials may circumvent the use of elastin or 
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other elastic components and may aid in the straightforward development of scaffold 
for the repair of dynamic tissues. By varying the extent of crosslinking, compression 
and corrugation various degrees of elasticity may be obtained in line with the 
characteristics of tissues that undergo repeated elastic deformation like the blood 
vessels, ligaments, bladder, skin, and the gastrointestinal tract [44-46]. For instance, 
a scaffold for bladder repair should be able to expand many times from its contracted 
size without a significant increase in pressure, subsequently contract to release the 
urine and repeat this micturition cycle over and over again [46]. The elasticity in the 
PCC-tube is primarily oriented in a longitudinal direction. It should be noted that for 
tissues such as blood vessels or the gastrointestinal tract the elasticity is orientated 
in a circumferential direction to enable the diameter to expand. With an adaptation of 
the methodology developed it may be possible to meet these requirements and create 
a collagen scaffold that is in compliance with the elasticity of these tissue.
5.  Conclusion
Collagen, generally known for providing strength and rigidity to tissues, was given 
elastic-like characteristics by combining compression, corrugation and crosslinking. 
The induced elasticity is likely entropy-driven and the procedure used does not reduce 
the cytocompatibility of the collagen. The technology may be useful for the construction 
of scaffolds for regenerative medicine of dynamic organs with intrinsic elasticity.
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Table 1.  Degree of crosslinking
Scaffold
Amime groups
[nmol / mg collagen] ± SD
Reduction of free 
amine groups
n
Non-crosslinked 247 ± 15 - 9
P-tube 128 ± 17 48 %1 27
PC-tube 102 ± 14 59 %2 27
PCC-tube 112 ± 16 55 %2 27
1 Statistically different from PC-tube (P<0.001) and PCC-tube (P<0.01), one-way ANOVA with Bonferroni post-hoc test.
2 Difference between PC-tube and PCC-tube was not significant, one-way ANOVA with Bonferroni post-hoc test.
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Appendix
Figure A .1.  Schemat ic  over v iew of  cus tom-made c lamp for  tubular  scaf fo lds .  To allow for the 
mechanical evaluation of the scaffolds in tubular form a custom-made clamp was made to fit the Zwick/
Roell device. The adaptor cylindrical shape could be inserted into a tubular scaffold after which a clamp 
fitted with a rubber ring could be used to secure the sample in place. Several openings were added to 
the design of the adaptor to allow for free flow of air/fluid during repeated stretch and relaxation cycles.
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Abstract
Tubular collagen scaffolds have been used for the repair of damaged hollow organs in 
regenerative medicine, but they generally lack the ability to reversibly expand in radial 
direction, a physiological characteristic seen in many native tubular organs. In this 
study, tubular collagen scaffolds were prepared that display a shape recovery effect 
and therefore exhibit radial elasticity. Scaffolds were constructed by compression of 
fibrillar collagen around a star-shaped mandrel, mimicking folds in a lumen, a typical 
characteristic of empty tubular hollow organs, such as ureter or urethra. Shape recovery 
effect was introduced by in situ fixation using a star-shaped mandrel, 3D-printed clamps 
and cytocompatible carbodiimide crosslinking. Prepared scaffolds expanded upon 
increase of luminal pressure and closed to the star-shaped conformation after removal 
of pressure. In this study, we applied this method to construct a scaffold mimicking 
the dynamics of human urethra. Radial expansion and closure of the scaffold could 
be iteratively performed for at least 1000 cycles, burst pressure being 132 ± 22 mmHg. 
Scaffolds were seeded with human epithelial cells and cultured in a bioreactor under 
dynamic conditions mimicking urination (pulse flow of 21 s every 2 h). Cells adhered 
and formed a closed luminal layer that resisted flow conditions.
In conclusion, a new type of a tubular collagen scaffold has been constructed with 
radial elastic-like characteristics based on the shape of the scaffold, and enabling the 
scaffold to reversibly expand upon increase in luminal pressure. These scaffolds may 
be useful for regenerative medicine of tubular organs.
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1.  Introduction
Regenerative medicine (RM) of tubular or hollow organs is a developing field integrating 
a number of disciplines including material science, engineering, biomedical and clinical 
research [1]. Reconstruction of organs such as blood vessels [2], the gastrointestinal 
tract [3, 4], urogenital [5-7] and respiratory system [8] using RM constructs has been 
investigated and some constructs, e.g. tracheal scaffolds, have been successfully 
implanted in patients [9]. The majority of RM approaches apply scaffolds that function 
as a temporal extracellular matrix to direct tissue generation. Collagen has been 
extensively used as scaffolding biomaterial for tubular organs, due its wide availability, 
excellent biocompatibility and straightforward processing methods [10, 11]. However, 
collagen scaffolds often have limited strength [12] and lack inherent flexibility/elasticity, 
which restrict their use as tubular scaffolds. Elasticity is an important characteristic for 
tubular organs, e.g. for those organs such as the esophagus, stomach, ureter and urethra 
that are closed in the resting state, but expand when food or urine passes [13, 14]. 
The lumen of the ureter or urethra, for example, is partly star-shaped and closed when 
no urine is present, but opens during voiding due to urine pressure (Figure 1) [15-17]. 
After voiding, the smooth muscle layer surrounding the urethral lumen contracts 
and the lumen returns to its collapsed position by folding of the urethral wall. Upon 
increase in pressure, unfolding allows expansion of the lumen of the urethra. A rigid 
collagen scaffold would not comply with the native dynamics of the urethra, and 
Figure 1.  H is to logica l  images o f  c ross-sec t ions o f  the ureter  and urethra .  A)  H&E staining of 
human ureter showing the star-shaped lumen. B-C)  Azan staining of human urethra (corpus spongiosum 
of the penis) in closed B)  and opened C)  position showing the characteristic folded lumen that can expand 
to a circular lumen during urination. By courtesy of Dr. L.G. Poels and Dr. P.H.K. Jap (www.POJA-Collection-
Microscopic-Anatomy.com). Scale bars represent 500 µm.
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therefore scaffolds should be endowed with elasticity and shape memory. Recently, we 
developed a method to induce longitudinal elasticity in tubular collagen scaffolds by a 
process combining compression, corrugation and chemical crosslinking [18]. However, 
in the human body most tubular structures are fairly rigid in the longitudinal direction 
and display elasticity in a radial direction. We therefore adapted the methodology to 
construct tubular scaffolds with radial elasticity in order to comply with the dynamic 
characteristics of tubular organs. Using this method, the elasticity results from the 
inherent material properties as well as the unique design of the folded scaffold wall. To 
illustrate this innovative technology we describe here the construction a star-shaped 
folded collagen scaffold which exhibits shape recovery effect and is elastic in nature 
along the radial direction. 
2.  Materials  and methods
2.1.  Scaf fold construction
Insoluble type I collagen was purified from bovine achilles tendon [19]. A 1.0% (w/v) 
collagen suspension was prepared by mixing insoluble type I collagen with 0.25 M 
acetic acid. After overnight swelling, the suspension was homogenized at 2,500 rpm 
using a laboratory mixer (Silverson L5M-A, Chesham, UK). After removal of air bubbles 
by centrifugation at 100 g, the suspension was placed inside a 60 ml polypropylene 
mold (inner diameter 25 mm) with a centered stainless steel mandrel (diameter 15 
mm), frozen at -20°C, and lyophilized (Zirbus sublimator 500II, Bad Grund, Germany).
After lyophilization, the wall of the scaffold was compressed by placing the scaffold 
including mandrel between two flat aluminum objects and applying pressure and 
a rolling motion until a thin tubular sheet of collagen was obtained (Figure 2A). The 
mandrel was removed from the scaffold and a custom star-shaped mandrel (Figure 2B) 
printed from polyamide 12 (Nylon-12, Stratasys, Eden Prairie, Minnesota, USA) using 
a Fortus 360mc 3D-printer (Stratasys) was inserted into the lumen of the compressed 
scaffold. The scaffold was compressed around this five tip star-shaped mandrel. To 
fixate the scaffold, star-shaped 3-D printed compression clamps (Figure 2B) were 
placed around the scaffold, followed by crosslinking at ambient temperature for 3 h 
using 33 mM N-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, 
Merck Schuchardt OHG, Hohenbrunn, Germany) and 6 mM N-hydroxysuccinimide (NHS, 
Fluka Chemie AG, Buchs, Switserland) in 50 mM 2-morpholineoethane sulphonic acid 
(MES buffer, pH 5.0) (USB, Ohio, USA) containing 40% ethanol [19]. The constructs 
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Figure 2 .  Const ruc t ion of  a  fo lded,  s tar-shaped scaf fo ld wi th radia l  e las t ic i t y.  A)  Schematic 
representation of construction process. A porous tubular collagen scaffold is compressed between two 
surfaces under a rolling motion resulting in a compressed tubular scaffold. This scaffold is manually 
compressed around a five point star-shaped mandrel, fixed with custom-made clamps and crosslinked in 
the star-shape position using EDC/NHS. B)  3-D printed polyamide mandrel and clamp used in production 
process. C) Macroscopic view of scaffold in closed and partially open position. D) Expansion and relaxation 
(folding, unfolding) of scaffold after injection and removal of water (with bromophenol blue for detection 
of potential leakage).
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were incubated for 3 h at ambient temperature, but clamps were removed after 2 h. 
After crosslinking, the scaffolds were washed with 0.1 M Na2HPO4 (Merck, Darmstadt, 
Germany), 1.0 M NaCl, 2.0 M NaCl and demineralized water. Constructs were stored in 
70% ethanol at ambient temperature until further use.
2.2.  Scaf fold characterization
2.2.1.  Macroscopic charac ter ization
Macroscopic images were photographed using a Canon EOS-1DX Mark II with Canon 
macro objective (Canon, Melville, NY, USA). Supplementary movies were recorded with 
a Sony Cybershot DSC-H10.
2.2.2.  Scanning Elec tron Microscopy
Scanning electron microscopy (SEM) was used to analyze the morphology and 
structure of the scaffolds. Scaffolds were washed with demineralized water, frozen 
at -80°C and lyophilized. The dry samples were placed on a stub with double-sided 
carbon tape and sputtered with an ultrathin gold layer for 60 s (Scancoat Six Sputter 
Coater, Edwards, Crawley, United Kingdom). Examination was performed in a Sigma300 
scanning electron microscope (Carl Zeiss AG, Oberkochen, Germany) at an accelerating 
voltage of 10 kV.
2.2.3.  Mechanical  charac ter ization
Mechanical properties of the scaffolds were characterized using fatigue and burst 
pressure analysis using a Zwick/Roell Z2.5 tensile testing apparatus (Zwick/Roell, Ulm, 
Germany). Using a 60 ml syringe, water was injected into the star-shaped scaffold, 
which was closed at one end with a clamp and at the other end with a tube connected 
to a pressure transducer (Edwards, Irvine California USA) connected to the tensile 
tester software. Bromophenol blue was added to the water to detect leakage through 
the scaffold. For burst pressure analysis (n=8), the scaffold was filled at a velocity of 
13 ml/min until rupture. To analyze fatigue characteristics (n=8), the scaffold was 
filled with 10 ml water in 5 s and emptied in 10 s. This cycle was repeated 1000 times 
and for every cycle the peak pressure was measured. After the fatigue test, scaffolds 
were subjected to a burst pressure analysis. The burst pressure of a scaffold with a 
round lumen (compressed tubular scaffold in Figure 2A), not subjected to star-shaped 
compression, was also analyzed to investigate its effect on radial strength. To compare 
the mechanical properties of the scaffold with native tissue, the burst pressure of 
excised pig urethras (n=5) was analyzed similarly. 
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2.3.  Culture of  urothelial  cel ls  on scaf folds using a 
bioreactor system and voiding conditions
2.3.1.  Cel l  culture
SCaBER cells (ATCC, Manassas, VA, USA), a urothelial cell line derived from a squamous 
bladder carcinoma, were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium with GlutamaxTM (GIBCO, Life Technologies) enriched with 10% fetal bovine 
serum (GE healthcare, PAA Laboratories, Pasching, Austria), 100 IU/ml penicillin and 100 
µg/ml streptomycin (GIBCO, Life Technologies) at 37°C and 5% CO2. At 80% confluency, 
cells were passaged using 0.05% (w/v) trypsin-EDTA (Life Technologies). SCaBER cells 
were used as we were merely interested in cellular attachment and maintenance. 
SCaBER cells can be cultured in large quantities needed for the bioreactor experiment 
and have previously been used as a first in vitro evaluation step for biomaterials [20].
2.3.2.  Cel l  seeding on star-shaped scaf fold
Scaffolds (7 cm length, 15 mm inner diameter) were extensively washed in 0.1 M 
phosphate buffered saline (PBS, pH 7.4) (4x 1 h and 1x overnight using at least 250 
mL) and subsequently sterilized by 25 kGy gamma irradiation (Synergy Health, Ede, 
The Netherlands). The sterile star-shaped scaffolds were closed at both ends by 5-0 
Monocryl™ (Johnson & Johnson) sutures to prevent cells from leaking out. Next, 8.0 x 
106 cells in 7 ml were injected into the lumen of the scaffold via a 25G Microlance™ (BD, 
Drogheda, Ireland) needle. Seeded scaffolds were transferred to a 50 ml tube with 25 
ml culture medium and rotated at 10 rpm in a 37°C incubator. After 24 h, sutures were 
removed and scaffolds were transferred to a T75 flask (Greiner Bio-One) and cultured 
for 3 days at 37°C and 5% CO2. 
2.3.3.Dynamic cel l  culture in bioreactor
After 3 days of static culture, one quarter of the scaffold was transferred to a culture 
flask for further static culture as control. The other part was transferred to a Bose 
ElectroForce bioreactor (Eden Prairie, Minnesota, USA) using a custom-made reaction 
chamber (Lifetec Group, Eindhoven, The Netherlands). Tubes were connected to both 
ends of the star-shaped scaffold and the scaffolds were subjected to pulse flow of 21 
s every 2 h using a gear pump (Bose, Eden Prairie, Minnesota, USA), mimicking the 
average voiding characteristics in men [21]. The bioreactor contained 125 ml culture 
medium and was connected to a reservoir containing 250 ml culture medium to prevent 
depletion of culture medium. Cell-seeded scaffolds were cultured for 3 days in the 
bioreactor system. Three independent experiments were performed.
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2.3.4.  Morphological  evaluation
Sample preparation for scanning electron microscopy
Part of the cultured scaffold was fixed with 2% glutaraldehyde in 0.1 M phosphate 
buffer (PB, pH 7.4), followed by three washings with PB. After dehydration with an 
ascending gradient of ethanol solutions (30, 50, 70 and 100% v/v), samples were dried 
using a Polaron Critical Point Drier (Quorum Technologies, Ringmer, United Kingdom). 
Dry samples were analyzed with SEM as described in section 2.2.2.
(Immuno)histochemistry
Scaffolds were harvested and fixed in 4% (w/v) paraformaldehyde in phosphate 
buffered saline (PBS, pH 7.4). After washing with 0.1 M PBS, an ascending series of 
ethanol (70, 96, 99, 100% v/v) and xylene, the scaffolds were embedded in paraffin 
and sectioned (5 µm) using a Microm HM340E microtome (ThermoFischer). Slides were 
deparaffinized and stained with haematoxylin and eosin (HE).
In addition, scaffolds were embedded in TissueTek (Sakura Finetek Europe, Alphen aan 
de Rijn, The Netherlands), frozen using dry-ice cooled isopentane (2-methylbutane, 
Sigma Aldrich, St. Louis, USA) and ultrathin sections (5 µm) were obtained using 
a Microm HM 500OM Cryostat Microtome (Heidelberg Instrument Mikrotecknik, 
Heidelberg, Germany). Slides were immunostained for type I collagen, cytokeratin 
18, and cell nuclei (4’,6-diamidino-2-phenylindole, DAPI). Slides were blocked with 5% 
(v/v) normal goat serum (Sigma Aldrich, St. Louis MO, USA) in PBS with 1% (v/v) bovine 
serum albumin (BSA, Merck, Darmstadt, Germany) for 15 min. Slides were incubated for 
30 min with a mouse-anti-human cytokeratin 18 antibody (1:400, Mubio Products BV, 
Maastricht, The Netherlands) followed an incubation of 30 min with a rabbit-anti-bovine 
type I collagen antibody (1:250, Millipore, Cambridge, UK) followed by 3 washings with 
PBS. Secondary antibodies Alexa fluor 594-conjugated goat-anti-mouse IgG antibody 
and Alexa fluor 488-conjugated goat-anti-rabbit (both Invitrogen, Eugene, OR, USA) 
were consecutively incubated for 30 min followed by 3 washings with PBS. Cell nuclei 
were stained with 5 ʅg/ml DAPI (Sigma Aldrich, St. Louis MO, USA) for 15 min. Sections 
were washed 3 times with PBS and mounted with coverslips using Dako Fluorescence 
Mounting Medium (Agilent Technologies, Amstelveen, The Netherlands). Slides were 
analyzed using a Leica DM600B microscope (Leica Microsystems) and images were 
processed using ImageJ 1.48v (National Institutes of Health, USA). Brightness and 
contrast were manually adjusted for all photos including controls.
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2.4.  Statistical  analysis
GraphPad PRISM 5, version 5.03 (GraphPad Software Inc, La Jolla, CA, USA) was used 
for statistical analysis. For the burst pressure tests (section 2.2.3), different groups 
were compared using a one-way ANOVA with Bonferroni post-hoc tests. 
3.  Results
3.1.  Morphological  characterization
Tubular collagen scaffolds were created by swelling, homogenizing, freezing and freeze-
drying of a fibrillar type I collagen suspension. To mimic the folded wall morphology 
of an empty urethra (Figure 1), compression around a five tip star-shaped mandrel in 
combination with carbodiimide crosslinking was applied which resulted in a scaffold 
with a star-shaped lumen which was almost closed (Figure 2). The lumen could be 
expanded to the unfolded state with a diameter similar to the one before the star-
shaped compression (15 mm) by applying mechanical pressure (Figure 2D). When the 
pressure was removed, the lumen automatically returned to the star-shape in which 
it was crosslinked (shape memory, see movie 1). The shape-memory mechanism is 
entropy driven and observed in aqueous, but not dry, conditions (see movie 2).
SEM analysis of cross-sections of the scaffolds showed a star-shaped lumen and 
a porous inner structure of the luminal region (Figure 3A,B) and the tip region 
(Figure 3C,D). Further analyses revealed that the luminal surface of the scaffold was 
predominantly closed and smooth (Figure 3E,F), whereas the outside was also closed 
but had a more rough surface (result not shown). The thickness of the wall varied from 
approximately 150 µm (most central part of the fold) to 400 µm (most distal part of the 
fold), in line with the preparation method in which the walls are manually compressed 
against the mandrel. 
3.2.  Mechanical  characterization
To analyze biomechanical properties, the scaffolds were subjected to burst pressure 
and fatigue tests. The star-shaped scaffolds had an average burst pressure of 132 ± 
22 mmHg (n=8) (Figure 4A). Scaffolds that were first exposed to 1000 stretch-relax 
cycles (fatigue test) followed by burst pressure analysis showed a slightly lower, 
non-significant, burst pressure of 111 ± 14 mmHg (n=8). Round scaffolds that were 
not subjected to star-shaped compression (compressed tubular scaffold from Figure 
2A) had an average burst pressure of 52 ± 21 mmHg, indicating that the star-shaped 
4
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compression added radial strength to the scaffolds. Excised native pig urethras with 
part of the muscular tissue still present showed a burst pressure of 274 ± 93 mmHg 
(n=5). The fatigue test further indicated that the scaffolds kept their mechanical 
characteristics after exposure to 1000 filling and emptying cycles. The peak pressure 
measured during the filling cycles slightly decreased over time, especially in the initial 
phase, but stabilized in later cycles. In Figure 4B a representative graph of the peak 
pressure for every cycle is given showing a decrease in pressure from approximately 
28 mmHg to 24 mmHg.
Figure 3.  Microscopic evaluat ion of  the s tar-shaped col lagen scaf fo ld .  A-D) Cross-sectional SEM 
images of the overall luminal region (A+B)  with the tip region (C+D)  of the star-shaped scaffold showing 
the general morphology and porous structure. E+F)  SEM images of the luminal surface of the scaffold 
showing a mainly smooth and closed surface without pores. 
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3.3.  Dynamic cel l  culture in bioreactor 
To investigate whether cells remain attached to the star-shaped scaffold under dynamic 
conditions that they would experience under voiding conditions in vivo, SCaBER cells 
were seeded on scaffolds and cultured in a bioreactor system. Cells were first cultured 
for 3 days under static conditions to allow adherence to the scaffold. After this initial 
culture phase, the lumen of the scaffold was partly covered with monolayers of SCaBER 
cells (see Appendix, Figure A.1).
Next, the cell-seeded scaffolds were cultured for 3 more days in a bioreactor under 
dynamic flow conditions reflecting human voiding behavior. All scaffolds that were 
dynamically stimulated showed patency without graft failure. Shape memory was 
observed during the whole stimulation process. For comparison, static culture 
conditions were also applied. H&E staining of cross-sections of the scaffold showed 
that cells were distributed throughout the entire scaffold and formed multilayers under 
dynamic conditions (Figure 5A).
The thickness of the cell layers varied from a monolayer up to a layer of 5 to 6 cells in 
thickness (Figure 5A, inset), with about 75% of the lumen covered (Figure 5B). Cells 
Figure 4.  Mechanica l  proper t ies  of  the tubular  s tar-shaped,  e las t ic  scaf fo ld .  A)  Burst-pressure 
of round scaffolds without star-shaped compression, star-shaped scaffolds before and after fatigue test 
(both n=8), and of native pig urethras (n=5). Tubes were closed at both ends and water was pumped into the 
lumen until rupture while continuously monitoring the pressure. Bars represent mean ± standard deviation. 
One way ANOVA with Bonferroni post-hoc test, *** P<0.0001. B) Representative graph of a fatigue test of 
1000 expansion and closure cycles. Each dot represents a peak pressure at one specific cycle.
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resided on the scaffold’s luminal surface with almost no penetration into the scaffold 
wall. 
Figure 5.  Star-shaped scaf fo ld af ter  in i t ia l  cul ture per iod fo l lowed by 3 days dynamic cul ture. 
A)  H&E staining of cross-sections of cell-seeded star-shaped scaffolds. Panoramic view of H&E stained 
scaffolds cultured with cells under dynamic conditions for 3 days showing almost entire coverage of the 
luminal surface. Enlargements show that cells did not penetrate the scaffold but remained at the luminal 
surface. B) SEM image of the luminal surface of a scaffold cultured in a bioreactor showing cells partly 
covering the luminal surfaces. White arrows indicate the edge of the cell sheet. C)  Immunostaining of 
dynamically cultured scaffold stained for cell nuclei with DAPI (blue), type I collagen (green) and cytokeratin 
18 (red) showing that cells mainly reside on the scaffold’s surface and express cytokeratin.
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The mechanical stress caused by the pulse flow of 21 s every 2 h did not cause 
detachment of the cells from the scaffold when compared to the statically cultured 
scaffold (see Appendix A, Figure A.2.). Immunostaining for cytokeratin 18 indicated the 
epithelial character of the cultured cells (Figure 5C).
In general, no differences were observed between scaffolds cultured under static or 
dynamic conditions, indicating that the pulse flow did not have an effect on cellular 
attachment and maintenance. Moreover, cell numbers increased in time for both the 
static and dynamic condition as assessed by H&E staining (see Figure 5 and Appendix 
Figure A.1+A.2), indicating cytocompatibility. 
4.  Discussion
Tubular collagen scaffolds have been used in regenerative medicine of hollow organs 
such as blood vessels [2, 22], urogenital system [6, 23] and gastro-intestinal tract [24], 
but clinical translation is still limited. A number of methods have been developed to 
improve the morphology, 3D pore architecture and fiber alignment to enhance tissue 
regeneration [25]. To improve strength and to control biodegradability, crosslinking 
is often applied. In addition, biological active components such as growth factors [26] 
and glycosaminoglycans [19] have been used to stimulate the regeneration process. 
However, less attention has been paid to physiologically crucial mechanical properties 
such as elasticity and folding-unfolding. Especially for the many dynamic organs 
in the body ranging from lung to skin and from blood vessels to urethra, scaffolds 
should be developed with biomechanical characteristics that comply with the native 
organ, thus facilitating regeneration. A number of organs in the body physiologically 
“collapse” and become flat-folded when no food (e.g. esophagus) or urine (e.g. urethra) 
is present. In an empty state these organs are characterized by the process of infolding, 
in which the wall folds upon itself and forms a folded, star-shaped, lumen. Folding 
is an intrinsic characteristic of the wall, primarily caused by muscle tissue and the 
appropriate extracellular matrix. Mimicking these characteristics may be an advantage 
for regenerative medicine of such organs. In this study we aimed to construct tubular 
scaffolds with radial elastic-like characteristics enabling the scaffold to expand and 
close in radial orientation, using only fibrillar type I collagen as a biomaterial. 
As a proof of concept a star-shaped, folded scaffold was prepared to mimic the 
morphology and dynamics of the urethra. The technology used, based on inducing 
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entropy-driven elasticity by a molding and crosslinking process, is easily adaptable to 
other organs by modification of the molds and mandrels used. The scaffold presented 
here may be further optimized to have a diameter similar to the average diameter of 
the male urethra; approximately 6 mm in its expanded position during voiding [27]. 
Patient-specific adaptation of e.g. size and diameter can easily be realized by adapting 
the molds and mandrels.
The burst pressure of the scaffolds prepared was 132 ± 22 mmHg. A recent study 
of Pinnagoda et al. showed that a burst pressure strength of approximately 77.4 
± 2.4 cmH2O, comparable to 56.9 ± 1.8 mmHg, would be sufficient for successful repair 
of the urethra in a rabbit model [11]. For females, the mean urethral closure pressure 
is 60 mmHg in standing position [28]. For males the maximal urethral closure pressure 
ranges up to 150 cmH2O (110 mmHg) [29]. Vardar et al. showed that collagen scaffolds 
for ureter repair with a maximum intra-luminal pressure of 22.4 ± 0.1 cmH2O (16.5 ± 0.1 
mmHg) were in range with physiological pressures in adults [30]. Overall, the developed 
star-shaped scaffold is expected to be strong enough to withstand intra-luminal and 
physiological relevant pressures for urethra and ureter repair, but more dedicated 
experiments should be performed to confirm this.
Collagen scaffolds crosslinked with EDC and NHS are generally biocompatible in vivo 
[31, 32] and cytocompatible in vitro [10, 19], also in combination with compression 
techniques [18]. With our strategy to implant acellular scaffolds, cells from adjacent 
tissue migrating into the scaffold will experience mechanical stress when the scaffold 
expands and closes. We therefore assessed cellular behavior under dynamic culture 
conditions in a bioreactor mimicking the mechanical stress to which residing urothelial 
cells are exposed in the urethra (pulse flow of 21 s every 2 h).
Seeded SCaBER cells did not detach from the scaffold under static and dynamic culture 
conditions. About 75% of the lumen was covered by one or more layers of cells after 
three days of dynamic culturing, an important aspect as the urothelium functions as 
barrier to prevent leakage of urine to the underlying tissue [33]. Longer culturing may 
result in complete coverage. Overall, the expansion and closure of the scaffold does 
not seem to affect cytocompatibility. Our strategy for in vivo implantation is the use 
of acellular constructs without prior cell seeding where endogenous urothelial cells 
will line the lumen of the scaffold. This approach is feasible as indicated by Nuininga 
et al. [34].
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To the best of our knowledge, collagen scaffolds with radial elastic-like characteristics 
have not been reported before. This scaffold type may broaden the opportunities for 
use of collagen to regenerate hollow organs. By varying the concentration of collagen, 
the casting molds, and the extent of crosslinking, tailor-made tubular constructs can 
be prepared that have the ability to expand and automatically close. By using this 
technique, scaffolds can be prepared that comply with movements of dynamic tissues, 
such as those present in the urogenital and gastrointestinal system.
5.  Conclusion
In this paper, an enabling technology was developed to construct tubular collagen 
scaffold with elastic-like characteristics in a radial direction. Scaffolds expanded 
upon increase of luminal pressure, and automatically collapsed after the pressure 
was released (shape recovery). Scaffolds were cytocompatible. The technology may 
be useful for the construction of scaffolds for the regeneration of tubular tissue with 
radial elasticity such as blood vessels, ureter, urethra, esophagus, bowel or bile duct.
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Appendix
Figure A .1.  Star- shaped scaf fo ld  a f te r  in i t ia l  (3  days)  cu l ture  per iod .  Panoramic view of H&E 
staining of cross-sections of cell-seeded star-shaped scaffold cultured for 3 days showing that cells spread 
throughout the entire lumen of the scaffold. Enlargements show that the luminal surface is only partly 
covered  with SCaBER cells.
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Figure A .2 .  Star-shaped scaf fo ld af ter  in i t ia l  cu l ture per iod fo l lowed by 3 days s tat ic  cul ture. 
Panoramic view of H&E staining of cross-sections of cell-seeded star-shaped scaffold cultured under static 
conditions showing that cells maintained in the scaffold. Enlargements show that especially in the tip 
region the luminal surface is completely covered with a monolayer of cells, while the surface is only partly 
covered in the inner region of the lumen.
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Abstract
Collagen has been extensively used as a biomaterial, yet for tubular organ repair 
synthetic polymers or metals (e.g. stents) are typically used. In this study we report a 
novel type of tubular implant solely consisting of type I collagen, suitable to self-expand 
in case of minimal invasive implantation. Potential benefits of this collagen scaffold 
over conventional materials include improved endothelialization, biodegradation 
over time and possibilities to add bioactive components to the scaffold, such as anti-
coagulants.
Implants were prepared by compression of porous scaffolds consisting of fibrillar type 
I collagen (1.0-2.0% (w/v)). By applying carbodiimide crosslinking to the compressed 
scaffolds in their opened position, entropy-driven shape memory was induced. The 
scaffolds were subsequently crimped and dried around a guidewire. Upon exposure 
to water, crimped scaffolds deployed within 15-60 s (depending on the collagen 
concentration used), thereby returning to the original opened form. The scaffolds were 
cytocompatible as assessed by cell culture with human primary vascular endothelial 
and smooth muscle cells. Compression force required to compress the open scaffolds 
increased with collagen content from 16 mN to 32 mN for 1.0 to 2.0% (w/v) collagen 
scaffolds.
In conclusion, we report the first self-expandable tubular implant consisting of solely 
type I collagen that may have potential as a biological vascular implant.
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The main function of tubular structures, such as blood vessels or bile ducts, is the 
transportation of fluids. These structures may become blocked due to atherosclerotic 
diseases (e.g. stenoses) or malignancies. Biomaterials have proven to be effective tools 
to ensure patency of tubular structures. Currently the majority of devices for clinical 
use are permanent implants, mostly metals or medical textiles such as expanded 
polytetrafluoroethylene (ePTFE). The concept of biodegradability has gained interest 
over the last years as it comes with obvious benefits. The absence of foreign body 
material at long term follow-up may reduce the risk of complications such as occlusion 
of blood vessels and infection [1]. Currently used biodegradable implants for tubular 
tissues, often prepared from synthetic polymers or magnesium, only play a supportive 
role in keeping the structure open, but do not actively facilitate re-endothelialization. 
Materials of biological origin such as type I collagen may be more suitable as they are 
well known for their excellent biocompatibility [2].
Another important feature for tubular implants from biological origin would be the 
ability to self-expand (shape memory). Biodegradable thermally-induced shape 
memory tubular implants prepared from synthetic polymers have been developed and 
the Igaki-Tamai PLLA-based coronary stent has been successfully evaluated in humans 
[3]. However, alternatives prepared from materials of only natural origin are lacking.
Recently, a novel method was developed to endow collagen implants with entropy-
driven shape memory using straightforward carbodiimide crosslinking in combination 
with compression techniques [4]. The method was used to create a star-shaped 
tubular scaffold with a shape memory designed for luminal closure[5]. In the current 
communication, we report the construction of a novel tubular implant consisting of 
only type I collagen, with an inverse shape-memory. This scaffold has the ability to self-
expand from a crimped state to a tubular shape, similar to a self-expandable stent used in 
vascular disease treatment. Parameters such as deployment time, cytocompatibility and 
mechanical compression strength are addressed. To the best of our knowledge, this is the 
first self-expanding scaffold in the field of vascular medicine that consists of solely type 
I collagen and which may be suitable for minimally invasive implantation procedures,
i.e. it does not require the use of open surgery with accompanying risks of infection [6].
Tubular collagen scaffolds with a luminal diameter of 4 and 6 mm were prepared from 
insoluble fibrillar type I collagen purified from bovine Achilles tendon by swelling 
the collagen (1.0%, 1.5% and 2.0% w/v) in 0.25 M acetic acid followed by a casting, 
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molding, freezing and lyophilization process [4, 7]. These tubular scaffolds (Figure 1, 
step 1) were used as the starting point for preparation of the self-expandable collagen 
scaffolds. Scaffolds were compressed between two aluminum objects by applying 
pressure under a rolling motion until the scaffold had a film-like appearance (Figure 
1, step 2). Next, carbodiimide crosslinking was applied to stabilize the construct in 
the tubular film-like shape that it should have after implantation in a blood vessel. 
This step is crucial in inducing shape-memory. For crosslinking, the scaffolds were 
incubated in 50 mM 2-morpholineoethane sulphonic acid (MES buffer, pH 5.0, USB, 
Ohio, USA) containing 40% (v/v) ethanol, 33 mM N-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC, Merck Schuchardt OHG, Hohenbrunn, Germany) and 
6 mM N-hydroxysuccinimide (NHS, Fluka Chemie AG, Buchs, Switserland), followed by 
subsequent washing steps with 0.1 M Na2HPO4 (2 x 1h), 1.0 M NaCl (2 x 15 min), 2.0 M 
NaCl (2 x 15 min) and demineralized water (6 x15 min) after which they were placed 
in 70% (v/v) ethanol (Figure 1, step 3). Subsequently, tubular scaffolds were placed 
over a metal guidewire, crimped with 500 kPa using an automated radial compression 
machine (Blockwise Engineering, Tempe, AZ, USA) and air-dried for 15 min (Figure 1, 
steps 4+5).
Figure 1.  Produc t ion process of  the se l f- expandable vascular  implant .  Step 1)  Porous tubular 
collagen scaffolds with a luminal diameter of 6 mm (or 4 mm, not shown) were used as starting point. Step 
2)  The scaffolds were manually compressed between two flat objects and chemically crosslinked with the 
mandrel present. Step 3)  Compression and crosslinking resulted in a collagen scaffold with a film-like 
appearance. This scaffold was used for mechanical testing. Step 4) The compressed scaffold was crimped 
around a metal guide wire using a automated compression machine and air-dried in crimped position. 
Step 5) . The dry crimped collagen scaffold around a guide wire in crimped position that can expand upon 
exposure to water. Scale bar = 6 mm.
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To visualize the self-expanding property, the crimped scaffolds with original diameters 
of 6 mm were placed in a plastic tube with an internal diameter of 7 mm using a 
metal guide wire. Water was pumped through the tube using a 50 ml syringe to allow 
scaffolds to expand. In this experiment collagen scaffolds made from suspensions 
containing 1.0%, 1.5% and 2.0% (w/v) collagen were analyzed. Videos and images were 
recorded using a Sony HDR-CX405 camera (Sony, Tokyo, Japan). To show that the self-
expandability also works in the presence of blood plasma, the 1% scaffolds were also 
exposed to human blood plasma, obtained from a healthy volunteer.
To assess the ability of the tubular scaffolds to withstand compressive force, a tensile 
tester (Zwick/Roell Z2.5, Ulm, Germany) was used to apply force using a 20 mm square 
block as depicted in Figure 2C. This test simulated local compression of the scaffolds 
and subsequently the ability of the scaffolds to return to their original diameters was 
observed. A strain rate of 10 mm/min was applied until the scaffolds (6 mm diameter, 
60 mm length, 1.0%, 1.5% and 2.0% (w/v) collagen) were compressed to 50% of their 
original diameter. A self-expandable metal (nitinol) stent with comparable dimensions 
was similarly compressed to make a rough comparison of compression force between 
our scaffolds and existing devices. Applied force and displacement were recorded. 
Cytocompatiblity of three scaffolds (4 mm diameter, 1.0%, 1.5% and 2.0% (w/v) 
collagen) was evaluated by a cell culture experiment with human primary endothelial 
cells and human smooth muscle cells (Sciencecell, Carlsbad, CA, USA). In brief, scaffolds 
were cut to a length of 1 cm, placed in 1.5 mL Eppendorf tubes and washed with 70% 
(v/v) ethanol for disinfection. Next, scaffolds were washed extensively with phosphate 
buffered saline (PBS, pH 7.4) after which 1 mL cell suspension in endothelial growth 
medium-2 (Lonza, Basel, Switzerland) or smooth muscle cell medium (Sciencecell, 
Carlsbad, CA, USA) containing 1.3 x 105 cells was added. Seeded scaffolds were cultured 
overnight under rotation at 10 rpm in a 37°C incubator. After 24 h, scaffolds were 
transferred to 6-wells plates, cultured for 6 days, fixed with 4% paraformaldehyde in 
PBS and embedded in paraffin. Sections (4 µm) were stained with haematoxylin/eosin 
using fluoroshield mounting medium (Sigma, St Louis, MO, USA) and analyzed using a 
Leica DMLB microscope (H&E).
A self-expandable tubular implant was developed using a simple method based 
on chemical crosslinking of collagen, combined with compression and subsequent 
crimping of the scaffold. Upon exposure to water, the scaffold instantly deployed and 
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fixed to the tube wall, after which the metal guide wire could be easily removed (Movie 
1, 1.0% (w/v) collagen scaffold). Deployment time increased with a higher collagen 
content as the 1.0% collagen scaffolds fully deployed within 15 s, followed by within 25 s 
and 60 for the 1.5% and 2.0% scaffolds, respectively (Figure 2A). The 1.0% scaffolds were 
also tested upon exposure to human blood plasma, where they fully expanded in 45 s.
When submerged in water the collagen scaffolds fully expand, and after mechanical 
compression in water the scaffolds always returned to their fully expanded state.
Compression strength of the expanded collagen scaffolds increased with increasing 
collagen content; 16 mN, 29 mN and 32 mN for the 1.0, 1.5 and 2.0% (w/v) scaffolds 
respectively  (Figure 2C). For the 1.5 and 2.0% (w/v) construct significantly more force 
is required for 50% compression (p<0.001, one-way ANOVA with Bonferroni post-hoc 
test). However, compared to the self-expandable nitinol stent the collagen scaffolds 
are relatively weak at this stage, as a force of 1 N was required for 50% compression of 
the nitinol stent. The cytocompatibility study showed that both cell types covered the 
majority of the surface on which they were seeded after six days of culturing (Figure 
2B). H&E-staining showed that endothelial cells displayed an endothelial cell-like 
morphology. Note that due to the applied seeding procedure, both endothelial and 
smooth muscle cells were present on both the luminal side and the outside of the 
scaffold, but did not penetrate into the interior of the scaffold as shown by H&E (Figure 
2B, zoomed views). The scaffold shown in Figure 2 is a 1.0% (w/v) collagen scaffold 
which was also representative for the 1.5 and 2.0% (w/v) as those scaffolds also showed 
a confluent lining. Overall these results indicate appropriate cytocompatibility.
The collagen-based, tubular-shaped implant described can be crimped or folded to a 
fraction of its original size, but will re-expand upon exposure to water or blood plasma. 
This makes it a suitable material for minimally invasive implantation techniques. 
Vascular medicine was chosen as an example as the use of self-expandable devices 
is common practice in patient care in the treatment of vascular injuries in acute (e.g.
vessel perforation) and semi-acute (e.g. pseudoaneurysm) situations [8]. Vascular 
stents and endografts are inserted through endovascular sheaths and expanded 
on delivery, contact with liquids can be avoided until the construct is at the correct 
location. For secure positioning without displacement in a vessel with blood flow rapid 
expansion is essential and it is therefore advantageous that the scaffold deploys in less 
than one minute and presses firmly against the vessel wall to ensure maintenance of 
blood flow and to minimize the risk of migration of the device after implantation [9].
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A common limitation of vascular implants is the lack of re-endothelialization, thus the 
inability of endothelial cells to grow onto the implant. The observation that endothelial 
cells covered a large part of the luminal surface is promising in this respect. Cells did 
not migrate into the wall of the implant. This may be especially relevant for smooth 
muscle cells which may impair vascular healing due to excessive proliferation [10]. The 
observation that these cells could not enter the scaffold indicates that the collagen 
may provide a temporary barrier that may help to prevent intimal hyperplasia and 
restenosis [11]. In addition, the use of flexible collagen scaffolds may circumvent a 
Figure 2 .  Scaf fo ld dep loyment ,  c y tocompat ib i l i t y  and mechanica l  charac ter i zat ion .  A)  The 
crimped tubular collagen scaffolds of 1.0, 1.5 and 2.0% (w/v) were exposed to water inside a plastic tube. 
All scaffolds deployed within 1 min, a higher collagen content resulted in a longer deployment time, scale 
bar is 1 cm. B) Overview of endothelial cells and smooth muscle cells seeded on 1% collagen scaffolds with 
enlargements. Scale bars are 1 mm and 10 µm. C) Schematic representation of the mechanical analysis 
(left) and the results depicted in a graph (right) showing the force needed for compression of the tubes.
5
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 166
166
Chapter 5
common limitation of metal vascular implants which is the occurrence of stress 
fractures due to their rigidity, restricting their use in bending points (i.e. groin or knee).
The shape-memory principle, which is driven by newly-established hydrophobic 
interactions upon crosslinking [4], may not only be relevant for treatment of vascular 
damage, but can also be applied for a number of other organs like bile ducts [12]. In 
combination with modern imaging techniques a personalized 3D-printed mold for the 
collagen scaffold may be created for any desired shape and application.
The main limitation of the current tubular-shaped scaffolds for both vascular and other 
applications is the relatively poor compression strength. Increasing collagen content 
in the suspension improved the compression strength. However, scaffold strength 
can only be increased up to a certain limit using this method. Collagen content above 
2% complicates the scaffold production process because of the high viscosity of the 
collagen suspension. Whether this is a problem in vivo in the field of vascular medicine 
remains to be assessed: human veins also compress easily yet are successfully used 
as arterial conduits [13]. In case of vascular implants the stiffness of the stent must be 
large enough to resist migration, therefore these scaffolds require fortification and 
optimization for in vivo use. Additional methods to reinforce the collagen scaffold 
include the use of synthetic biodegradable polymers, or (biodegradable) metal meshes.
Collagen is often applied as a biomaterial because of its biodegradability and 
biocompatibility, but it has also been associated with thrombogenicity in blood vessel 
applications. Gelatin (denatured collagen), however, has been used to impregnate 
Dacron vascular grafts used in clinical practice, so as to make the material less 
permeable. This coating was not associated with increased thrombosis or restenosis 
[14]. When thrombogenicity presents as a problem, the material can be coated with 
heparin to prevent blood clotting using the same carbodiimide crosslinking step 
applied in this study [15].
In this short communication, we report the first self-expandable tubular implant 
consisting of solely type I collagen. It may allow implantation using minimal invasive 
techniques as it deploys within 60 s and is cytocompatible for vascular endothelial and 
smooth muscle cells. The implant may have potential for use as a biological vascular 
implant.
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Abstract
Type I collagen scaffolds for tissue reconstruction often have impaired mechanical 
characteristics such as limited stiffness and lack of strength, resulting in a disbalance 
with the surrounding tissue. In this study, a new technique is presented to fine-tune 
stiffness and biodegradability of collagen scaffolds by treatment with concentrated 
salt solutions.
Collagen scaffolds were prepared by a casting, freezing and lyophilization process. 
Scaffolds were treated with 90% saturated salt solutions, the salts taken from the 
Hofmeister series, followed by chemical crosslinking. Results show that treatment 
with highly soluble salts consisting of a divalent cation in combination with a 
monovalent anion, e.g. calcium chloride, resulted in fast shrinkage of the scaffolds up 
to approximately 10% of the original surface area. Effective salts were mostly at the 
chaotropic end of the Hofmeister series. Scaffolds were evaluated microscopically, 
biochemically and biomechanically, and the tissue response upon in vivo implantation 
was studied. Scaffolds shrunken by CaCl2 were used to evaluate salt-induced effects. 
Electron microscopy revealed a reduced pore size in scaffolds as well as a swollen, less 
organized structure of collagen fibrils. Biochemical analysis confirmed shrinkage to the 
level of individual collagen molecules. ICP-mass spectrometry and FTIR measurements 
indicated that no calcium deposits remained in the CaCl2 treated scaffolds. Using 
nanoindentation, shrunken scaffolds were shown to be more than 10 times stiffer than 
non-shrunken control scaffolds (7.4 x 103 Pa vs. 4.0 x 102 Pa, with peak values up to 3.0 
x 104 Pa). Subcutaneous implantation of CaCl2 treated scaffolds in rats showed similar 
biocompatibility compared to H2O and NaCl treated scaffolds. However, in contrast 
to H2O and NaCl treated scaffolds, CaCl2 treated scaffolds maintained their structural 
integrity without signs of major degradation after 3 months. 
In conclusion,  high concentrations of chaotropic salts can be used to adjust the 
mechanical characteristics of collagen scaffolds without affecting biocompatibility. 
This technique may be used in regenerative medicine to stiffen collagen scaffolds to 
better comply with the surrounding tissues. A molecular mechanism of the shrinkage 
is given. 
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1.  Introduction
Type I collagen has been extensively used in the field of tissue engineering and 
regenerative medicine, particularly as a scaffolding material and as a controlled release 
system [1]. Its excellent biocompatibility, widespread availability and straightforward 
processability render collagen a very useful biomaterial [2] that has been used in 
many (pre)clinical studies to repair tissues like skin [3], cartilage [4] and parts of the 
urogenital system [5]. However, type I collagen scaffolds often show poor mechanical 
characteristics in applications where the scaffold is exposed to mechanical stress [6]. 
Hence, collagen seems more suitable for soft tissues than for hard or stiff tissue such as 
bone. In addition, when large defects are to be repaired, e.g. in hernia diaphragmatica, 
mechanical strength is often insufficient [7].
To strengthen collagen scaffolds, techniques such as chemical crosslinking using e.g. 
carbodiimide or glutaraldehyde are applied [8-10]. Alternatively, other components 
can be added to the collagen in order to enhance mechanical properties. Typically, 
synthetic polymers such as PLLA [11], PCL [12] or PGA [13] have been used in this 
respect. However, addition of other components generally complicates the preparation 
process, may impair biocompatibility, and imposes additional regulatory constraints.
Increasing the concentration of insoluble type I collagen in a porous scaffold is another 
way to enhance mechanical stiffness [14]. However, this procedure is poorly controllable 
for insoluble fibrillar collagen since maximum concentrations correspond to about 2% 
(w/v) using the currently applied preparation techniques, which is insufficient for stiff 
tissues.
In this study, a method is presented that enables the construction of a micro porous 
collagen scaffolds with a defined stiffness that display little degradation in vivo for 
at least 3 months. The method is based on fast and extensive shrinkage of collagen 
scaffolds by treatment with highly concentrated salt solutions. The influence of several 
salts selected from the Hofmeister series is assessed. The Hofmeister series of salts 
is a classification of anions and cations based on their ability to increase or decrease 
protein stability, and to influence surface tension and solubility [15]. Salt-induced 
shrunken scaffolds are characterized both in vitro and in vivo. The use of this method 
may expand the applications of collagen-based constructs in the regeneration of 
tissues with defined stiffness.  
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2.  Materials  and methods
2.1.  Materials
N-Hydroxysuccinimide (NHS) was obtained from Fluka Chemie AG, Buchs, Switserland. 
Acetic acid, ammonium chloride (NH4Cl), ammonium sulfate ((NH4)2SO4), bovine 
serum albumin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), ethanol, 
glutaraldehyde, hydrogen chloride, nitric acid, paraformaldehyde, sodium chloride 
(NaCl), sodium hydrogen phosphate (NaHPO4) and sodium sulfate (Na2SO4) were from 
Merck, Darmstadt, Germany. Glycine was from Scharlau Chemicals, Barcelona, Spain. 
Barium perchlorate (Ba(ClO4)2), barium sulfate (BaSO4), calcium chloride (CaCl2), calcium 
sulfate (CaSO4), magnesium chloride (MgCl2), magnesium perchlorate (Mg(ClO4)2), 
2-(N-morpholino)ethane sulfonic acid (MES) and trinitrobenzene sulfonic acid (TNBS) 
were from Sigma Aldrich, St. Louis, MO, USA. Barium chloride (BaCl2) and magnesium 
sulfate (MgSO4) were from VWR International, Radnor, PA, USA.
2.2.  Methods
2.2.1.  Preparat ion of  shrunken col lagen scaf folds
Preparation of porous collagen scaffolds
Type I collagen fibrils were purified from bovine Achilles tendon using extractions steps 
with aqueous solutions of NaCl, urea, diluted acetic acid, acetone and demineralized 
water [16]. Purified collagen was suspended in 0.25 M acetic acid (0.8% w/v), swollen 
overnight, and subsequently homogenized using a Silverson L5M-A laboratory mixer 
(Silverson, Chesham, UK) by mixing for 6 min at 2,500 rpm (3 min with general purpose 
disintegrating workhead and 3 min with a slotted workhead). Next, the suspension was 
deaerated using centrifugation at 100 g for 30 min. The suspension was poured into 
12-well plates (1.5 mL) and 6-well plates (4 mL), frozen for 4 h at -20°C and lyophilized 
(Zirbus sublimator 500II, Bad Grund, Germany).
Shrinkage of scaffolds by Hofmeister series of salt treatment
To analyze the effect of different concentrated salt solutions, non-crosslinked 
porous scaffolds (Ø 22 mm) were exposed to 4 mL of 90% saturated salt solutions 
in demineralized water. Twelve salts were selected from the entire spectrum of the 
Hofmeister series (see Supplementary Table 1). To enhance penetration of the salt 
solution into the scaffold, the surface tension of 4 mL 90% saturated salt solutions 
was reduced by the addition of 10 µL 100% (v/v) ethanol. As a control, scaffolds were 
incubated in demineralized water with 10 µL ethanol. After 48 h, the surface of the 
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scaffolds was scanned (Epson V750 PRO) and the surface area was measured using 
image analysis software (ImageJ version 1.47i, NIH, Bethesda, MD, USA). For the 
salts that showed high shrinkage (more than 90% compared to original surface), the 
shrinkage was determined at different concentrations. All experiments were performed 
three times independently.
Shrinkage process for CaCl2
We focused on CaCl2, as it proved to be one of the most effective salts (see Results 
section). As controls, scaffolds were treated with NaCl (salt treatment, but no shrinkage) 
and demineralized water (H2O). Scaffolds were shrunken in an ascending series of CaCl2
to achieve gradual shrinkage. Briefly, they were first incubated for 15 min in 1 M CaCl2
or 1 M NaCl, followed by 15 min 2 M, and 30 min 4 M salt solution. Control scaffolds 
were incubated for 30 min in demineralized water. Macroscopic images were taken 
and videos of the shrinking process with CaCl2 were recorded with a Sony Cyber-shot 
DSC-H10 (Sony, Minato, Tokyo, Japan).
Stabilization of scaffolds by chemical crosslinking
After incubation in 4 M salt solution or demineralized water, scaffolds were immediately 
crosslinked using a carbodiimide zero-length crosslinker. In brief, scaffolds were 
incubated in 4 mL 50 mM MES buffer, pH 5.0, containing 40% (v/v) ethanol, 33 mM
EDC and 6 mM NHS for 3 h. Next, the scaffolds were extensively washed 6 times with 
demineralized water to remove residual crosslinking reagents and salt. Non-crosslinked 
scaffolds were also washed 6 times with demineralized water. Finally, scaffolds were 
placed in 70% (v/v) ethanol and stored at -20°C until use.
Sterilization of the scaffolds
Scaffolds used for in vivo evaluation were sterilized in PBS using gamma radiation at 
25 Gy from a 60Co source (ISO 9001; Synergy Health BV, Ede, The Netherlands). Before 
sterilization, Æ 6 mm discs were cut from the scaffolds after which they were washed 
6 times with PBS to remove ethanol. 
2.2.2.  Scaf fold charac ter ization
Scanning electron microscopy
For scanning electron microscopy, crosslinked scaffolds were washed in demineralized 
water to remove storage medium, and subsequently frozen at -80 °C. The frozen 
scaffolds were lyophilized, mounted on stubs with double-sided carbon tape, and 
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coated with an ultrathin gold layer (Scancoat Six Sputter Coater, Edwards, Crawley, 
United Kingdom). The samples were evaluated with a Sigma 300 field emission 
scanning electron microscope (Carl Zeiss B.V., Sliedrecht, The Netherlands) with an 
accelerating voltage of 10 kV. The pore sizes of the different scaffolds were determined 
using ImageJ analysis software.
Transmission electron microscopy
Scaffolds were fixed in 2% (w/v) glutaraldehyde in 0.1 M phosphate buffer (PB), pH 7.3 for 
24 h at 4°C. After washing steps in PB, scaffolds were treated with 1% osmium tetroxide 
in 0.1 M PB for 1 h. Next, scaffolds were washed in PB, dehydrated in graded series of 
alcohol and embedded in Epon 812. Sections (1 µm) were cut, stained with toluidine 
blue and examined with a light-microscope (Dialux 20, Leitz). Ultrathin sections 60 nm 
were cut, followed by treatment with uranyl-acetate/lead-citrate for double contrast. 
Sections were imaged using a transmission electron microscope (JEOL 1010).
Determination of stiffness
The stiffness of CaCl2, NaCl and H2O treated collagen scaffolds were measured with the 
PIUMA nano-indenter (Optics11, Amsterdam, The Netherlands; Figure 3A) [17]. Before 
the measurement, scaffolds were incubated in PBS for 30 min followed by a passivation 
step of 60 min in 5% bovine serum albumin in PBS to prevent adhesion of the probe 
to the scaffolds.
Per sample, 25 indentions were performed in a grid of 1 x 1 mm with a distance of 200 
µm between individual indentations (Figure 3B). For soft samples, an indenter probe 
with a stiffness of 0.05 N/m was used and for stiffer samples a probe with a stiffness of 
0.47 N/m. Both probes had a tip diameter of 180 µm. The indentation depth, reached 
with a speed of 5 µm/s, was 15 µm and the probe was kept in place for 2 s (indentation 
time). Each scaffold type was measured 3 times independently.
Calcium analysis of CaCl2 treated scaffolds
Two distinct methodologies were used to determine potential remnants of the CaCl2
shrinking treatment. Inductively coupled plasma mass spectrometry (ICP-MS) was 
performed to detect elemental calcium, and Fourier transform infrared spectroscopy 
(FTIR) was performed to detect the presence of calcium-containing compounds which 
may have been formed after CaCl2 treatment.
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For the ICP-MS measurement, scaffolds were first hydrolyzed with 50% (v/v) nitric 
acid and subsequently diluted to a final concentration of 0.05 mg/ml in 1% nitric acid. 
Samples were analyzed using a Xseries I – ICP-MS (Thermo Fisher Scientific, Waltham, 
MA, USA). The total calcium content was calculated based on the measurement of the 
43Ca isotope as 40Ca interfered with other elements. One-way ANOVA with Bonferroni 
post-hoc testing was performed to determine statistical differences.
Fourier Transform Infrared Spectroscopy (FTIR, Spectrum Two, Perkin Elmer, Waltham, 
MA, USA) was used to study the presence of calcium-containing compounds in the 
scaffolds. The FTIR spectra were measured in Attenuated Total Reflectance mode, with 
a spectral resolution of 4 cm−1, a scan speed of 0.2 cm s−1 and 10 scans per measurement.
Differential scanning calorimetry
Differential scanning calorimetry (DSC Q1000, TA Instruments, New Castle, DE, USA) was 
used to assess potential denaturation of type I collagen caused by the salt treatment 
by measuring the denaturation temperature of non-crosslinked scaffolds treated with 
CaCl2, NaCl and H2O. Purified insoluble type I collagen (starting material for scaffold 
preparation) was used as a control. Samples (~1 mg) in aluminium pans with 25 ʅL 
PBS were heated from 1 to 80°C with a rate of 5°C/min. The endothermic peak was 
determined using TA Instruments Universal Analysis 2000 software (Version 4.5A).
Gel electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
to assess potential denaturation of collagen in the scaffold after salt treatment. Briefly, 
2-3 mg of non-crosslinked collagen scaffolds was digested overnight at ambient 
temperature in 75 µL 0.25 M acetic acid containing 3 mg/mL pepsin after which an equal 
volume of a 2-fold concentrated non-reducing sample buffer was added. Samples and 
controls were loaded on an 8% (w/v) polyacrylamide gel without prior heating. After 
running at 150 V, the gel was stained with 0.1% (w/v) Coomassie Brilliant Blue solution.
Evaluation of the degree of crosslinking
The degree of crosslinking of the salt treated scaffolds was calculated by assaying 
the loss of primary amine groups after crosslinking using a TNBS assay [18]. After salt 
treatment, crosslinking and rinsing steps with water, the scaffolds were lyophilized 
and subsequently incubated for 30 min in 4% (w/v) NaHPO4 at 22 °C. Subsequently, 
samples were incubated for 2 h at 40 °C in 0.5% (w/v) TNBS in demineralized water, after 
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which the samples were hydrolyzed with 6 M HCl for 1.5 h at 60 °C. Absorbance at 420 
nm was measured with a spectrophotometer (Bio-Tek, Bad Friedrichshall, Germany). 
Glycine was used for the calibration curve. Non-crosslinked controls for each condition 
were used to calculate the percentage of crosslinked amine groups. Experiments were 
performed in triplicate in three different experiments.
2.2.3.  In  vivo evaluation of  salt  treated scaf folds in a  rat  model
The study was approved by the Ethical Committee on Animal Research of the Radboud 
University Nijmegen, The Netherlands (RU-DEC 2013-144) and executed according to 
Dutch legislation and guidelines for the use of laboratory animals.
Nine male Wistar rats (Harlan Laboratories, Horst, The Netherlands) of 3 months old 
(~400 g) were housed in trios in a controlled environment (19-21°C, 12-12 h day/night 
cycle) with ad libitum access to food and water.
Using Microsoft Excel, the rats were randomly divided over three experimental groups. 
Rats were anesthetized with 2-3% (v/v) isoflurane, and received buprenorphine by 
intramuscular injection as analgesic. Three different scaffolds (a CaCl2 treated scaffold, 
a NaCl treated scaffold, and a H2O treated scaffold) were randomly implanted in 
three different subcutaneous pockets created on the back of each rat. At the time of 
implantation, researchers performing evaluations were blinded for the type of scaffold 
by naming them A, B and C. Reference sutures (Prolene 5.0, Ethicon, Somerville, NJ) 
were placed next to the scaffold. Wounds were sutured using Prolene 5.0 and for 
reinforcement of the sutures hog rings were placed over the wound. Immediately 
after surgery and 12, 24, 36 and 48 h later, rats received additional buprenorphine via 
intramuscular injection. During the whole experiments the general health condition 
of the rats was monitored. At 3 days (group 1), 14 days (group 2) and 90 days (group 3) 
after implantation the animals were sacrificed using carbon dioxide gas. Scaffolds were 
excised from the subcutaneous pockets, fixated using 4% (w/v) paraformaldehyde in 
phosphate buffer (pH 7.4) and embedded in paraffin. Sections (5 µm) were obtained 
using a HM 340E Electronic Rotary Microtome (Thermo Fisher Scientific, Waltham, MA, 
USA). Tissue sections were stained with haematoxylin/eosin and Elastin Von Masson. To 
visualize calcifications, a Von Kossa and an Alizarin red staining were performed. Blinding 
was applied for the animal experiments; however, at time of evaluation the blinded 
feature of this study was lost due to the distinct characteristics of each scaffold type.
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3.  Results
3.1.  Ef fect  of  salts  f rom the Hofmeister  series  on col lagen 
scaf folds
To evaluate the effect of the Hofmeister salts on porous disc-shaped collagen scaffolds, 
scaffolds were incubated for 48 h in 90% saturated solutions. For a number of salts 
(e.g. CaCl2) large shrinkage of the scaffolds was observed, whereas other salts caused 
intermediate, minor or no shrinkage (Figure 1). The surface area was shrunken for 
more than 90% in case of CaCl2 (93±1%, Figure 1A), Ba(ClO4)2 (91±1%), MgCl2 (93±1%), 
and Mg(ClO4)2 (94±1%) (Figure 1B). The process was extremely fast: within 30 s the 
scaffold had almost completely shrunken (Movie 1). Salts that caused only limited 
shrinkage were MgSO4 (8±11%), Na2SO4 (13±7%), NaCl (15±8%), NH4Cl (20±9%), CaSO4
(28±14%), and BaCl2 (39±8%). (NH4)2SO4 and BaSO4 displayed no shrinkage. In general, 
salts containing divalent cations in combination with monovalent anions, resulted in 
major shrinkage of the scaffold.
Focussing on salts that induced shrinkage of >90%, we studied the minimal 
concentration required to achieve full shrinkage of the scaffold (Figure 1C). For 
Mg(ClO4)2 and Ba(ClO4)2 this was 1 M, whereas for CaCl2 and MgCl2 it was 1.5 and 3 M, 
respectively. Being one of the most effective salts for shrinkage, CaCl2 was selected 
for further studies, and we compared this salt treatment to treatment using NaCl and 
H2O only.
3.2.  Morphological  characterization
Scaffolds treated with CaCl2, NaCl and H2O were characterized with scanning and 
transmission electron microscopy. Cross-sectional images revealed that salt treated 
scaffolds remained porous (Figure 2, left panels). CaCl2 treated scaffolds displayed 
circular pores but, compared to the H2O treated scaffold, the pore size decreased 
from 40 – 120 µm to 20 – 60 µm. In the NaCl treated scaffolds, the pore structure had 
somewhat flattened and the size of pores was slightly decreased.
CaCl2 treatment had a distinct swelling effect on the individual collagen fibrils in the 
scaffolds. The fibrils in the pore wall of CaCl2 treated scaffolds appeared distended, 
resulting in the loss of the characteristic banding pattern, whereas clear striation 
patterns were visible in NaCl and H2O treated scaffolds (Figure 2B-C, right panels). 
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Figure 1:  The shr inkage e f fec t  o f  d i f fe rent  sa l t s  f rom the Hofmeis ter  ser ies  on 0 .8  % (w/v) 
co l lagen scaf fo lds .  A)  Type I collagen scaffold before and after exposure to 4 M CaCl2. B)  The effect of 
90% saturated salt solutions (x-axis) on the surface area of on collagen scaffolds. Note that Ba(ClO4)2, CaCl2, 
MgCl2, and Mg(ClO4)2 induced shrinkage to over 90% compared to control scaffolds, n=3. Statistical analysis: 
One-way ANOVA with Bonferroni post-hoc test, p<0.001. Note: due to variability in solubility, the 90% 
saturated salt solutions vary in molarity (see Supplementary Table 1). C)  The effect of salt concentration 
(x-axis) on the degree of shrinkage (y-axis) for a subset of salts that showed over 90% shrinkage in Figure 
1B, n=3.
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3.3.  Mechanical  characterization
The shrinking process may have an effect on the mechanical properties of the 
scaffolds due to the increased collagen content per volume. Therefore, the stiffness 
was assessed using nanoindentation (Figure 3A). CaCl2, NaCl and H2O treated scaffolds 
were measured three times independently with 25 indentations on different locations 
per scaffold (Figure 3B). CaCl2 scaffolds (7.4 x 10
3 Pa) were stiffer compared to the NaCl 
(1.2 x 103 Pa) and the H2O treated scaffolds (4.4 x 10
2 Pa). Peak values even showed a 
stiffness of more than 3.0 x 104 Pa, most likely when the tip indented exactly on top 
of a pore wall indicating that the stiffness of CaCl2 treated collagen material is even 
higher than 7.4 x 103 Pa.
3.4.  Presence of  calcium or calcium-containing compounds 
in col lagen scaf folds
Inductively coupled plasma mass spectrometry showed that the CaCl2 treated scaffold 
contained only 17.8±5.2 ppb calcium corresponding to 0.36±0.03 ng per µg scaffold 
(Table 1). The NaCl and H2O treated scaffolds contained 0.25±0.02 and 0.29±0.1 ng 
calcium per µg scaffold respectively, which were both not significantly different from 
the CaCl2 treated scaffold (one-way ANOVA with Bonferroni post-hoc testing, p>0.05). 
This suggests that no remnants of the calcium treatment were present in the CaCl2
Figure 2: Morphological character ization of col lagen scaf folds . Scanning and transmission electron 
microscopical images of A)  a CaCl2 treated scaffold showing the altered pore structure and the swollen 
fibrils without banding pattern; B,  C )  NaCl B)  and H2O C)  treated scaffolds showing the characteristic 
striation of collagen fibrils indicated with black arrows.
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shrunken scaffolds. Using Fourier-transform infrared spectroscopy no absorption 
peaks were detected that could be attributed to calcium-containing compounds (Table 
1).
3.5.  Degree of  crossl inking 
The degree of crosslinking in the CaCl2, NaCl, and H2O treated scaffolds was estimated 
by loss of primary amine groups (Figure 4). Non-crosslinked CaCl2, NaCl, and H2O 
treated scaffolds contained 241±41, 244±43, 246±37 nmol of primary amine groups 
per mg collagen, respectively, whereas crosslinked scaffolds had 81±12, 111±8 and 
139±10 nmol. The reduction of primary amine groups was 66% for the CaCl2 treated 
scaffold, 55% for the NaCl treated scaffold and 42% for the H2O treated scaffold (Figure 
4A). The difference in crosslinking percentage between the three scaffolds types were 
statistically different as assessed by a one-way ANOVA with Bonferroni post-hoc 
testing, p<0.05.
3.6.  Degree of  denaturation
Electron microscopical images of CaCl2 treated scaffolds displayed swollen fibrils 
which may be caused by partial denaturation induced by CaCl2. Differential scanning 
calorimetry showed that denaturation temperature was reduced from 58±2°C (type 
I collagen) to 47±1°C after calcium treatment indicating denaturation (Figure 4B). The 
denaturation temperature of the H2O (59±1°C) and NaCl (59±1°C) treated scaffolds did 
not change significantly from purified insoluble type I collagen.
Figure 3.  Mechanica l  charac ter izat ion us ing nanoindentat ion .  A)  Working mechanism of PIUMA 
nanoindentation equipment: a probe (1) connected to a cantilever (2) indents the sample (3) and bends 
through. The degree of bending is measured via an optical cable (4) and converted to the degree of stiffness. 
B) Locations of indentation on the scaffold visualized with a representative SEM image. C) The stiffness of 
CaCl2, NaCl and H2O treated scaffolds measured with a PIUMA nanoindentation apparatus. Each condition 
was tested in triplicate with 25 indentations per scaffold. Bars represent mean ± standard error of the 
mean. One way ANOVA with Bonferroni post-hoc test, *** p<0.0001.
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 183
183
A salt-based method to adapt stiffness and biodegradability of porous collagen scaffolds
Figure 4. Biochemical and biophysical character ization of CaCl2,  NaCl and H2O treated scaf folds . 
A)  Degree of crosslinking (TNBS-assay) indicating differences between scaffolds (n=3, one–way ANOVA 
with Bonferroni post-hoc test, *p<0.05, **p<0.01). B)  Denaturation temperature (Td) of purified insoluble 
type I collagen and various scaffold types indicated that CaCl2 treatment lowered the Td (n=6, one–way 
ANOVA with Bonferroni post-hoc test, ***P<0.001). C) SDS-PAGE gel of purified insoluble type I collagen, 
CaCl2, NaCl and H2O treated scaffolds with and without pepsin treatment indicating that CaCl2 treatment 
causes denaturation of the triple helix. The red arrows indicate the location of ɲ, ɴ, and ɶ bands after pepsin 
digestion and the black arrows indicates the location of ɲ bands after CaCl2 treatment.
SDS-PAGE substantiated that CaCl2 treatment induced denaturation (Figure 4C). When 
insoluble type I collagen is not denatured, no bands will be visible on an SDS-PAGE gel, 
as shown by the control samples (H2O and NaCl treated scaffolds). The CaCl2 treated 
collagen showed clear collagen ɲ-chain bands (black arrows) indicating denaturation 
of the insoluble type I collagen fibrils. In the lanes loaded with pepsin treated samples, 
ɲ, ɴ, and ɶ bands were detected for H2O and NaCl treated scaffolds (see red arrows in 
Figure 4C), while for CaCl2 treated scaffolds a smear was observed. Pepsin usually does 
not cleave intact type I collagen triple helices, but if the helix is partially denaturated it 
will become susceptible for pepsin cleavage over the entire helix, resulting in a smear. 
Consequently, the results of the SDS-PAGE indicate that CaCl2 induced denaturation 
of the triple helix.
3.7.  In vivo biocompatibi l ity
All rats survived surgery without complications and did not seem to experience any 
discomfort caused by the subcutaneously implanted scaffolds throughout the entire 
study. The surgical wounds healed normally.
In the rats sacrificed 3 days after implantation, the original shape of all scaffolds was 
maintained, but they were covered with a macroscopically visible layer of fibrous 
tissue. Visual signs of inflammation were absent, but histologically a mild immune 
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response was observed for all scaffolds based on the presence of granulocytes and 
macrophages. For the CaCl2 treated scaffolds, granulocytes and giant cells were located 
at the rims of the scaffold (Figure A.1).
In the rats sacrificed 14 days after implantation, all scaffolds were partially encapsulated 
and upon excision it appeared that the H2O and NaCl treated scaffolds had lost their 
original shape, while the CaCl2 treated scaffolds looked intact. Microscopic analysis 
showed increased cellular infiltration in H2O and NaCl treated scaffolds, which may 
contribute to the deformation, possibly by biodegradation of the scaffold (Figure A.1).
In the rats sacrificed 90 days after implantation scaffolds treated with H2O and NaCl 
showed to be deformed indicating degradation, whereas the CaCl2 treated scaffolds 
still looked intact. All scaffolds were fully encapsulated as can be observed in the H&E 
staining in Figure 5. H&E and Elastin von Masson (EvM) stainings indicated that cells 
(giant cells, monocytes, macrophages and fibroblasts) infiltrated the H2O and NaCl 
treated scaffolds (Figure 5B+C, left and middle panel). Cell migration was limited for the 
CaCl2 treated scaffolds as cells were only observed in the outer edges of the scaffold 
(Figure 5A, left and middle panel). For all scaffolds the immunological reaction was mild. 
Alizarin Red and Von Kossa stainings indicated the absence of calcium/calcification in 
the implanted scaffolds (Figure 5C, right panels). See Figure A.2 for positive controls 
(human bone tissue).
4.  Discussion
4.1.  Scaf fold proper ties
Over the years, methods to enhance stiffness of insoluble type I collagen scaffolds have 
been widely investigated. Generally, crosslinking techniques are applied to stabilize 
collagen scaffolds, which increase their overall strength, cohesion and stiffness [9]. 
However, for a number of applications this is not sufficient and (synthetic) polymers 
have been added to further improve mechanical properties [19]. In this study, a simple 
method is described to adapt the stiffness of collagen scaffolds and increase their 
strength. The method is based on treatment with a concentrated salt solution resulting 
in major shrinkage of the scaffolds, thus increasing the collagen concentration in the 
walls of the porous constructs. The method resulted in rigid collagen scaffolds that 
were more than 10 times stiffer than untreated scaffolds, while in vivo biocompatibility 
was maintained. 
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By adjusting the type and concentration of the salt used, the method may allow 
the construction of scaffolds with a specific stiffness. This is relevant since every 
tissue in the human body has its own characteristic stiffness caused by a distinct 
composition of the extracellular matrix. In recent years it has become clear that 
stiffness of the extracellular matrix plays an important role in differentiation of stem 
cells [20]. Consequently, to achieve optimal tissue regeneration it is important to take 
the stiffness of the target tissue into account when designing biomaterials. Current 
applications of collagen scaffolds are often limited to soft tissues, e.g. skin. Scaffolds 
Figure 5:  B iocompat ib i l i t y  of  CaCl2,  NaCl ,  and H2O t reated scaf fo lds s tudy in a  subcutaneous 
rat model .  In the left panel H&E overview images are depicted of a CaCl2 treated scaffold A), a NaCl treated 
scaffold B), and a H2O treated scaffold C)  90 days after implantation. On the right, enlarged images of similar 
magnification are shown for every scaffold type. Image 1: H&E staining, 2: Elastin von Masson staining, 
3:Alizarin Red staining, 4:Von Kossa staining.
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treated with the shrinking method showed to have an average stiffness of 7.4 x 103 Pa 
with peak values of 3.0 x 104 Pa. Consequently, this may expand the application range 
of collagen scaffolds to harder tissues such as muscle (~7-18 kPa), cartilage (~25 kPa) 
and unmineralized bone (~35 kPa) [21, 22].
4.2.  Molecular  mechanism of  shrinkage
To investigate the molecular mechanism responsible for the shrinkage, the effect of salts 
from the Hofmeister series on collagen scaffold was analyzed. Only highly concentrated 
salts with divalent cations (Ca2+, Mg2+ and Ba2+, all at the chaotropic site of the series) 
Figure 6.  Schematic representation of proposed molecular mechanism of shr inkage. A)  Ca2+ ions 
destabilize the triple helix by first binding to carboxylic groups and secondly by disrupting the hydrogen 
bonds inside the triple helix resulting in swelling of the triple helix, making it thicker but shorter. B)  The 
fibril structure changes dramatically after addition of Ca2+ ions: they become thicker and shorter. C)  The 
thicker and shorter fibrils result in shrinkage of the collagen scaffold.
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in combination with an anion (not being sulfate) were able to induce shrinkage up to 
90% of the initial surface area. EM images of shrunken collagen scaffolds showed that 
fibrils were swollen and had lost their characteristic banding pattern. A phenomenon 
described in leather research as ‘lyotropic swelling’, may explain the shrinkage [23]. 
During lyotropic swelling, cations such as Ca2+ disrupt the hydrogen bonds that stabilize 
the triple helical structure. The cations interact with negatively charged carboxylic 
groups, thereby attracting water inside the helix, causing it to swell. For collagen, we 
propose the mechanism displayed in Figure 6. Type I collagen molecules consist of 2 D1
and 1 D2 polypeptide chains, which are very close together (triple helix conformation), 
and are shifted one amino acid with respect to each other. This brings the carboxylic 
groups of the Glu and Asp amino acid residues in e.g. two D1 chains (~100 Glu/Asp per 
chain) in close proximity to each other. Bivalent cations such as Ca2+ bind very well to 
two close carboxylic groups, and this may be an initiating event in the denaturation 
of the triple helix and the subsequent swelling process. In contrast to reversible 
collagen swelling with 0.25 M acetic acid at pH 2.5 where fibrils start to repel each 
other because they have a similar charge due to the pH effect, lyotropic swelling takes 
place inside the triple helix and is irreversible [24]. When triple helices are exposed to 
high concentrations of cations such as Ca2+, the triple helix gets disrupted (Figure 6A, 
upper panel) causing the helix to swell. As a consequence, additional Ca2+ can enter the 
inner core of the helix and disrupt the hydrogen bonds that stabilize the helix structure 
resulting in (partial) denaturation of the triple helix. However, the (natural) covalent 
bonds between the individual triple helices are not affected (Figure 6A, middle panel), 
preventing the fibril to fall apart. Consequently, as the helices swell, they become 
thicker and shorter (Figure 6A, lower panel). On the level of fibrils this will lead to 
swollen but shortened fibrils (Figure 6B). When this occurs throughout the scaffold it 
will result in an increased thickness of the pore walls and reduced pores sizes ultimately 
leading to shrinkage and stiffening of the entire scaffold. This process is irreversible 
and it was observed that the scaffolds remain shrunken upon removal of CaCl2.
4.3.  Biocompatibi l ity  and potential  applications
Type I collagen has shown to be a biocompatible scaffolding material in many studies 
[25] also in combination with EDC/NHS crosslinking [26, 27]. After CaCl2 treatment the 
collagen triple helix was partly denaturated as indicated by a decrease in denaturation 
temperature and the appearance of (pepsin-sensitive) ɲ-chains on SDS-PAGE. 
However, subcutaneous implantations of the CaCl2 treated scaffold revealed a similar 
cellular response as observed for H2O and NaCl treated scaffolds indicating proper 
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biocompatiblity. The major difference was that the CaCl2 treated scaffolds were barely 
infiltrated by cells explaining that the scaffolds were still looked intact 90 days after 
implantation maintaining their morphology. Biodegradability was clearly decreased 
and this may open ways to prepare collagen-based scaffold with long-term integrity. 
The method developed to stiffen collagen scaffolds opens new opportunities in the 
field of regenerative medicine. By manipulating a number of parameters such as 
collagen concentration, CaCl2 concentration or shrinkage time, scaffolds with varying 
stiffness may be created. The preparation of such a wide stiffness range may serve as an 
in vitro platform for stem cell research to further investigate the role of stiffness on stem 
cell differentiation in a natural 3D extracellular matrix. Currently, this role is generally 
evaluated using synthetic hydrogels prepared from e.g. polyacrylamide [20, 28, 29]. A 
3D environment created from a natural component of the human extracellular matrix 
would resemble the native stem cell niche more closely and may be advantageous to 
further elucidate the molecular mechanism involved in tissue regeneration and stem 
cell differentiation.
The in vivo results indicated that 90 days after implantation the CaCl2 treated scaffolds 
were intact, not deformed by surrounding tissue, and hardly populated by cells in 
contrast to untreated scaffolds. The CaCl2 treated scaffolds seemed to act as a very 
slow degrading implant maintaining their morphological and mechanical properties 
over a long time period. In this respect, a function as a reservoir facilitating sustained 
release of drugs (e.g. anti conception) or antigens (immunization) may be anticipated. 
The biocompatibility in combination with the slow degradation properties of CaCl2
treated scaffolds may be interesting as a coating for medical implants such as glucose 
sensors as shown in a study by Yu et al. [30].
5.  Conclusions
In this study, a method was developed to enhance stiffness of porous scaffolds prepared 
from type I collagen using concentrated salt solutions, as exemplified by CaCl2. The 
observed shrinking effect, likely driven by the disruption of stabilizing hydrogen bonds 
in the triple helix, resulted in stiffer scaffolds with retention of microporosity, with 
reduced biodegradability, and similar biocompatibility compared to control scaffolds. 
The method may be useful for the construction of collagen scaffolds with stiffness in 
line with the tissue to be regenerated,  but also e.g. as a slow drug delivery system.
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Table 1.  Presence of calcium in the CaCl2, NaCl and H2O treated scaffolds
Scaffold type
ICP-MS
Calcium content
(ng calcium per µg collagen scaffold)
FT-IR
Presence of calcium-containing compounds
CaCl2 scaffold 0.36 ± 0.03 None
NaCl scaffold 0.25 ± 0.02 None
H2O scaffold 0.29 ± 0.1 None
7.  Appendix
Supplementar y Table 1:  Hofmeister series of salts used in this study.
Salts
Maximum solubility in 
water (g/L)
90% saturated 
solution (g/L)
Molarity of 90% saturated 
solution (mol/L)
Decrease in surface 
area (% of control)
NH4Cl 395
 1 355.5 7.38 20
(NH4)2SO4 764 
1 687.6 5.78 -14
BaCl2 370 
1 333 1.78 39
Ba(ClO4)2 1985 
1 1786.5 5.90 91
BaSO4 0.0031 
1 0.00279 1.33E-05 -3
CaCl2 745 
1 670,5 6.71 93
CaSO4 3.0 
1 2.7 0.022 28
MgCl2 543 
1 488.7 5.70 93
Mg(ClO4)2 993 
1 893.7 4.45 94
MgSO4 360 
1 324 2.99 8
NaCl 360 1 324 6.16 15
Na2SO4 195 
2 175.5 1.37 13
Data on maximum solubility in water were derived from 1PubChem (National Center for Biotechnology, National Institute 
of Health, USA), and 2The Solubility Table of Wikipedia, the Free Encyclopedia.
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Figure A .1.  B iocompatib i l i t y of  CaCl2,  NaCl ,  and H2O treated scaf fo lds s tudy in a subcutaneous 
rat  model .  H&E images of a CaCl2 treated scaffold, a NaCl treated scaffold, and a H2O treated scaffold 3 
days after implantation (left panel) and 14 days after implantation (right panel). Scale bars are 200 µm.
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Figure A .2 .  Posi t ive contro l  used to evaluate exper imental  samples us ing the Von Kossa and 
Al izar in  Red s ta in ing .  A)  Bone tissue staining with Alizarin Red in which calcium is visible in red. B)
Von Kossa staining of bone tissue in which calcium phosphate is visible in brown. Scale bars are 200 µm.
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Summary
Tissue engineering, defined as the process of regenerating tissues or organs to restore 
or enhance normal function, is a discipline which has been extensively investigated 
over the last 25 years with the ultimate aim to reduce dependence on donor organs. 
Many tissue engineering strategies make use of constructs (scaffolds) to be implanted 
in a tissue defect to restore tissue function. Occasionally constructs remain in the body 
permanently to keep fulfilling their function. However, the scaffold mostly functions as 
a biodegradable artificial extracellular matrix which temporarily provides mechanical 
strength, carries pre-seeded (stem)cells or guides cells from the neighboring tissue into 
the defect and facilicates regeneration by the body’s own healing mechanisms. During 
regeneration, infiltrating cells slowly degrade the implant and create their own ECM 
resulting in newly formed body tissue. The scaffold plays a key role in the regenerating 
process, therefore the choice of the biomaterial is of utmost importance. In general, 
scaffolds can be prepared from 1) decellularized tissues or 2) molecularly defined 
biomaterials from natural or synthetic origin. In Chapter 1 an overview was given of 
molecularly defined biomaterials and processing methodologies used in the field of 
tissue engineering and their potential clinical applications. 
Type I collagen has been extensively used as a biomaterial for the preparation of 
implants due to its wide availability from various animal sources, biodegradability 
and excellent cross-species biocompatibility. In addition, collagen implants can 
easily be tailored by straightforward casting and molding processes to fit the defect 
that has to be restored. Collagen implants can also be functionalized with specific 
biologically active components such as glycosaminoglycans or growth factors 
stimulating regeneration of the target tissue. However, less attention has been paid 
to the mechanical characteristics of collagen scaffolds. Ideally, scaffolds would display 
similar mechanical characteristics as the ECM of the target tissue. The aim of this thesis 
was to develop novel methods to modulate the (mechanical) properties of collagen 
constructs thereby expanding the possibilities for clinical applications.
In Chapter 2, a systematic review and meta-analysis was presented of all pre-clinical 
and clinical studies performed on tissue engineering of the urethra. The aim was to 
find evidence for the efficacy for the use of tissue engineering for urethral repair and 
investigate trends with regard to the use of cellular vs. acellular implants, the type of 
biomaterial used, and the animal model chosen. After critical evaluation of the data, 
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the efficacy of the use of tissue engineering for urethral repair could not be established 
due to a lack on randomized controlled studies. However, outcome data of the meta-
analysis (complication-rate, functionality, and study completion) was comparable to 
standard treatments described in clinical literature indicating that tissue engineering 
is a promising strategy for urethra repair.
In Chapter 3, a novel method is described to induce elasticity in rigid tubular scaffolds 
consisting of solely type I collagen. In the extracellular matrix, collagen usually provides 
structural support and adds strength but not elasticity, a characteristic required in 
dynamic tissues such as lungs, blood vessels, the gastro-intestinal tract and the 
urogenital system. By straightforward chemical crosslinking in combination with 
compression and corrugation tubular collagen scaffolds with a folded or corrugated 
structure were created. This unique corrugated structure allowed the scaffold to be 
repeatedly stretched in longitudinal direction without damaging the scaffold itself. 
When the stretching force was released, the scaffold instantly returned to its corrugated 
state showing that the scaffold had shape memory. Other important parameters such 
as cytocompatibility and mechanical strength were not affected by this new processing 
method.
Most tubular structures in the human body however are not elastic in longitudinal, 
but in radial direction. In Chapter 4 it was shown how the method do induce elasticity 
described in Chapter 3 was adjusted in order to endow collagen scaffolds with elasticity 
in radial direction. By compressing the scaffold into a star-shape followed by chemical 
crosslinking, the star-shaped lumen of the scaffold was able to repeatedly expand 
upon exposure to internal pressure and close after the pressure has dropped (shape 
memory). This expanding and closing mechanism is also seen in many tubular tissues 
such as the esophagus, ureter and urethra. Expansion and closure of the collagen 
scaffold did not affect cell attachment as shown by cell culture under dynamic 
conditions mimicking voiding dynamics observed in the urethra.
In Chapter 5, a potential clinical application for shape memory collagen scaffolds was 
reported. By inverting the shape memory mechanism from the star-shaped scaffold as 
shown in Chapter 4, a self-expandable vascular implant was created consisting of solely 
type I collagen. It may be implanted using only minimal invasive surgical techniques 
in a compressed and folded state and subsequently deploy within one minute after 
implantation upon exposure to water. Cell culture with vascular endothelial cells 
7
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confirmed cytocompatibilty. This novel biodegradable vascular implant may be useful 
for vascular repair and may be an alternative for currently applied permanent implants 
prepared from synthetic or metal materials.
For other tissues, such as cartilage or bone, the scaffold should be rigid and stiff instead 
of elastic. In Chapter 6, a method is presented that can be applied to enhance the 
stiffness and rigidity of collagen scaffolds. By treatment with concentrated divalent salt 
solutions such as calcium chloride, collagen fibrils partly denatured causing shrinkage 
of the entire scaffold with preservation of the microporous structure. This shrinkage 
increased the stiffness of the scaffold 10-fold without affecting biocompatibility as 
assessed by subcutaneous implantations in a rat model. Using this new method 
collagen scaffolds may also be used for regeneration of hard tissues such as bone 
and cartilage without the need for additional components (e.g. ceramics or synthetic 
polymers) that are currently often added to collagen scaffold to enhance mechanical 
properties.
To conclude, type I collagen is a widely applied biomaterial in the field of tissue 
engineering, but clinical translation is often hampered by mismatched mechanical 
characteristics. In this thesis, collagen scaffolds were manipulated using a variety of 
methods, i.e. compression, corrugation, crosslinking and salt treatment, in order to 
alter shape and mechanical properties. These novel tools may be useful to prepare 
tailored-made collagen scaffold for the repair of many different tissues or organs.
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Future perspectives
The need for alternative treatment options for tissue or organ repair is obvious. The 
world-wide lack of donor organ and the donor-related problem with immune rejection 
have stimulated the rise of tissue engineering since the early 90’s [1]. Today, over 25 
years later, patients in need of a new organ are still mostly dependent on organ donors 
as de-novo creation of new organs in a laboratory is more complicated than expected 
by early researchers. Expectations that researchers would be able to generate fully 
functional organs that could replace damaged organs are therefore still not met. 
Nevertheless, due to our growing knowledge of fundamental molecular mechanisms 
of processes in the human body step-by-step progress towards the ultimate goal of 
creating functional organs on demand is being made.
Tissue regeneration is an interplay of complex processes such as cellular signaling, 
proliferation/differentiation of (stem) cells and extracellular matrix remodeling. For the 
field of tissue engineering it is of importance to gain more insight in the mechanisms 
involved in this interplay. On the level of stem cells major progress has been made 
such as the discovery of the induced pluripotent stem cells [2] and the easily accessible 
adipose derived stem cells [3]. With external stimuli, e.g. growth factors or enriched 
culture media, the differentiation of these stem cells can be directed into one specific 
cell type in tissue culture plates. However, since an organ or tissue consist of more than 
one cell type in a specific three dimensional structure, an artificial extracellular matrix, 
or scaffold, is an essential ingredient in guiding the development of cells into functional 
tissue. Novel techniques such as 3D printing of artificial ECMs [4] and hydrogels [5] 
can play an important role as tools to study the development of (stem) cells in a 
3D-environment as they show superior resemblance to the in vivo situation. Besides 
culturing in a 3D-environment, it is advantageous to culture cells under dynamic 
conditions as this reduces the discrepancies between static culturing conditions in 
vitro and the dynamic environment cells experience in vivo [6]. Ultimately, this would 
lead to a better extrapolation from in vitro results to an in vivo setting.
On the level of the scaffold, it has been shown that the 3D shape of scaffolds is 
important as it contributes to special mechanical characteristics such as elasticity and 
shape memory (Chapters 3 and 4). In addition, shape (e.g. the harmonic-like structure) 
can also play a role in the development of cells. Caco-2 cells, a human epithelial cell 
line derived from a colon carcinoma, cultured on a type I collagen scaffold with a 
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folded structure similar as presented in Chapter 3 showed to have an entirely different 
morphologies dependent on the location within the scaffold (Figure 1). In the inner fold 
of the scaffold, the cells displayed a round morphology, while on the outside of the 
tip region, the cells displayed a stretched morphology (Figure 1). This indicates that a 
specific 3D-structure may have an effect on the differentiation of cells. In this respect, 
collagen scaffolds with various shapes, prepared using the techniques described in this 
thesis, can serve as a model to study the development of stem cells in a 3D environment 
which may yield more valuable information that 2D cultures in plastic culture plates.
Besides its role as a supportive structure for the cells, the scaffold also serves as 
signaling agent. In recent years it has become clear that cellular behavior is not only 
guided by external stimuli but also by intrinsic mechanical signals from the ECM, 
also called mechanotransduction [7]. It has been shown in several studies that the 
mechanical properties of the substrate to which cells attach have major influence 
on differentiation of stem cells [8]. For example, stiff scaffolds tend to stimulate 
differentiation of mesenchymal stem cells towards smooth muscle cells or bone 
lineage, whereas soft scaffolds direct the cells towards adipogenic and chrondrogenic 
differentiation [9, 10]. Current studies investigating the effect of mechanosignaling 
mostly use synthetic matrices prepared from polyacrylamide. With the scaffolds 
developed in this thesis, it may be possible to use scaffolds prepared from natural 
Figure 1.  Caco -2 ce l ls  seeded on co l lagen scaf fo ld with fo lded s t ruc ture.  The 3D-structure of 
a collagen scaffold influenced the morphology of the cells. In the inner folds the cells display a round 
morphology while at the outer folds the cells display a stretched morphology. Scale bar = 400 µm.
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biomaterials for these studies, which better resemble the natural microenvironment 
of (stem) cells. 
In this thesis, novel methods are described to create type I collagen scaffolds with a 
tissue-specific shape and mechanical properties that better resemble the mechanical 
properties of the extracellular matrix of the tissue to be regenerated. Nevertheless, 
there may still be room for improvements with the respect to the composition of the 
scaffolds as the scaffolds described in this thesis consists only of type I collagen. A 
native extracellular matrix consists of multiple components that give it their structure 
and cell-adhesive properties, including collagen, elastin, laminin, fibronectin, and 
heparan sulfate [11]. By adding additional components to a type I collagen scaffold, it 
will better mimic the native extracellular matrix, which may ultimately result in better 
tissue regeneration [12]. However, as each tissue has its own complex characteristic 
ECM it seems impossible to exactly mimic its composition and translate this into a 
multi-component scaffold. In addition, this will result in complex preparation processes 
resulting in expensive scaffolds. However, as it is quite clear that the ECM of some 
tissues contains a characteristic component, e.g. type II collagen for cartilage [13], 
calcium phosphate for bone [14] or type IV collagen for epithelial tissue [15], it may be 
advantageous to add them to the type I collagen-based scaffold. It will be key to find 
a good balance between the degree of complexity of the scaffold and the enhanced 
effect of the additional components.
Next to the hurdles to be taken in fundamental research as described above, there 
are other hurdles to take for the tissue engineering society at the level of translational 
research. In the field of fundamental research, a lot of progress has and still is being 
made. However, when considering the potential of tissue engineering and the number 
of clinical applications, it may be concluded that tissue engineering is underperforming 
[16]. To let patients benefit from fundamental discoveries on the short-term, the 
efficiency of clinical translation must be increased.
The process of developing novel therapies does not only take place in the laboratory. 
It is a multidisciplinary process involving many parties including medical doctors, 
pharmaceutical industry, regulatory bodies and researchers. In the current situation, 
the communication is often very poor. From the initial phase of development, all 
parties should intensively collaborate in order to maximize the chance of developing 
a successful therapy. As medical doctors are treating patients, they have the 
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knowledge about the clinical need and which specifications novel medical devices 
have to meet. Straightforward properties such as handability in the operating room 
can easily be defined by the end-users. Consequently, researchers can take into 
account these requirements already early in the developmental process. On the other 
hand researchers have the obligation to actively go into the clinic and present novel 
developments and techniques. Another very important party, which is often neglected 
in current clinical translation, is the industry. They possess specific knowledge that is 
often lacking at universities or hospitals, especially with regards to the feasibility of 
industrial production and accompanying legal requirements. A simple example is the 
sterilization of the scaffolds, which can have significant effects on the characteristics 
of a scaffold such as mechanical properties or  immune responses in vivo compared to 
in vitro results [17]. An active scaffold loaded with fragile growth factors may lose its 
activity after sterilization. Another example is the use of raw materials and chemicals. 
Currently, in the in vitro and pre-clinical stages of development often raw materials and 
chemicals are used that are not allowed to be used in the clinical phase. In this phase, 
pharmaceutical grade materials and chemicals have to be used and this can result 
in significant changes in the end-product which will reduce the efficiency of clinical 
translation even further. If researchers already take industrial issues into account 
during the developmental process, clinical translation may increase. An additional 
party involved in the process of clinical translation are the regulatory bodies which 
determine legislation and audit adherence to the regulation. In April 2017, the new 
European Medical Device Regulation was released which is more defined and strict 
compared to previous regulation [18]. The introduction of the strict regulation was 
necessary to guarantee patient safety as medical devices became more complicated 
over the years. For researchers, it is difficult to apply every single rule of this regulation 
because indepth knowledge is lacking. Clinical translation would be stimulated when 
regulatory bodies would actively communicate with researchers and aid them to 
comply with the Medical Device Regulation. Another critical step in the translational 
chain are pre-clinical studies. As shown in Chapter 2, the quality of animal studies in 
the field of urethral tissue engineering is poor, especially with regard to experimental 
setup and reporting of results [19]. A randomized controlled experimental setup 
should be used to increase the reliability of study outcome. Only well-designed animal 
studies should be allowed, on one hand to increase efficiency of translation of tissue-
engineered product to the clinical and on the other hand to extract as much valuable 
data from animals as possible from an ethical point of view. Furthermore we should 
strive for a system where all animal studies are centrally registered and where study 
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results are published open access analogous to a database such as ClinicalTrials.gov 
from the National Institute of Health (USA). 
 As the predictive value of animal studies has become a topic of discussion, research 
for alternatives gained interest. Tissue engineering can also play an important role 
in the development of these alternatives. Developments such as 3D cell cultures 
(e.g. organoids) [20] and organ-on-a-chip technologies [21, 22] are already used for 
screening of drugs in vitro. Collagen scaffolds may be used to create artificial organs for 
comparable applications. For example, a collagen scaffold resembling the morphology 
of intestines with the crypt and villus structure seeded with lgr5+ stem cells similar as 
shown in figure 1, may form artificial intestinal tissues organs which can be used for 
research purposes.
In this thesis, new methods are described to modify collagen scaffold and endow them 
with desired properties for tissue specific applications opening up new opportunities 
for the field of collagen-based tissue engineering. On the one hand the techniques 
may be very useful to develop scaffolds which can be used as a platform to study the 
tissue regeneration in vitro in a setting better resembling the microenvironment that 
cells would experience in vivo. On the other hand, the techniques presented in this 
thesis can be valuable tools to create tissue-specific scaffolds resembling the native 
composition and the native morphological and mechanical properties. Consequently, 
it may be possible to use collagen-based scaffolds for the repair of a multitude of 
tissues. If researchers collaborate with clinicians, industry and regulatory bodies, and 
keep investing in fundamental research to elucidate the molecular pathways of tissue 
development and regeneration, artificial organs on demand could become reality in 
the future. 7
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Samenvatting
Tissue engineering is een discipline in de medische wetenschappen die de laatste 
jaren sterk is op komen zetten als gevolg van het grote tekort aan donorweefsel. 
Tissue engineering heeft als doel om nieuwe weefsels of organen kunstmatig te 
creëren zodat ziek of beschadigd weefsel vervangen kan worden. Een veel toegepaste 
methode hiervoor is het gebruik van biologisch afbreekbare constructen, zogenaamde 
‘scaffolds’, die worden geïmplanteerd op de plaats van het defect waar weefselvorming 
nodig is. Deze scaffold heeft als taak om cellen uit omliggende weefsels naar het defect 
te leiden en om tijdelijk stevigheid te bieden aan het gehele weefsel. De scaffold 
fungeert met andere woorden als een kunstmatige en tijdelijke extracellulaire matrix. 
Tijdens het regeneratieproces breken cellen de scaffold langzaam af en creëren ze hun 
eigen extracellulaire matrix. Na verloop van tijd zal de scaffold helemaal afgebroken 
zijn en zal het oorspronkelijke defect helemaal gevuld zijn met lichaamseigen weefsel. 
Omdat de scaffold een zeer belangrijke rol speelt in het regeneratieproces is de keuze 
voor het biomateriaal waarvan de scaffold gemaakt erg van belang. Er kan onderscheid 
gemaakt worden tussen twee klassen van materialen: 1) gedecellulariseerde weefsels 
en 2) moleculair gedefinieerde materialen van biologische of synthetische origine. In 
Hoofstuk 1 is een overzicht gegeven van moleculair gedefinieerde materialen die veel 
worden gebruikt inclusief fabricatiemethoden en mogelijke klinische toepassingen.
In Hoofstuk 2 wordt een overzicht gegeven van alle preklinische en klinische studies 
over het gebruik van tissue engineering voor plasbuisreconstructie in de vorm van een 
systematisch review met meta-analyse. Het doel van dit review was om bewijs te vinden 
voor de doelmatigheid van het gebruik van tissue engineering voor het behandelen 
van plasbuisdefecten. Daarnaast is onderzocht of het toevoegen van (stam)cellen, de 
materiaalkeuze en het gekozen diermodel invloed hadden op de uiteindelijke uitkomst. 
Na een kritische evaluatie bleek dat er geen harde conclusie getrokken kan worden over 
de doelmatigheid van tissue engineering door het ontbreken van controle groepen in de 
studies. Uit de data van de meta-analysis kon wel geconcludeerd worden dat de mate 
van complicaties, functionaliteit en studieuitval vergelijkbaar was met conventionele 
behandelingen voor plasbuisreconstructie. De resultaten in dit hoofdstuk laten zien 
dat tissue engineering voor plasbuisreconstructie veelbelovend kan zijn mits nieuwe 
studies op een goede manier worden opgezet en uitgevoerd.
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In de extracellulaire matrix geeft collageen over het algemeen stevigheid aan de 
weefselstructuur, maar het draagt niet bij aan de elasticiteit van het weefsel. Voor 
dynamische weefsels zoals het gastro-intestinaal of urogenitaal stelstel is dit echter 
essentieel. In Hoofdstuk 3 is een nieuwe methode beschreven om buisvormige 
scaffolds bestaande uit type I collageen elastische eigenschappen te geven. Door 
gebruik te maken van een chemische koppelingsreactie in combinatie met compressie- 
en vouwstechnieken is een scaffold gemaakt met een geplooide structuur die 
herhaaldelijk kan worden opgerekt in de lengterichting zonder dat er schade aan de 
scaffold ontstaat. Na het strekken keert de scaffold uit zichzelf terug naar de geplooide 
toestand. Deze nieuwe methode geeft de collageenscaffold een vormgeheugen zonder 
de celbiocompatibiliteit en mechanische sterkte aan te tastes.
De meeste buisvorminge structuren in het menselijk lichaam zijn echter niet 
elastische in de lengte richting maar in de radiale richting (van binnen naar buiten). 
In Hoofdstuk 4 wordt uitgelegd hoe de methode om elastische collageenscaffolds te 
maken kan worden aangepast om scaffolds te creëren die elastische eigenschappen 
bezitten in de radiale richting. Door de buisvormige scaffold samen te drukken tegen 
een stervormige staaf en vervolgens met een chemische behandeling te fixeren 
ontstaat een collageenscaffold met een stervormig lumen. Dit stervormig lumen kan 
herhaaldelijk openen en sluiten door middel van een stijgende en dalende druk net 
zoals de scaffold met vormgeheugen uit hoofdstuk 3. Dit open- en sluit mechanisme 
komt ook voor in verschillende buisvormige weefsels zoals de slokdarm, urineleider 
en plasbuis. Na een celkweekexperiment onder dynamische omstandigheden welke 
urineren nabootst kon worden geconcludeerd dat  het openen van het stervormige 
lumen geen negatieve gevolgen heeft voor de celhechting.
In Hoofdstuk 5 wordt een mogelijk klinische applicatie gepresenteerd waarbij gebruikt 
wordt gemaakt van het vorm-geheugen mechanism van de stervormige-scaffold zoals 
beschreven in hoofdstuk 4. Door het omkeren van het vorm-geheugen is een vasculair 
implantaat gemaakt van type I collageen dat uit zichzelf kan ontvouwen. Door de 
compressie- en vouwtechnieken kan het implantaat geplaatst worden gebruikmakend 
van minimaal invasieve chirurgische methodes. Na plaatsing zal de scaffold in contact 
komen met water (bloed) en binnen een minuut ontvouwen en zich vastzetten tegen de 
wand van het bloedvat. Een celkweekexperiment heeft aangetoond dat cellen goed op 
het implantaat kunnen hechten. Dit innovatieve biologisch afbreekbaar implantaat kan 
mogelijk worden gebruikt voor het herstel van beschadigde bloedvaten en is wellicht 
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een alternatief voor de huidige implantaten gemaakt uit synthetische materialen of 
metalen. 
In andere weefsels zoals bijvoorbeeld bot biedt de extracellulaire matrix juist 
stijfheid en rigiditeit in plaats van elasticiteit. In Hoofdstuk 6 is een nieuwe techniek 
gepresenteerd die gebruikt kan worden om collageenscaffolds stijver en meer rigide 
te maken. Door het collageen te behandelen met concentreerde zoutoplossingen 
zoals calcium chloride, worden de collageenfibrillen gedeeltelijk ontvouwen met als 
gevolg krimping van de collageenscaffold. Door deze krimping werd de stijfheid van 
de scaffold 10 maal zo hoog zonder dat de biocompatibliteit werd aangetast zoals 
aangetoond door middel van onderhuidse implantaties in een rat model. Deze nieuwe 
techniek biedt mogelijkheden om collageenscaffolds ook toepasbaar te maken voor 
de regeneratie van harde weefsels zoals bijvoorbeeld bot.
Samenvattend worden in dit proefschrift diverse innovatieve technieken beschreven 
zoals compressie, vouwing, chemische versteviging en zoutbehandelingen die gebruikt 
kunnen worden om de 3D structuur en mechanische eigenschappen van de scaffold 
te manipuleren. Met behulp van deze technieken kunnen op maat gemaakte scaffolds 
van type I collageen worden gecreëerd met de gewenste eigenschappen die nodig zijn 
voor optimale regeneratie van verschillende weefsels of organen.
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 207
207
Samenvatting en toekomstvisie
Toekomstvisie
De noodzaak voor het ontwikkelen van alternatieve therapieën die het gebruik 
van orgaandonoren kunnen verminderen is duidelijk. Het wereldwijde tekort aan 
orgaandonoren en de bijkomende complicaties zoals afstotingsreacties hebben 
sinds het begin van de jaren negentig de ontwikkeling van tissue engineering in gang 
gezet [1]. Vandaag de dag, 25 jaar later, zijn patiënten nog steeds voor het grootste 
gedeelte afhankelijk van donororganen omdat het de-novo creëren van nieuwe 
organen in een laboratorium toch moeilijker is gebleken dan in eerste instantie 
voorspeld werd. Verwachtingen dat onderzoekers op korte termijn zouden slagen 
om functionele kunstorganen te maken die zieke organen kunnen vervangen zijn nog 
steeds een illusie. Desondanks, door de alsmaar groeiende kennis van fundamentele 
moleculaire mechanismen van processen in het menselijk lichaam, wordt er stap voor 
stap vooruitgang geboekt om het einddoel te bereiken; het maken van functionele 
organen op bestelling.
Weefselherstel is een complex samenspel van processen zoals cellulaire communicatie, 
celdeling, celdifferentiatie van stamcellen en modellering van de extracellulaire matrix 
(ECM). Voor tissue engineering is het van groot belang om meer inzicht te krijgen 
deze mechanismen. Op het gebied van stamcellen is enorme progressie gemaakt 
Figuur  1.  Caco -2 ce l len gekweek t  op een co l lageenscaf fo ld  met  een gevouwen s t ruc tuur. 
De 3D-structuur van een collageenscaffold heeft een invloed op de morfologie van de cellen. Aan de 
binnenkant van de vouw hebben de cellen een ronde morfologie terwijl de cellen aan de buitenkant een 
gestrekte morfologie hebben. Scale bar = 400 µm.
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zoals de ontdekking van geïnduceerde pluripotente stamcellen [2] en de relatief 
eenvoudig verkrijgbare vetstamcellen [3]. Door externe signalen, zoals groeifactoren of 
kweekmedium, is het mogelijk om differentiatie van deze stamcellen te sturen richting 
een specifiek celtype in 2D in een kweekschaaltje op het laboratorium. Echter, een 
orgaan of weefsel bestaat uit meerdere celtypes met een specifieke 3D-structuur. 
Daarom is een kunstmatige ECM, ook wel scaffold genoemd, noodzakelijk om de 
celdifferentie en celgroei te sturen in de richting van functioneel weefsel. Nieuwe 
technieken zoals het 3D printen van ECM [4] en hydrogelen [5] kunnen een belangrijke 
rol spelen bij de bestudering van het gedrag van stamcellen in een 3D-omgeving omdat 
dit een betere weerspiegeling is van de situatie in het menselijk lichaam. Daarnaast 
kan het kweken onder dynamische condities, in bijvoorbeeld bioreactoren, de 
verschillen verkleinen tussen het kweken van cellen in het lab ten opzichte van hoe 
cellen groeien in ons lichaam [6]. Uiteindelijk kunnen deze methoden leiden tot een 
betere extrapolatie van een in vitro celkweekexperiment naar het menselijk lichaam.
Kijkend naar de scaffold is het duidelijk geworden dat de 3D-structuur zeer belangrijk 
is, omdat deze bijdraagt aan de mechanische eigenschappen zoals elasticiteit en 
vormgeheugen (hoofdstuk 3 en 4). Daarnaast kan de vorm (bijv. de harmonica-achtige 
structuur) van de scaffold ook een rol spelen in de differentiatie van cellen. Caco-2 
cellen, een humane epitheel cellijn geïsoleerd uit een darmtumor, lieten na kweek op 
een collageenscaffold met een gevouwen structuur zoals weergegeven in hoofdstuk 3 
een morfologie zien die afhankelijk was van de locatie in de scaffold (Figuur 1). Aan de 
binnenkant van de vouw hebben de cellen een ronde vorm, terwijl op de uiteinden van 
de vouwen de cellen een meer gestrekte morfologie hebben. Dit resultaat duidt er op 
dat de 3D-structuur van de scaffold een invloed heeft op celdifferentiatie. In dit opzicht 
zouden scaffolds met een specifieke structuur, gemaakt met de technieken beschreven 
in dit proefschrift, kunnen dienen als een model om het gedrag van stamcellen te 
bestuderen.
Naast een ondersteunende rol voor cellen om aan te hechten, heeft de scaffold ook 
een sturende functie. In de afgelopen jaren is het steeds meer duidelijk geworden dat 
het gedrag van cellen niet alleen bepaald wordt door externe stimuli, maar ook door 
de intrinsieke mechanische eigenschappen van de ECM, in dit geval de scaffold, ook 
wel mechanotransductie genoemd [7]. Diverse studies laten zien dat de mechanische 
eigenschappen van het substraat waarop de cellen gehecht zijn van grote invloed zijn 
op het differentiatiegedrag van stamcellen [8]. Scaffolds die erg stijf zijn, stimuleren 
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bijvoorbeeld de differentiatie van mesenchymale stamcellen richting spiercellen of bot. 
Minder stijve scaffolds zullen celdifferentiatie eerder in de adipogene of chrondrogene 
richting sturen [9,10]. Op dit moment worden in studies waarin mechanotransductie 
wordt bestudeerd met name gebruik gemaakt van 3D-scaffolds gemaakt van 
polyacrylamide. Met de technieken beschreven in dit proefschrift is het mogelijk om 
scaffolds met verschillende vormen en mechanische eigenschappen te maken van 
een natuurlijk biomateriaal, zoals collageen, wat meer overeenkomt de natuurlijke 
omgeving van stamcellen in het menselijk lichaam.
In dit proefschrift zijn enkele nieuwe technieken beschreven om collageen 
type I scaffolds te maken met een weefselspecifieke structuur en mechanische 
eigenschappen die beter overeenkomen met de ECM van het weefsel dat hersteld 
dient te worden. Desondanks is er nog veel ruimte voor verbeteringen, met name wat 
betreft de samenstelling van de scaffold. In dit proefschrift bestaan de beschreven 
scaffolds namelijk alleen uit collageen type I. De ECM in ons lichaam bestaat echter 
uit verschillende eiwitten en suikers, zoals andere typen collageen, elastine, laminine, 
fibronectine, en heparansulfaat [11]. Door het toevoegen van deze componenten aan de 
collageenscaffold kan de ECM van het te herstellen weefsel beter nagebootst worden, 
wat uiteindelijk kan resulteren in betere weefselregeneratie [12]. Omdat de ECM een 
zeer complex geheel is met een samenstelling die voor ieder weefsel weer anders is, zal 
het in de praktijk onmogelijk zijn om de ECM precies na te maken. Daarnaast zou het 
maken van een exacte kopie van de ECM een zeer kostbaar proces worden. Nochtans 
is het duidelijk dat de ECM van verschillende weefsels vaak een specifieke component 
bevat die een belangrijke rol speelt voor de uiteindelijke eigenschappen. De ECM van 
kraakbeen bevat bijvoorbeeld veel collageen type II [13], terwijl de ECM van botweefsel 
juist veel calciumfosfaat bevat [14]. Epitheelweefsel bevat op zijn beurt weer collageen 
type IV [15]. Het is waarschijnlijk gunstig voor het weefselherstel om deze belangrijke 
componenten toe te voegen aan de collageen type I scaffold. Voor onderzoekers is het 
zaak om een goede balans te vinden tussen de mate van complexiteit van de scaffold 
en extra voordelen van het toevoegen van extra componenten.
Naast de noodzaak om meer inzicht te krijgen in de fundamentele mechanismen van 
weefselherstel zijn er nog andere hordes die genomen moeten worden door de tissue 
engineering gemeenschap op het gebied van klinische translatie. Ondanks de grote 
voortgang die de afgelopen jaren geboekt is in het fundamentele onderzoek valt het 
aantal klinische toepassingen van tissue engineering in de praktijk nog tegen. Er kan 
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geconcludeerd worden dat tissue engineering ondermaats presteert vergeleken met 
de hoge verwachtingen van begin jaren 90 [16]. Om patiënten op korte termijn echt te 
laten profiteren van de nieuwe ontwikkelingen in tissue engineering zal de efficiëntie 
van de klinische translatie verbeterd moeten worden.
Het ontwikkelingsproces van nieuwe therapieën vindt niet alleen plaats in het 
laboratorium. Het is een multidisciplinair proces waarbij meerdere partijen betrokken 
zijn zoals clinici, de farmaceutische industrie, wet- en regelgevers en onderzoekers. 
Vandaag de dag is de communicatie tussen deze partijen vaak niet optimaal. Al vanaf 
de eerste fase van het ontwikkelingsproces zouden deze partijen intensief met elkaar 
moeten samenwerken om de kans dat een therapie succesvol toegepast kan worden bij 
patiënten te vergroten. Aangezien clinici dagelijks in aanraking komen met patiënten 
weten zij precies waar de problemen liggen met huidige therapieën en waar eventuele 
nieuwe therapieën aan moeten voldoen. Een simpele eigenschap van bijvoorbeeld een 
scaffold, zoals handelbaarheid op de operatiekamer, kan veel betere worden ingeschat 
door de eindgebruiker dan door de onderzoeker op het lab. Idealiter wordt deze 
klinische input al in een vroeg stadium in het ontwikkelingsproces meegenomen door 
onderzoekers. Van de andere kant bekeken hebben onderzoekers ook de verplichting 
om actief naar de clinici te gaan en hen te informeren over nieuwe mogelijkheden en 
technieken.
Een andere zeer belangrijke partij in het translatieproces, die er vaak niet bij betrokken 
wordt, is de farmaceutische industrie. Juist daar ligt enorm veel kennis die ontbreekt 
bij universiteiten en ziekenhuis vooral op het gebied van industriële productie en 
bijkomende wet- en regelgeving. Een simpel voorbeeld is bijvoorbeeld de sterilisatie 
van scaffolds. Sterilisatie kan namelijk een significant effect hebben op de scaffold, 
bijvoorbeeld op de mechanische eigenschappen, de immunogeniciteit, of de activiteit 
van toegevoegde groeifactoren [17]. Een ander voorbeeld waar onderzoekers vaak 
niet goed van op de hoogte zijn is regelgeving met betrekking tot het gebruik van 
grondstoffen en chemicaliën. Op dit moment worden bij in vitro en preklinisch 
onderzoek vaak materialen en chemicaliën gebruikt die niet toegestaan zullen zijn 
in klinisch onderzoek met patiënten. In deze fase van de ontwikkeling zijn namelijk 
grondstoffen en chemicaliën nodig die zijn goedgekeurd voor klinisch gebruik. Deze 
verandering kan soms enorme gevolgen hebben voor bijvoorbeeld de eigenschappen 
van de scaffold. Als wetenschappers zich hier al van bewust zijn in een vroeg stadium 
van het ontwikkelingsproces kunnen deze problemen voorkomen worden. De 
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efficiëntie van de translatie van laboratorium naar de patiënt zal hiermee waarschijnlijk 
verbeterd worden.
Verder hebben de organisaties die gaan over wet- en regelgeving een belangrijke rol in 
het ontwikkelingsproces van laboratorium naar de kliniek. Vanaf april 2017 is de er een 
nieuwe Europese regelgeving van kracht met betrekking tot medische hulpmiddelen, 
waaronder ook scaffolds vallen [18]. Deze nieuwe regelgeving is strenger en meer 
gedetailleerd dan de oude regelgeving die niet meer actueel was door de snelle 
ontwikkeling binnen tissue engineering in de laatste jaren. Voor onderzoekers is lastig 
om rekening te houden met al deze wetten en regelgeving omdat diepgaande kennis 
over dit onderwerp ontbreekt. Klinische translatie zou gestimuleerd kunnen worden als 
de wet- en regelgevers op een actieve manier communiceren richting de onderzoekers 
en hen helpen om te voldoen aan eisen van de medische hulpmiddelen regelgeving.
Een cruciale stap van om nieuwe therapieën bij de patiënt te krijgen is preklinisch 
onderzoek in diermodellen. Zoals is gebleken uit Hoofdstuk 2 van dit proefschrift, is de 
kwaliteit van preklinisch onderzoek, dit geval voor tissue engineering van de plasbuis, 
voor verbetering vatbaar. Voornamelijk de experimentele opzet en de rapportage van 
resultaten liet te wensen over [19]. Om de betrouwbaarheid van preklinisch onderzoek 
te verbeteren zijn gerandomiseerde studies met controlegroepen noodzakelijk. Om 
de efficiëntie van translatie van tissue engineering therapieën te vergroten, maar ook 
vanuit een ethisch oogpunt zouden in de toekomst alleen goed opgezette dierstudies 
uitgevoerd mogen worden. Daarnaast moet er gestreefd worden naar een systeem wat 
voor iedereen toegankelijk is waarin alle dierstudies wereldwijd geregistreerd staan 
en waarin resultaten gerapporteerd worden zoals dit ook al gebeurd voor klinische 
studies met patiënten met als voorbeeld ClinicalTrials.gov van het National Institute 
of Health (USA).
Naast ethische bezwaren is er ook steeds meer een discussie gaande over de 
voorspelbare waarde van dierstudies voor klinisch succes. Als gevolg hiervan heeft 
het onderzoek naar alternatieven voor dierexperimenten een vlucht genomen. Tissue 
engineering kan hierin een belangrijke rol spelen. Ontwikkelingen zoals 3D celkweken 
zoals organoids [20] en de orgaan-op-een-chip technologie [21,22] worden vandaag 
de dag zelfs al gebruikt voor het in vitro screenen van mogelijke nieuwe medicijnen. 
Collageenscaffolds kunnen wellicht ook gebruikt worden voor dit doel, bijvoorbeeld 
een scaffold die de vorm heeft van de darm (crypten en villi) kan worden bezaaid 
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met lgr5+ stamcellen vergelijkbaar met de situatie weergegeven in figuur 1. Op deze 
manier wordt een kunstmatig stukje darmweefsel gecreëerd die misschien gebruikt 
kan worden om de opname van medicijnen door de darm te bestuderen.
In dit proefschrift worden nieuwe methoden beschreven die gebruikt kunnen 
worden om collageenscaffolds  een specifieke 3D structuur en andere mechanische 
eigenschappen te geven. Dit biedt nieuwe mogelijkheden voor het gebruik van 
collageenscaffolds in tissue engineering. Aan de ene kant kunnen de beschreven 
technieken gebruikt worden om scaffolds te maken die als platform kunnen dienen 
om het regeneratieproces beter in vitro te kunnen bestuderen. Aan de andere kant 
bieden de nieuwe technieken onderzoekers manieren om weefselspecifieke scaffolds 
te creëren die de ECM van het te herstellen weefsel beter kunnen nabootsen wat betreft 
3D structuur en mechanische eigenschappen. Hopelijk kunnen op deze manier in de 
toekomst collageenscaffolds worden ingezet om de regeneratie van een variëteit aan 
organen en weefsel te stimuleren. Als onderzoekers beter gaan samenwerken met 
clinici, farmaceutische industrie, wet- en regelgevers, en blijven investeren in het 
ontrafelen van de fundamentele moleculaire mechanismes van weefselherstel dan 
zouden kunstmatige gemaakte organen op bestelling in de toekomst best eens realiteit 
kunnen worden.
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Luuk Versteegden (17 December 1988) was born in Lieshout and raised in Lierop 
(both North-Brabant, the Nederlands). In 2007 he graduated from the St. Willibrord 
Gymnasium in Deurne, after which he started with the bachelor study Molecular Life 
Sciences at the Radboud University in Nijmegen. During this bachelor, Luuk was a board 
member of the BetaBedrijvenBeurs Foundation in charge of organizing career events 
for students. After Luuk completed his bachelor study, he started with the master 
Molecular Life Sciences at the Radboud University Nijmegen. As part of this master, 
Luuk performed internships at the Department of Biochemistry and the Department 
of Urology, two research departments within the Radboud Institute for Molecular 
Life Sciences of the Radboud university medical center. In his first internship under 
supervision of Dr. Van Kuppevelt and Dr.ir. Daamen, Luuk investigated the use of 
microcapsules for local delivery of chemotherapeutic drugs. In his second internship 
under supervision of Dr. Oosterwijk, he investigated the use of tubular collagen 
constructs for urological applications such as urethra repair. In October 2012, Luuk 
obtained his master degree after which he started a PhD-project at the Department 
of Biochemistry under supervision of promoter Prof.dr. Brock and copromotores 
Dr. Van Kuppevelt and Dr.ir. Daamen to study the use of collagen constructs in 
regenerative medicine. The results of this research are described in this thesis and 
several international journals. Furthermore, Luuk has visited multiple international 
conferences and symposia where he presented his work. Luuk was member of the 
RIMLS PhD programme committee where he represented the PhD students of the 
Radboud Institute of Molecular Life Sciences. In addition he was responsible for 
the organization of the yearly PhD retreat. During the course of the PhD study, Luuk 
supervised several bachelor and master students from Biomedical Sciences and 
Medical Biology. After Luuk completed his PhD project in December 2016, he worked 
as a project manager at BioMed Elements in Nijmegen. As of January 2018, Luuk is 
working at Devro B.V. in Gendt as development project leader where he is applying his 
knowledge of collagen to develop collagen gels for the food industry. 
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Curriculum Vitae
Luuk Versteegden (17 december 1988) is geboren te Lieshout en getogen te Lierop 
(beiden Noord-Brabant). In 2007 behaalde hij zijn gymnasiumdiploma aan het 
St. Willibrord gymnasium te Deurne waarna hij startte met de bacheloropleiding 
Moleculaire Levenswetenschappen. Tijdens zijn bachelorstudie was Luuk bestuurslid 
van Stichting BetaBedrijvenBeurs waar hij betrokken was bij de organisatie van 
carrière-evenementen voor studenten. Na de bachelor te hebben afgerond, begon 
Luuk in 2010 met de aansluitende Engelstalige master Molecular Life Sciences. Tijdens 
de master liep Luuk stage bij de afdeling Biochemie en de afdeling Urologie, twee 
onderzoeksafdelingen binnen het Radboud Institute for Molecular Life Sciences 
verbonden aan het Radboudumc. Tijdens de eerste stage onder begeleiding van Dr. 
Van Kuppevelt en Dr.ir. Daamen deed hij onderzoek naar het gebruik van microcapsules 
voor locale afgifte van chemotherapie. In zijn tweede stage onder leiding van Dr. 
Oosterwijk onderzocht Luuk het gebruik van tubulaire collageenconstructen voor 
urologische toepassingen zoals de reconstructie van de urethra. In oktober 2012 
behaalde Luuk zijn masterdiploma en hij startte aansluitend in november 2012 met 
zijn promotieonderzoek bij de afdeling Biochemie onder leiding van promotor Prof.
dr. Brock en copromotores dr. Van Kuppevelt en Dr.ir. Daamen waarin het gebruik 
van collageen in de regeneratieve geneeskunde centraal stond. De resultaten van 
het onderzoek zijn beschreven in dit proefschrift en gepubliceerd in verschillende 
internationale tijdschriften. Daarnaast heeft Luuk meerdere internationale 
congressen en symposia bijgewoond waar hij zijn werk heeft gepresenteerd. Tijdens 
het promotieonderzoek was Luuk lid van het PhD-progammacomité waarbij hij de 
promovendi van het Radboud Institute for Molecular Life Sciences vertegenwoordigde 
en verantwoordelijk was voor de organisatie van de jaarlijkse PhD-retraite. Daarnaast 
heeft Luuk tijdens zijn promotieonderzoek verschillende bachelor- en masterstudenten 
van de studies Biomedische Wetenschappen en Medische Biologie begeleid. Na het 
afronden van zijn promotieonderzoek eind 2016 heeft Luuk gewerkt als projectmanager 
bij BioMed Elements te Nijmegen. Vanaf januari 2018 is Luuk werkzaam bij Devro B.V. 
als development project leader waar hij zijn opgedane kennis van collageen toepast 
bij de ontwikkeling van collageengelen voor de voedingsmiddelenindustrie.
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Versteegden LRM*, Ter Meer M*, Lomme RMLM, Van Der Vliet JA, Schultze Kool LJ, 
Van Kuppevelt TH, Daamen WF. “Self-expandable tubular collagen implants”. 2018; 
provisionally accepted.
De Jonge PKJD, Sloff M, Janke HP, Versteegden LRM, Kortmann BBM, De Gier RPE, 
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engineered templates and subcutaneous preimplantation”. Tissue Engineering Part 
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Kuppevelt TH. “Design of an elasticized collagen scaffold: a method to induce elasticity 
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Van Bracht E, Versteegden LRM, Stolle S, Verdurmen WP, Woestenenk R, Raavé R, Hafmans 
T, Oosterwijk E, Brock R, Van Kuppevelt TH, Daamen WF. “Enhanced cellular uptake 
of albumin-based lyophilisomes when functionalized with cell penetrating peptide 
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Portfolio 
Graduate School Radboud Institute for Molecular Life Sciences
Courses and Workshops Year ECTS
RIMLS Graduate School Introductory Course 2013 2.0
Hands-on-training in synthesis of evidence in animal sciences 2013 0.4
Course on laboratory animal science 2013 3.0
Scientific integrity course 2014 1.0
Academic writing 2014 3.0
Career management for PhD-students 2016 0.8
Seminars and Lectures
Miscellaneous (including oral presentations) 2012-2016 4.0
Departmental seminars (including oral presentations) 2012-2016 4.0
Noon Spotlight (1x) 2013 0.1
Seminars (8x) 2013-2014 0.8
Technical Forum (6x) 2013-2014 0.6
Radboud Research Rounds (5x) 2014-2016 0.5
Symposia and Congresses
RIMLS PhD-retreat, Wageningen, The Netherlands # 2013 0.5
World Conference on Regenerative Medicine, Leipzig, Germany # 2013 1.25
3rd IRB International PhD student symposium, Barcelona, Spain # 2013 1.0
Radboud Frontiers Symposium, Nijmegen, The Netherlands 2013 0.5
RIMLS PhD-retreat, Wageningen, The Netherlands # 2014 0.5
Matrix Biology Europe Conference, Rotterdam, The Netherlands # 2014 1.25
Radboud Frontiers Symposium, Nijmegen, The Netherlands # 2014 0.5
RIMLS PhD-retreat, Veldhoven, The Netherlands # 2015 0.75
TERMIS World Congress, Boston, United States ## 2015 1.5
Symposium in systemic review and meta-analysis in translational preclinical 
science, Aarhus, Denmark *
2015 0.75
RIMLS PhD-retreat, Veldhoven, The Netherlands * 2016 0.75
6th Freiberg Collagen Symposium, Freiberg, Germany * 2016 1.25
Teaching
Lecturing Biomedical Sciences 2013-2014 1.0
Daily supervision of bachelor and master students of Medical Biology and 
Biomedical Sciences
2013-2016 13.6
Other
- Member of RIMLS PhD Programme committee 2013-2014 1.0
- Organization of RIMLS PhD-retreat (2x) 2014-2015 4.0
TOTAL:  50.27
Oral and poster presentations are indicated with a * and # after the name of the activity, respectively.
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Dit is ‘m dan, mijn proefschrift! Eindelijk klaar na vijfenhalf jaar! Het is hard werken 
geweest, en zeker de laatste loodjes waren af en toe best zwaar, maar ik ben stiekem 
best trots op het eindresultaat. Veel mensen hebben hieraan een steentje bijgedragen, 
want zonder hulp van (co)promotoren, collega’s, vrienden en familie is promoveren 
onmogelijk. Ik wil daarom graag iedereen die op wat voor manier dan ook heeft 
bijgedragen aan dit proefschrift enorm bedanken voor alle hulp en steun de afgelopen 
jaren. 
Beste Toin en Willeke, ik was al bijna op weg Brussel om te starten met een master 
bedrijfskunde toen jullie me aanboden om promotieonderzoek te gaan doen bij de 
afdeling Matrixbiochemie. In eerste instantie was ik er zelf niet van overtuigd dat ik de 
ideale promovendus was. Maar jullie vertrouwen in mij gaf de doorslag om alsnog in 
Nijmegen te blijven. Tot op de dag van vandaag heb ik hier nog geen seconde spijt van 
gehad. Ik wil jullie beiden ontzettend bedanken voor jullie vertrouwen in mij.
Beste Toin, ik ken bijna niemand die zo bevlogen is in zijn vak als jij. Er is geen 
biochemische reactie in het lichaam waar jij de werking niet van kent. Jouw 
onuitputtelijk bron van kennis samen met je enthousiasme voor de biochemie hebben 
enorm veel bijgedragen aan dit mooie proefschrift wat hier nu voor ons ligt. Ik wil je 
ontzettend bedanken voor je begeleiding tijdens mijn promotietraject. 
Beste Willeke, bedankt voor al je hulp de afgelopen jaren. Waar ik af en toe even van de 
planning afweek zorgde jij er altijd voor dat alles toch de juiste richting in ging en dat de 
deadlines gehaald werden. Jouw praktisch inzicht bij het opzetten van experimenten 
heeft me enorm geholpen, net zoals jouw scherpe blik op de manuscripten. Kleine 
foutjes die niemand zag werden door jou altijd opgemerkt. Bedankt voor alles!
Geachte professor Brock, beste Roland, ik wil u bedanken voor het feit dat ik mijn 
promotieonderzoek mocht uitvoeren bij de afdeling Biochemie en dat u mijn promotor 
bent geweest. De gesprekken met u over de vorderingen van mijn onderzoek hebben 
mij geholpen bij het stellen en realiseren van doelen met als gevolg dat ik mijn 
promotieonderzoek binnen een mooie termijn en met mooie publicaties heb kunnen 
voltooien. 
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Henk, mijn begeleider tijdens mijn masterstage, mede-promovendus, research 
partner, paranimf, maar vooral een hele goede vriend. Ik weet eigenlijk niet waar ik 
moet beginnen om jou te bedanken. Toen mijn masterstage naar York niet door kon 
gaan regelde jij dat ik via een constructie met de afdeling Urologie bij jou stage kon 
lopen. Deze stage heeft er uiteindelijk voor gezorgd dat ik promotieonderzoek kon 
gaan doen. In de eerste fase van mijn promotieonderzoek heb je me vaak laten zien 
hoe je op het lab experimentele opstellingen, mallen voor scaffolds, of andere zaken 
in elkaar knutselde. Dit geknutsel heeft er uiteindelijk toe geleid dat we samen enkele 
mooie artikelen hebben weten te publiceren. Naast het serieuze gedeelte hebben we 
ook heel veel gelachen en lol gemaakt, op het lab, maar zeker ook in de Laaf, in De 
Fuik, en tijdens de Vierdaagse. Het was echt een geweldige tijd! In onze toekomstige 
carrières ben ik ervan overtuigd dat onze paden nog vaak zullen kruisen. Henk, het 
is een eer om jou hier aan mijn zijde te hebben als paranimf. Ik wens jou, samen met 
Frederieke, Mia en Toby, het allerbeste voor de toekomst en ik hoop dat we elkaar nog 
lang blijven zien, niet alleen als collega’s maar ook als vrienden. Henk, bedankt jonge!
Ook wil ik graag al mijn andere collega’s van Matrixbiochemie bedanken! Arie, bedankt 
voor je hulp en de leuke gesprekken, van de Champions League tot wereldreizen, 
alles kwam voorbij. Ik hoop over een paar jaar nog een keer bij jou thuis op bezoek te 
komen in Bali. Els, bedankt voor de leuke tijd en voor je hulp, zeker bij al die honderden 
bestellingen die je hebt gedaan voor mij met bestelbriefjes die ik altijd maar voor de 
helft invulde (excuses nog daarvoor -). Elly, bedankt voor alles wat ik van je geleerd 
hebt op het gebied van collageen en tissue engineering. Zonder jouw ervaring was het 
een stuk moeilijker geweest om dit boekje vol te krijgen. Marianne, als U-genootjes 
hebben we veel lief en leed gedeeld. Verschillende hoogtepunten, maar ook dingen 
die een afgewezen artikel of een mislukt experiment relativeerde. Ik heb heel veel 
respect voor je. Bedankt Marianne! Theo, bedankt voor al je hulp op het gebied van 
microscopie en fotobewerking, maar zeker ook bedankt voor alle speciaalbiertjes die 
we samen in de Laaf gedronken hebben. Het was altijd kei gezellig!
Ik wil ook graag alle onderzoekers van Matrixbiochemie bedanken waar ik mee heb 
samengewerkt. De ‘oude’ garde, Etienne, Myrtille, Xander, Katrien, bedankt dat jullie 
mij wegwijs hebben gemaakt op de afdeling tijdens mijn stage en in het begin van mijn 
promotieonderzoek. Danique, bedankt voor de korte maar leuke samenwerking en 
heel veel succes gewenst met je verdere promotieonderzoek. 
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En dan de club van onderzoekers waar ik het grootste deel van mijn promotie samen 
mee heb gewerkt. Corien, Michiel, René en Sophieke, bedankt voor de super leuke tijd 
die ik met jullie heb gehad. Jullie zorgden ervoor dat ik altijd met plezier naar mijn werk 
ging, ook als het even tegenzat met experimenten of manuscripten. De vele gezellige 
avondjes in de Laaf en de AIO-weekendjes waren echt geweldig 
Corien, het samen lekker klagen over mislukte experimenten of afgewezen artikelen 
deed me altijd erg goed, maar het lachen om onze flauwe grappen ga ik echt missen! 
Michiel, medebewoner van de Mansion, wat hebben we veel gelachen zowel op het werk 
als thuis. De trip naar Boston voor het TERMIS congres was echt een hoogtepunt, net als 
het jaarlijkse feest bij ons voor de deur tijdens de Vierdaagse! Geweldige herinneringen! 
René, de avondjes Laaf inclusief afterparty, de rondjes met de wielrenfiets, de whisky 
proeverijen, wat een mooie herinneringen uit onze promotietijd. Sophieke, jouw 
doorzettingsvermogen en ‘7 uur ’s ochtends tot 2 uur ’s nachts mentaliteit’ hebben me 
vaak gemotiveerd tijdens mijn promotieonderzoek. Ook jouw vele culinaire restaurant 
tips kon ik altijd erg waarderen, ik heb vaak lekker gegeten dankzij jou!
We waren met z’n allen echt een geweldig clubje bij elkaar, zonder jullie zou mijn promotietijd 
nooit zo leuk zijn geweest. Super bedankt en ik hoop jullie allemaal nog lang te blijven zien.
I also want to thank all my students for their contribution to this thesis. Rens, Timo, 
Dimitris, Hemn, Ellen, Evy, Kenny, thank you all for the great work you did during your 
internships. I wish you the best in your future careers.
Ook wil ik alle collega’s van de andere werkgroepen binnen de afdeling Biochemie 
hartelijk danken voor de hulp tijdens mijn promotieonderzoek, de leuke dagjes-uit en 
de gezellige jaarlijkse kerstdiners.
Naast Matrixbiochemie is er nog een afdeling waar ik me altijd erg thuis heb gevoeld, 
namelijk bij Urologie. Ik wil dan ook iedereen van de afdeling Urologie enorm bedanken 
voor de leuke samenwerking. Geachte prof. Feitz, beste Wout, u was dan wel niet officieel 
lid van mijn begeleidingsteam, maar zo voelde het altijd wel voor mij. Bedankt voor uw 
hulp en uw altijd motiverende woorden ‘typen typen typen’. Egbert, Paul (Geutjes), 
bedankt voor jullie ondersteuning. Dorien, bedankt voor al je hulp op het lab met 
celkweekexperimenten en kleuringen, maar vooral bedankt voor je gezelligheid. Kees, 
bedankt voor je hulp, je interesse in mijn onderzoek en de leuke gesprekken. Marije, we 
hebben veel samengewerkt bij verschillende projecten, zoals het NovioTissue project, 
het gekrompen scaffolds project en het PhD-retreat committee. Bedankt voor de leuke 
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en gezellige samenwerking. Paul, bedankt voor de leuke tijd in de Mansion en de super 
leuke samenwerking op het lab. We hebben heel veel gelachen en lol gemaakt, maar wat 
hebben we samen veel geklaagd over de voortgang van ons systematic review. Vaak zaten 
we onderuit gezakt op het kennisplein met onze handen in het haar kijkend naar de meest 
onoverzichtelijke Excelsheet ooit gemaakt. Maar wat is het uiteindelijk een mooi artikel 
geworden! Bedankt Paul! Herr Peter, ik wil je graag bedanken voor de geweldige tijd in 
Nijmegen, zowel op het werk als thuis in de Mansion. Het was altijd super gezellig. Bedankt 
voor je hulp en interesse in mijn onderzoek, maar vooral bedankt voor je vriendschap!
Naast collega’s van de afdeling Matrixbiochemie en Urologie zijn er nog veel andere 
collega’s die hebben bijgedragen aan dit proefschrift.
Rob en Joanna, bedankt voor jullie hulp (en geduld) bij het schrijven van het systematic 
review. Het is uiteindelijk een prachtig artikel geworden in een heel mooi tijdschrift.
Tijdens mijn promotieonderzoek hebben we veel samengewerkt met het 
onderzoeksteam van de afdeling Heelkunde onder leiding van Prof. Harry Van Goor. 
Hartelijk dank voor de leuke en vruchtbare samenwerking. Roger en Edwin bedankt 
voor de hulp met de Zwick en de gezelligheid op jullie lab. Marja, bedankt voor onze 
leuke samenwerking die uiteindelijk heeft geresulteerd in een mooi hoofdstuk in dit 
proefschrift, wat hopelijk snel gepubliceerd gaat worden.
Huib, als ik de elektronenmicroscoop weer eens niet aan de praat kreeg, of ik als ik 
die ene opname net even niet scherp in beeld kreeg, dan hoefde ik maar te roepen of 
je kwam je me helpen. Bedankt!
Mark, bedankt voor de prettige samenwerking. Als we een technische vraag hadden of 
als er iets 3D-geprint moest worden dan stond je altijd direct voor ons klaar. 
Patricia, in de afgelopen jaren hebben we regelmatig samengewerkt en dat was altijd 
erg leuk. Het was mooi om te zien hoe dicht het onderzoek in de medische industrie 
en de voedingsindustrie bij elkaar liggen. Onze samenwerking heeft dan ook zeker 
bijgedragen aan de resultaten beschreven in dit proefschrift. Hartelijk dank!
Geachte prof. Buma, beste Pieter, bedankt voor het feit dat u mijn mentor was tijdens 
mijn promotieonderzoek. Onze gesprekken en uw advies hebben me heel erg geholpen 
om op koers te blijven met mijn onderzoek.
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I also want to thank all the members of the RIMLS PhD-programme committee for 
the great time I had together with you representing all PhD-students of the RIMLS. In 
addition, I want to thank the people of the organization committee of the yearly PhD-
retreat for the great collaboration.
The research described in this thesis was part of the NovioTissue project, therefore 
I want to thank all the people involved in this project for the great and successful 
collaboration.
Kaspar, Pieter, Tonny, Bas, Jasper, Dion en Inge, bedankt voor de korte maar leuke 
tijd bij Future Chemistry/Biomed Elements. Ik vond het erg fijn dat ik bij jullie de 
mogelijkheid had om af en toe even naar de overkant van de straat te rennen om 
de laatste puntjes op de i te zetten voor dit proefschrift. Bedankt voor jullie hulp en 
interesse in mijn onderzoek.
I also want to thank all my Devro colleagues for their interest in my PhD-project and I 
appreciate the way I have been embraced by the Devro team during these first months. 
I look forward working together with all of you in the future.
Zonder collega’s kun je niet promoveren, maar zonder familie en vrienden ook zeker 
niet! Roy, Rob, Luuk, Maarten, in onze studietijd hebben we veel lol gemaakt! Ook 
daarna toen we afgestudeerd waren hebben we veel ontzettend veel gelachen samen. 
Bedankt voor jullie vriendschap! 
Peer, Lars, Willem, bedankt voor jullie interesse in mijn onderzoek en de leuke 
skivakanties.
Bert, Dirk, Dirk, Freek, Johnny, Karel, René, Rick, Robin en Thijs met jullie als vrienden 
was er in de weekenden altijd wat te beleven: voetbal kijken, een spelletje of gewoon 
wat ouwehoeren onder het genot van ‘un lekker pilske’. Het was altijd heerlijk om na 
een weekje Nijmegen weer in Brabant te zijn. Bedankt mannen! Ook mijn vrienden uit 
Lierop, Michiel, Roel, de TOPpers van het zaalvoetbal, bedankt voor jullie interesse in 
mijn onderzoek en de leuke weekenden. 
Marjo, Ron, Kris en Boris, de weekenden bij jullie op de Walstraat in Someren waren 
altijd kei gezellig! Bedankt! 
518779-L-bw-Versteegden
Processed on: 17-4-2018 PDF page: 225
225
Curriculum Vitae, List of publications, Portfolio, Dankwoord
Dianne, het grootste en vooral het zwaarste gedeelte van mijn promotieonderzoek 
stond jij aan mijn zijde. De leuke dingen die we samen deden zoals lekker uiteten, een 
terrasje pakken, met de backpack naar Thailand, of gewoon een rondje wandelen met 
Boris, waren altijd geweldig en zorgden ervoor dat ik iedere maandag weer helemaal 
relax en vol motivatie naar mijn werk ging. Jouw spontaniteit, pluk-de-dag mentaliteit 
en je motiverende woorden hebben me enorm geholpen tijdens mijn promotie, zeker 
als ik me weer eens te druk maakte over de voortgang van mijn onderzoek of om 
andere (vaak nutteloze) dingen. Bedankt voor alles wat je voor me gedaan hebt!
Pleun, mijn kleine zusje, die helemaal alleen naar New York kwam gevlogen nadat ik 
naar een congres in Boston was geweest! Wat was dat een gave vakantie! Het was echt 
super gaaf om met jou On Top of the Rock te staan en over de Brooklyn Bridge te lopen. 
Misschien dat dit jaar de rollen omgedraaid zijn en dat ik jou kan komen opzoeken in 
Amerika. Bedankt zusje!
Dirk, we hebben samen een hele tijd doorgebracht in Nijmegen. Onze gedeelde liefde 
voor pizza, shoarma, döner en kapsalon zorgde ervoor dat we vaak samen genoten van 
een heerlijk diners. Nu sta je hier als paranimf naast me, en waarschijnlijk sta jij over 
een paar jaar op mijn plek, aangezien ik al een tijdje niet meer in de enige Versteegden 
ben op Pubmed. Heel veel succes met je carrière, en hopelijk vieren we dan over een 
paar jaar weer een promotie! Dirk, bedankt!
Papa en mama, jullie hebben altijd alles voor mij gedaan en mij gesteund in alles wat 
ik deed. Jullie bleven interesse tonen in mijn promotieonderzoek, ook al was dit vaak 
niet mijn favoriete gespreksonderwerp. Papa, samen met jou in de weekenden een 
rondje maken op de wielrenfiets was geweldig, even ontspannen en bijbuurten, met 
als hoogtepunt onze fietsvakantie in Italië vorig jaar. Ik hoop dat we nog veel kilometers 
mogen maken samen. Mama, jij hebt er altijd voor gezorgd dat ik in Lierop een echt 
thuis had en dat ik niets te kort kwam. Voor jouw steun en zorgzaamheid ben ik echt 
heel dankbaar. Papa, mama, ik had me geen betere ouders kunnen wensen. Bedankt 
voor alles! 
Luuk
Lierop, April 2018
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Uitnodiging
voor het bijwonen van de 
openbare verdediging van het 
proefschrift 
new 
characteristics 
for collagen-
based scaffolds 
in regenerative 
medicine:
Modulating 3D structure 
and biomechanical 
properties 
op donderdag 7 juni 2018 
om 12:30 precies in de aula 
van de Radboud Universiteit, 
Comeniuslaan 2, Nijmegen.
U bent van harte welkom bij deze 
plechtigheid en de aansluitende 
receptie ter plaatse.
Luuk Versteegden
l.versteegden@gmail.com
Paranimfen
Henk Hoogenkamp
hh@futurefoodsbv.com
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